Title: "POMC; the physiological power of hormone processing"

Erika Harno[1], Thanuja Gali Ramamoorthy[1], Anthony P. Coll[2] and Anne White[1]

[1]Division of Diabetes, Endocrinology and Gastrointestinal Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK and [2]MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, UK

Correspondence to:
Professor A. White,
Division of Diabetes, Endocrinology and Gastroenterology,
School of Medical Sciences,
Faculty of Biology, Medicine and Health, University of Manchester,
Manchester Academic Health Sciences Centre,
3.016 AV Hill Building,
Manchester,
M13 9PT,
UK.
Tel.: +44 (0)161 275 5178
E-mail address: anne.white@manchester.ac.uk

TABLE OF CONTENTS

I. INTRODUCTION
II. OVERVIEW OF POMC PROCESSING
III. ENZYMES INVOLVED IN PROCESSING POMC TO DIFFERENT PEPTIDES
IV. THE CELLULAR PATHWAY TO SECRETION
V. RECEPTORS BINDING POMC-DERIVED PEPTIDES
VI. ROLES OF THE COMPONENT PEPTIDES OF POMC
VII. DISORDERED PROCESSING IN THE HYPOTHALAMUS; CHILDREN WITH OBESITY
VIII. DISORDERED PROCESSING IN THE HYPOTHALAMUS; MICE WITH OBESITY
IX. POMC PROCESSING IN THE SKIN
X. PITUITARY PROCESSING OF POMC: A KEY FACET IN REGULATION OF THE HPA AXIS
XI. POMC PROCESSING BY TUMORS
XII. ASSAYS FOR POMC DERIVED PEPTIDES – WHAT ARE YOU REALLY MEASURING?
XIII. BIOACTIVITY OF POMC AND DERIVED PEPTIDES
XIV. CONUNDRUMS AND FUTURE PERSEPECTIVES

ABSTRACT

Pro-opiomelanocortin (POMC) is the archetypal polypeptide precursor of hormones and neuropeptides. In this review, we examine the variability in the individual peptides produced in different tissues and the impact of the simultaneous presence of their precursors or fragments. We also discuss the problems inherent in accurately measuring which of the precursors and their derived peptides are present in biological samples. We address how not being able to measure all the combinations of precursors and fragments quantitatively has affected our understanding of the pathophysiology associated with POMC processing. To understand how different ratios of peptides arise, we describe the role of the pro-hormone convertases (PCs) and their tissue specificities and consider the cellular processing pathways which enable regulated secretion of different peptides that play crucial roles in integrating a range of vital physiological functions. In the pituitary, correct processing of POMC peptides is essential to maintain the hypothalamic-pituitary-adrenal axis and this processing can be disrupted in POMC expressing tumours. In hypothalamic neurons expressing POMC, abnormalities in processing critically impact on the regulation of appetite, energy homeostasis and body composition. More work is needed to understand whether expression of the POMC gene in a tissue equates to release of bioactive peptides. We suggest that this comprehensive view of POMC processing, with a focus on gaining a better understanding of the combination of peptides produced and their relative bioactivity, is a necessity for all involved in studying this fascinating physiological regulatory phenomenon.

I. INTRODUCTION

A. The Discovery of POMC as a Precursor

The phenomena of POMC as a hormone precursor emerged gradually over time as observations slowly filled in pieces of the puzzle. Long before the concept of hormone precursors was realized, the bronzed skin color described by Addison in his patient with adrenal insufficiency ("melasma suprarenale") gave perhaps the first hints of a connection between the hypothalamic, pituitary, adrenal (HPA) axis and skin colour. A similar link between the pituitary and pigmentation came from the studies of Allen and Smith (5, 376) who both noted that immersing tadpoles in pituitary extract made their skins darker. In humans too, large doses of porcine pituitary extract also appeared to cause pigmentation (218), with this active extract of the pars intermedia of the pituitary henceforth termed "melanocyte stimulating hormone" or MSH.

In 1932, Cushing extended his clinical reports of a polyglandular syndrome caused by basophilic adenomas of the pituitary by linking this finding with adrenal hyperactivity. In the 1930's work by Ingle and Kendall (177) showed that administration of large amounts of "cortin" , a purified adrenal extract, produced atrophy of the adrenal cortex in rats. Importantly they found that administration of the "adrenotropic principle" of the anterior pituitary was effective in preventing adrenal cortical regression following treatment with cortin. The first hints of a behavioural angle to pro-opiomelanocortin (POMC) biology came from studies by Ferrari in the 1950s, when "stretching-yawning syndrome" – a bizarre crisis of muscular tone - occurred following central administration of MSH. Many other studies assessing the effects of central α-MSH on motivational processes followed but it was not until 1976 that Panskepp observed for the first time that this peptide decreased food intake (294).

Viewed from the comfort and assured knowledge of the modern molecular world these observations and interventions could be considered overtly simplistic. However we believe that these classic observations should be regarded as essential building blocks not only for our understanding of POMC peptide processing but also for the work which subsequently tied together these seemingly diverse peptides.

B. The emergence of the precursor paradigm

It is likely that POMC arose over 500 million years ago by an insertion of the melanocortin sequences into a prepro-endorphin gene. Evidence for this comes from structural identities with other opioid precursors in both the N- and C-terminal regions of POMC (266). The common opioid gene was thought to arise during chordate evolution. There are four opioid genes which are on three chromosomes in the vertebrate genome. An intragenic duplication event in tetrapods is thought to have led to the presence of α-MSH, β-MSH and γ-MSH (265). The γ-MSH sequence is not present in teleosts and is found as a vestige in non-teleosts, whereas an additional melanocortin peptide, termed δ-MSH has been found in cartilaginous fish. This suggests a divergence in MSH sequences in cartilaginous, ray and lobe-finned fish (266).

The golden age for the precursor paradigm came in the 1960s and 1970s particularly when the first evidence for a precursor of insulin was unearthed by Don Steiner and his team (382, 383). Sequencing confirmed the existence of pro-insulin in 1968 (60) and subsequently pro-insulin was shown to be relatively less active compared to insulin (202). This inspiring work by Don Steiner paved the way for a much greater understanding of a whole range of pro-hormones particularly in relation to their processing.

High molecular weight forms of ACTH and β-LPH: Although adrenocorticotropic hormone (ACTH) and β-lipotropin (β-LPH) had been characterized separately, the concept that they were produced as part of a common precursor had not been considered and only emerged after a number of different approaches suggested the sequences for these different peptides in the same molecule (Figure 1) (reviewed in (66, 280)). Elegant studies by Yalow and Berson (433) using normal human pituitary extracts and an ectopic ACTH producing thymoma, indicated that ACTH was present in a high molecular weight form. These high molecular weight forms of ACTH were also identified in the mouse pituitary tumor cell line, AtT20 (119, 232). Lowry *et al.* (230) went on to use human pituitary extracts and precipitated a single pro-hormone using antibodies to the different peptides (228). This was made possible because previous work by Chrétien and Li (65) had discovered that the γ-LPH sequence was found within β-LPH and that it had the β-MSH sequence at its C-terminal. This led them to propose a pro-hormone theory (reviewed in (66)). The presence of an opioid peptide at the C-terminal of β-LPH was a serendipitous finding by Hughes *et al.* (173) when they identified the met-enkephalin sequence at the N-terminal of β-endorphin in the β-LPH molecule. This was confirmed by the sequencing of β-endorphin (154).

Figure 1: Processing of POMC in different tissues

In 1978, the concept that POMC was a pro-hormone for ACTH and β-LPH was confirmed in studies with the ACTH-secreting AtT20 cell line. Mains *et al.* radiolabeled amino acids in the cells and then used immunoprecipitation and SDS gel electrophoresis, enabling them to identify a 31Kd peptide recognized by antibodies to both ACTH and β-LPH (234). Roberts and Herbert utilized a similar approach but with cell-free translation and antisera to both peptides and reported similar results (329).

The emergence of the full structure of POMC: Not long after these studies, the precursor peptide was purified from rat pituitaries (335) and (rather strangely) from camel pituitaries (200). Michel Chrétien and Nabil Seidah then named the precursor, pro-opiomelanocortin to reflect the known roles of the peptides in the precursor (64). The same year, cloning cDNA from pituitary pars intermedia provided the gene sequence for bovine POMC (265) which was independently confirmed by protein sequencing (264). Similar approaches identified the sequences for the human (72, 391), mouse (407), rat (105) and pig (38) genes (69). Despite the sequence being highly conserved, there is some variation in the lengths of some of the peptides in different species (Figure 2). This led to

confusion when numbering the amino acids from the N-terminal of POMC as the amino acids in the smaller peptides were given different nomenclatures depending on the species (Figure 2). Nevertheless the structure of the gene itself is well conserved, especially in the regions covering the biologically active peptides including ACTH, α-MSH and β-endorphin (165). Importantly, there are a few key species differences which affect the processing and this will be covered in section II E after the details of processing have been described.

Figure 2: POMC protein sequence in different species

C. The tissue localization of POMC

There is a wealth of evidence that in a few key tissues, where both the POMC gene is expressed and peptides derived from the POMC precursor protein are released, POMC has an important and biologically meaningful role. These include the pituitary, the arcuate nucleus of the hypothalamus, the nucleus tractus solitarius, and the skin. However the POMC gene has been reported to be widely expressed throughout the body including in the testis (94, 151, 211, 309), ovary (62, 94), placenta (62), spleen (94), lung (94, 183), liver (94), thymus (183, 211), thyroid (94, 183), heart (253), kidney (94), lymphocytes (275), duodenum (94, 183), colon (94) and adrenal gland (94, 183, 211). Many of these studies were carried out using techniques such as northern blot and PCR and show expression, but not whether translation to the protein or processing occurs in these locations. In fact, it has been shown that many of these tissues contain a shorter mRNA transcript which would not be translated and therefore no peptide produced (69). Furthermore, in both humans and murine models lacking POMC, no obvious phenotypes relating to these diverse tissues have been reported. Therefore, even if active POMC peptides were made in these tissues, their functional significance would appear to be negligible.

The use of the POMC-Cre mouse line expressing a fluorescent protein has further confused our understanding of the expression patterns of POMC, especially in brain regions. POMC is widely expressed during development but this becomes more restricted in adulthood. However, the POMC-Cre manipulation will allow fluorescent protein to continue to be expressed in adulthood, even if POMC was only expressed in that particular region during a developmental period. This was first highlighted in the arcuate nucleus of the hypothalamus, where AgRP/NPY and POMC neurons are mutually exclusive in adulthood. However, the AgRP/NPY neurons expressed the POMC-Cre lineage in adulthood, although they did not continue to express POMC at this time (283). The same group carried out a further study using the POMC-Cre line examining other brain regions and found POMC recombination in regions including the hippocampus, regions of the cortex and midbrain (284). Peripheral tissues have not been examined, but this same extopic pattern may be true for POMC expression outside the brain. Furthermore, using the POMC-Cre mouse line to excise genes in POMC expressing tissues may lead to spurious deletion in other regions where it may not be truly relevant.

Expression the POMC gene is only one facet of a complex mechanism which

requires coordinate release of POMC protein and processing enzymes to generate a biologically relevant effect. We have concentrated on the pituitary, the hypothalamus, and skin where there is evidence for all these processes and for the roles of the peptides produced from these tissues.

II. OVERVIEW OF POMC PROCESSING

POMC is cleaved by pro-hormone convertases (PCs) at well-defined dibasic amino acid sequences. The type of pro-hormone convertase in a particular tissue defines the specific peptides produced. There is no doubt that the processing of pro-hormones is a very specific mechanism but why this is necessary has not been addressed in detail in this review (Figure 1).

Figure 1: Processing of POMC in different tissues

In the anterior pituitary, POMC is initially cleaved between the C-terminal of ACTH and the N-terminal of β-LPH (119) to yield pro-ACTH and β-LPH. This cleavage is carried out by pro-hormone convertase 1/3 (PC1/3) which cleaves at sites where there are dibasic amino acids. In this case, the cleavage is at the Lys-Arg site at the C-terminal of ACTH. There are other dibasic amino acid sequences in POMC indicating that any preference for cleavage at one site over another is most likely due to neighbouring amino acids or the resultant 3D structure allowing easier access to the active site of the convertase.

The next stage in cleavage occurs between the C-terminal of joining peptide and the N-terminal of ACTH. This releases ACTH and an N-terminal peptide containing N-POMC (also called pro-γ MSH) and joining peptide. The latter was discovered as the "missing fragment" in human POMC in 1981 (354). The human joining peptide is amidated and secreted as a homo-dimer, joined by a cysteine bridge (25). In humans it is thought that there is relatively little further processing in the anterior pituitary. This would result in N-POMC, joining peptide, ACTH and β-LPH as the major POMC-derived peptides released from the anterior pituitary.

A. Generation of MSH peptides

In the hypothalamus and pars intermedia of the anterior lobe of the pituitary (present in rodents and human fetal pituitaries, but rudimentary in adult humans), there is much more extensive processing of POMC. Again, the degree of processing is determined by which enzymes are expressed in the different tissues.

B. Generation of α-MSH from ACTH

Generation of α-MSH initially involves cleavage of ACTH by PC2 to give ACTH (1-17) and corticotrophin-like intermediate lobe peptide (CLIP), which represents ACTH (18-39) (Figure 1). To generate α-MSH from ACTH (1-17), C-terminal

amino acids are removed in a step-wise fashion by carboxy-peptidase E (CPE). Disruption to the activity of this enzyme has major consequences for processing (described later in Section VI). ACTH (1-13) is then amidated at the C-terminal by peptidyl-glycine α-amidating monooxygenease (PAM) to give ACTH (1-13)-NH_2, which is also known as des-acetyl α-MSH. This is then acetylated at the N-terminal by N-acetyl transferase (N-AT) to give α-MSH (152). The main effect of N-terminal acetylation is not obvious (261) as some functions are increased and others are blocked by this process. For instance, α-MSH is more potent in modulating pigmentation, memory and attraction, whereas des-acetyl α-MSH is more effective in blocking opiate analgesia (49, 273).

C. Generation of β-MSH and β-Endorphin from β-LPH

β-LPH is processed initially by cleavage of the amino acids between the C-terminal of γ-lipotropin (γ-LPH) and the N-terminal of β-endorphin (Figure 1). γ-LPH can then be processed at a Lys-Lys site to release β-MSH from its C-terminal. This Lys-Lys site is present in the human POMC sequence but not in that of rats or mice and therefore it is thought that β-MSH does not exist as a separate peptide in rodents (114).

The sequence of β-endorphin is the 31 amino acids at the C-terminal of POMC. The initial processing of POMC may only yield β-LPH, however cleavage can continue to give β-endorphin within the secretory granules before release from some pituitary corticotropic cells (439). Several studies have shown that in addition to β-endorphin (1-31) some further processing can occur to give β-endorphin (1-27) and β-endorphin (1-26) which are also present in pituitary and brain.

D. Generation of γ-MSH from N-POMC

The N-terminal region of POMC contains the sequence for the third melanocortin peptide γ-MSH (Figure 1). Pro-γ-MSH is often called N-POMC or N-POC (1-76 in humans and 1-74 in rat and mouse). In the human N-POMC sequence there is a pair of dibasic amino acids at 49/50 which would enable enzymatic cleavage to N-POMC (1-49) and γ_3-MSH (also known as Lys-γ_3-MSH) which has 27 amino acids. From the gene sequence, γ_3-MSH was not expected to include the first lysine, but the cleavage takes place at the C-terminal side of the arginine residue leaving lysine as the first amino acid in γ_3-MSH (29). As it is an extension to the predicted sequence it is sometimes included in the nomenclature. Further processing occurs to produce the γ_2-MSH sequence which is a dodecapeptide and then this can be cleaved to the 11 amino acid γ_1-MSH. However this processing can be restricted by glycosylation at Asn_{16} in γ_3-MSH (32).

E. Species Differences in POMC processing

Many of the melanocortin peptides are conserved among mammalian species, although there are some exceptions, which have consequences for physiology (Figure 2). Neither rats nor mice are able to produce β-MSH, as they lack the

dibasic residues required for cleavage at their N-terminal region (16). For guinea pigs there is speculation that they may also have a shorter version of β-MSH, as they have 2 sets of dibasic residues in the C-terminal region, which could potentially give rise to 2 variations of β-MSH (113).

In mouse, rat and guinea pig, γ_1- or γ_2-MSH may not exist because the C-terminal region does not have the dibasic amino acids to allow cleavage (113). This would suggest that rodents only have the extended γ_3-MSH peptide whereas in the human POMC sequence the γ_1-MSH peptide has flanking dibasic amino acids and therefore the potential for cleavage (Figure 2).

III. ENZYMES INVOLVED IN PROCESSING POMC TO DIFFERENT PEPTIDES

The very specific processing pathway for peptide hormones enables enzymatic cleavage of the precursors in a defined environment. While a lot is known about the pro-hormone convertases and the cleavage of pro-insulin, many of the mechanisms involving these cleavage processes were identified by studying the processing of POMC. In addition, there are a number of other enzymatic modifications which occur in the processing pathways to prepare the hormones for their roles (Figure 1).

A. Pro-hormone convertases (PCs)

The pro-hormone convertases (PCs) are a family of serine proteinases of the subtilisin/kexin type and although PC1/3 and PC2 are the most important for POMC processing, studies on PC4, PACE4, PC5/6, PC7, S1P/SKI-1 and PCSK9 have informed our knowledge of the mechanisms of proprotein processing. Much of the early work on the convertases has been reviewed by Bergeron *et al.* (2000), Seidah and Chretien (1999), Seidah (2011) and Chretien and Mbikay (2016) (22, 66, 349, 351).

The subtilisin endoproteases are highly homologous to human furin. These proteases are calcium dependent and cleave at single or dibasic amino acids. The cleavage occurs at the C-terminal of the pair of dibasic amino acids. In POMC the Lys-Arg (KR) site at the C-terminal of ACTH is cleaved first and then the Lys-Arg at the N-terminal of ACTH. The Lys-Lys-Arg-Arg site in ACTH which is cleaved to give ACTH (1-17) in the processing to α-MSH is not cleaved in human anterior pituitary corticotropes. This provides evidence that the adjacent amino acids influence the ability of the PCs to identify the cleavage sites. These types of cleavage sites are found in most peptide hormones and neuropeptides. It is thought that Arg-Lys and Lys-Lys sites are cleaved very slowly over days and this occurs only in melanotropes and not in corticotropes.

1. PC1/3 and PC2: How they got their names

Although POMC was identified as the precursor of ACTH and β-LPH in 1977 (235, 329), it took 15 years to discover the enzymes which cleave the peptides from POMC (reviewed in (66)). It was the identification of the yeast protease Kex2

that led to the breakthrough. The kex2-like subtilisins have similar catalytic mechanisms to trypsin-like proteases. This led to the identification of a human insulinoma cDNA encoding a pro-hormone convertase subsequently named PC2 (375). At about the same time a second group published the sequence of a mouse pro-hormone convertase which they referred to as PC1 (352). Smeekens and Steiner then isolated cDNA from the human insulinoma encoding a similar convertase and this convertase they named PC3 (374). This turned out to be identical to PC1, such that the nomenclature is now PC1/3.

2. Active pro-hormone convertases are cleaved from inactive precursors

All pro-hormone convertases are themselves derived from precursors and are trafficked to the secretory granules where POMC processing occurs. The maturation of PC1/3 from its precursor is described by Stijnen et al (387). PC1/3 has a signal peptide and an 80-90 amino acid prosegment at the N-terminal. The prosegment is thought to act as an intramolecular chaperone and a competitive inhibitor of the active site of the enzyme. In the endoplasmic reticulum, the inhibitory prosegment is removed by an autocatalytic process. A similar mechanism occurs for PC1/3 (153).

The precursor protein seems to act as a competitive inhibitor at the active site of the processed PC. In particular, Pro-PC1/3, expressed in its trans-conformation, is able to act as an inhibitor of PC1/3 (215). The prosegments of PCs may have inhibitory actions which are distinct for each PC, as they are different in each PC precursor (40).

After the prosegment of PC1/3 is proteolytically removed, which takes several minutes (446), the resulting 84kDa pro-hormone convertase moves to the trans Golgi network (TGN) and then to immature secretory granules (ISGs) where a C-terminal inhibitory peptide (185) is removed. This leaves a 66 kDa form which is much more active than the 84 kDa form (447). This C-terminal peptide has to be cleaved by PC1/3 in the ISGs to stop its inhibitory action on the catalytic domain, so that the mature 66 kDa form is fully active to cleave its target peptides. This suggests that the post-translational processing of the PCs is regulated very precisely. Too much active PC1/3 in the ER would generate the fully active form, but without some autocatalytic activity the inhibitory forms would not be removed. The C-terminal domain is also important for directing PC1/3 into secretory granules; without this the 66 kDa form would move to the constitutive pathway (350).

3. Activation of PC2: the role of 7B2

PC2 is also synthesized as part of a precursor but is processed within the TGN and ISG. There is a very distinct mechanism for activation of PC2, which takes 1-2h and provides the delay necessary for the correct stages of processing (reviewed in (393)). PC2 has a specific binding protein, 7B2, which is required for transport, folding and activation of PC2 (22). The N-terminal of 7B2 has a chaperone function while the C-terminal of 7B2 inhibits PC2 (136). 7B2 is thought to bind to the catalytic domain of PC2 and is required for the efficient

transport and activation of the enzyme (350). 7B2 and pro-PC2 form a complex in the endoplasmic reticulum (ER) and this enables trafficking to the TGN, where 7B2 is cleaved by furin. The C-terminal of 7B2 then binds pro-PC2 and acts as an inhibitor. As the complex is trafficked into the immature secretory granules, the change in pH enables the auto-catalytic processes to activate PC2. This in turn causes the cleavage of the C-terminal 7B2 peptide which releases the PC2 (244). Thus, the biosynthesis and activation of PC2 is tightly linked with that of 7B2.

When 7B2 is knocked out in mice (422), the activity of PC2 in the pars intermedia of the pituitary is prevented. The mice fail to produce α-MSH and instead have dramatically increased ACTH levels and display a Cushing's syndrome-like phenotype with central obesity. Mortality from the excess ACTH can be rescued by adrenalectomy (214). PC2 null mice have higher ACTH in the pars intermedia of the pituitary than 7B2 null mice, but the 7B2 null mice secrete more ACTH providing further evidence for the role of 7B2 in the regulated secretory process.

4. Role of proSAAS in inhibition of PC1/3

With the discovery of 7B2, there was a suggestion that endogenous inhibitors of PC1/3 might also exist. This led to the identification of proSAAS as a potential inhibitor of PC1/3. ProSAAS is expressed primarily in the brain and in other neuroendocrine tissues. Its overexpression in AtT20, mouse pituitary corticotroph adenoma cells, reduces POMC processing by inhibiting PC1/3, but PC2 is not affected (138).

5. Cellular site of action of PC1/3 and PC2

The subsequent identification of other members of this family of convertases, along with cellular localization studies has revealed that the majority of these endoproteases cleave peptides in the TGN or at the plasma membrane. In comparison, PC1/3 (238) and PC2 (238) cleave the peptides in dense core secretory granules (100). This is very relevant as their targets are primarily hormones and neuropeptides, like POMC, and the regulation of the release of the active peptides is critical for the function of these hormones. Although it has been suggested that PC1/3 does not have a transmembrane domain (238), the endogenous 84 kDa and 66 KDa forms of PC1/3 can associate with the secretory granule membranes in a lipid raft, with the N-terminal portion on the luminal side and the region 619-638 acting as a transmembrane domain. This leaves approximately 115 amino acids from the C-terminus of PC1/3 in the cytoplasm, although an α-helical domain at the C-terminus may associate with the cytoplasmic side of the secretory granule membrane. Therefore, the catalytic domain would be within the lumen of the secretory vesicle and cleavage at Arg_{617}-$Arg_{618,}$ adjacent to the membrane, would produce the mature PC1/3 (10). It has been suggested that the insertion into the membrane occurs in the rough ER cisternae and that PC1/3 is transported to the TGN in this form and subsequently packaged into secretory vesicles (10). Sorting PC1/3 and other enzymes to the regulated secretory pathway is an important mechanism and PC2 and carboxypeptidase E (CPE) may also associate with lipid rafts. However, an

alternative suggestion for PC1/3 is that the pro-region associates with lipid rafts and this facilitates the sorting to the secretory pathway (35).

6. Tissue specificity of PC1/3 and PC2 in the processing of POMC

Further confirmation of the function of PC1/3 and PC2 came from their tissue specificity in the mouse pituitary (352, 353), where PC1/3 and PC2 mRNA were detected in the pars intermedia, but only PC1/3 mRNA in the anterior lobe. There was some controversy as studies on the rat pituitary revealed a slightly more complex picture based on in-situ hybridization and co-localization (91). There were high levels of PC1/3 in the anterior pituitary but also lower but significant levels of PC2. However this was clarified when co-localization experiments indicated that the PC2 was not present in the cells that express POMC. In comparison the pars intermedia had much higher expression of PC2 than PC1/3 (91).

The presence of PC1/3 in the anterior pituitary enables the processing of POMC to ACTH, β-LPH, N-POMC (148) and presumably joining peptide, although there are very few studies that have focussed on the molar ratios of each of the peptides. The lack of readily available assays for N-POMC and joining peptide makes it difficult to measure these peptides in human plasma and to predict if there is processing between N-POMC and joining peptide. The absence of PC2 from the anterior pituitary means that further processing of the peptides does not occur.

In comparison, the presence of PC2 in the hypothalamus and skin causes the further cleavage of ACTH, β-LPH and N-POMC. This provides substrates for other enzymes to complete the processing to α-MSH, β-MSH and γ-MSH.

PC2 is also found in the pars intermedia of the pituitary, which is present in rodents and the fetal human pituitary. This means that processing is more extensive and the melanocortin peptides are released under the control of regulatory mechanisms, which are distinct from those in the anterior pituitary. When POMC was co-expressed with PC1/3 and PC2, using vaccinia virus vectors in cells that exhibit regulated secretion, a very similar cleavage pattern of processing was observed to that seen in the pars intermedia of the pituitary (15, 398). However, such studies have to be viewed with caution, because of potential degradation of the cellular environment by the virus, and because of some observed ambiguities in that glucagon was not processed from pro-glucagon by PC2 using a similar method.

7. POMC converting enzyme (PCE or Yapsin A)

Although many studies indicate that PC1/3 and PC2 are the major convertases, there are aspartyl-like proteases which may be involved in processing POMC in certain circumstances. A mammalian aspartyl protease was identified in 1985 called POMC converting enzyme (PCE) (224). This is immunologically related to Yapsin 1, which processes at paired basic residues in Kex2 deficient cell lines.

PCE cleaves POMC to give 21-23kD ACTH, 4.5kD ACTH and 13kD ACTH (glycosylated), β-LPH and β-endorphin. It also cleaves β-LPH to give β-MSH (222). The gene for PCE has not been cloned, and therefore no in-situ analysis has been undertaken (50).

B. Other processing enzymes involved in generating POMC-derived peptides

The further processing of POMC after the action of PC1/3 and PC2 involves multiple stages and many different enzymes (Figure 1). The production of α-, β-, and γ-MSH is particularly complex and occurs in the pars intermedia of the pituitary (in rodents) and in other tissues such as the arcuate nucleus of the hypothalamus and the skin.

1. Carboxypeptidase E

As stated above, the pro-hormone convertases process peptides usually at the carboxyl residue after the single or paired basic amino acid motif. After cleavage, the Lys and/or Arg residues are removed by carboxypeptidase E (CPE) also known as carboxypeptidase H or encephalin convertase (reviewed in (50)). Therefore, in the human anterior pituitary, once POMC has been processed by PC1/3 at the C-terminal of ACTH there is a Lys-Arg pair of amino acids that are then removed by a carboxypeptidase.

Similarly, in the production of α-MSH, CPE plays an important role in removing Lys and/or Arg residues from the C-terminus of ACTH (1-17). Then there is further removal of glycine to generate the 13 amino acid peptide which is post-translationally modified to generate α-MSH. This is described in more detail in section 2 below.

However there is more to the function of CPE than just its role in removal of basic amino acid residues and it may well be that its secondary role is the more important one for POMC processing. In 1997, Peng Loh's group showed that CPE also acts as a pro-hormone sorting receptor for the regulated secretory pathway (83). This function is necessary for pro-hormones to move from the TGN into secretory granules (see below). The importance of this role is indicated by the results from the *Cpe* gene deletion which highlights the miss-sorting of pro-hormones (83, 357).

2. Peptidylglycine α-Amidating Monooxygenase (PAM)

Peptidylglycine α-Amidating Monooxygenase (PAM*)* amidates the C-terminal of ACTH (1-13) in the pathway creating α-MSH but it can also amidate the C-terminal of joining peptide (reviewed in (210)). This process occurs when the POMC-derived peptides are in the secretory granules. It is difficult to find any evidence for a role for ACTH (1-13) without the subsequent modifications so this suggests PAM is critical in the generation of α-MSH.

As the name implies, PAM amidates the C-terminal of peptides after the basic amino acid residue has been cleaved by CPE, and primarily at glycine extended peptides such as is found in the processing to α-MSH. PAM is found in most large dense core secretory vesicles (120) and exists as a bifunctional enzyme with a peptidylglycine α-hydroxylating monooxygenase (PHM) domain which catalyses the first stage in the process and a peptidyl-α-hydroxyglycine α-amidating lyase (PAL) domain which catalyses the second stage. The PAL domain is attached to a transmembrane domain and a cytosolic domain so both catalytic units are held at the membrane but project into the lumen of the large dense core secretory vesicles (68). Secretory granule endoproteases cleave the two domains from the membrane so that they exist in the lumen of the granules. However there is also a naturally occurring soluble form called PHM4, made up of only the PAL domain and generated by alternative splicing (68). There is also evidence that PAM alters the organization of the actin cytoskeleton which is important in the release of secretory vesicles from cells (121).

The role of PAM in POMC processing in the hypothalamus has received little attention and there are currently no reports of mutations in humans that have resulted in obesity. If PAM is critical in the generation of α-MSH, in subjects carrying deleterious inactivating mutations, it may be there is a degree of redundancy in the system with other enzymes undertaking similar amidating activity to compensate.

3. N-acetyl transferase

Acetylation of the N-terminal amino acid residues of α-MSH and β-endorphin is important for the activity of these peptides. In general it is a process thought to protect peptides from aminopeptidases and therefore increase their stability although some peptides have N-terminal acetylation which targets them for degradation. N-terminal acetylation is generally restricted to intracellular proteins (429). Therefore the N-acetylation of these two peptides, whose role is to act at distant sites within the brain and the skin, remains intriguing and not fully explained.

A) ACETYLATION IN DIFFERENT TISSUES

The deacetylated form of α-MSH was identified in the pituitaries of a number of species as early as 1974 (see (273)), but studies in the 1980s suggested that most of the α-MSH is in the acetylated form in the pars intermedia the pituitary (97).

In the human and rat hypothalamus, deacetylated α-MSH (subsequently termed des-acetyl α-MSH) was found to be a major component when assessed with HPLC techniques (273). Subsequently the regional heterogeneity in the forms of α-MSH was investigated. In the arcuate nucleus of the hypothalamus, where this peptide has a major role, there was some α-MSH, but the majority was in the des-acetyl form. The amygdala and periaqueductal grey contained non-acetylated α-MSH and the nucleus accumbens had the mono- and di-acetyl (second acetyl group on the third amino acid) forms of α-MSH (97). In a separate study which

showed the prevalence of des-acetyl α-MSH in the arcuate nucleus, it was also suggested that acetylation occurred in the NTS because α-MSH was found there (113).

B) WHAT DOES N-TERMINAL ACETYLATION DO FOR α-MSH?

In *in vitro* studies, the potencies of des-acetyl α-MSH and α-MSH appear similar at MC3R and MC4R (Abbott ref 1 in this review). There is however some evidence that the two forms of α-MSH may activate intracellular signaling pathways differently and this could vary depending on the type of tissues and the different melanocortin receptors (429).

That there is a difference in biological function between des-acetyl α-MSH and α-MSH has been recognized for some time in terms of behavioural effects (273). However, there are also several *in vivo* studies showing differences in the potencies of the N-acetylated and the des-acetyl forms of α-MSH, in terms of food intake (reviewed in (258, 429)). These studies indicated that when des-acetyl and α-MSH are injected icv at the same dose, des-acetyl α-MSH had a much smaller effect on food intake (1, 261, 404). However a recent study in mice lacking endogenous α-MSH and des-acetyl α-MSH, demonstrated that when these peptides were administered they could each equally decrease body weight (259) presumably by reducing food intake.

What may be most relevant is that the N-terminal acetylation of α-MSH confers stability on the peptide (47, 156, 272, 336). Des-acetyl α-MSH is readily degraded by aminopeptidases where-as the N-terminal acetylation protects α-MSH from such degradation (156). Therefore, acetylation could be a mechanism by which the biological activities of POMC peptides are modulated, although further work needs to be carried out to fully understand the endogenous effects of the peptides.

There is also evidence that leptin induces an N-acetylase in mouse hypothalamus (156), so in addition to increasing the *POMC* gene expression, it was suggested that leptin could increase the biologically active α-MSH in relation to the less active des-acetyl α-MSH form. This suggests much greater subtlety in the control of POMC processing to melanocortin peptides. Some explanation is required, because the evidence points to very little of the active N-acetylated α-MSH relative to des-acetylated α-MSH in the arcuate nucleus (113), making it difficult to understand how α-MSH can have such a powerful role in regulating energy balance. There is speculation that the acetylation process occurs after the des-acetyl α-MSH has travelled along the neuron and just before secretion of the vesicles (258) in the paraventricular nucleus of the hypothalamus (PVN) (Figure 3). Therefore the relative concentrations of α-MSH and des-acetyl α-MSH in the arcuate nucleus would be less relevant.

To add to the complexity, there is evidence that α-MSH is processed by prolylcarboxypeptidase (PRCP) to give α-MSH (1-12), which is inactive. (see section 4 below for more details).

Figure 3: POMC processing in neurons

C) ACETYLATION OF β-ENDORPHIN

Non-acetylated β-endorphin is found in the arcuate nucleus of the hypothalamus but acetylated β-endorphin was thought to be the main form in the NTS (113). This again raises issues about the role of these post-translational modifications as acetylated endorphins do not bind to opiate receptors (3) and therefore the process of acetylation prevents opiate activity (92). However a more recent study has demonstrated opioid activity originating from POMC neurons in the NTS, indicating that non-acetylated β-endorphin may also be released from these neurons (54).

D) RATIONALIZATION OF ACETYLATION FUNCTION

There is evidence to suggest that the acetylation of α-MSH and β-endorphin is tissue specific and differs between the hypothalamus and pituitary (258). The presence of N-acetyltransferase in the processing cascade would increase α-MSH, thus potentiating α-MSH activity and acetylate β-endorphin thus reducing its function. Therefore this could be a mechanism to provide distinct melanotropic action and not opiate effects in the specific brain region.

4. Prolylcarboxypeptidase (PRCP)

A further cleavage of α-MSH can be carried out by prolylcarboxypeptidase (PRCP) giving α-MSH (1-12), which has been demonstrated to occur both *in vitro*, and *in vivo* (417). Additionally, there is evidence that prolyl endopeptidase (PREP, also known as prolyl oligopeptidase) can cleave the terminal amidated valine of α-MSH to also give α-MSH (1-12) (304). The function of α-MSH (1-12) is unclear as it does not activate MC4R and does not decrease food intake (417) and is therefore assumed to be inactive.

IV. THE CELLULAR PATHWAY TO SECRETION

Another critical arena that determines how POMC derived peptides are released from cells in the correct spatial and temporal patterns is the pathway across the component parts of the intracellular secretory pathway. It is important to note that much of the work in this area has been carried out in the mouse pituitary adenoma (AtT20) cell line. It remains to be determined how this secretory pathway may differ from that in hypothalamic neurons where there are long projections between regional nuclei. Nevertheless, there are much data which suggest POMC peptides follow at least 2 distinct pathways on their journey from translation to the extracellular space.

A. From the Endoplasmic Reticulum (ER) to the *trans*-Golgi Network (TGN)

After translation, all pro-hormones are moved into the ER where the N-terminal recognition signal anchors them to the membrane. The ER then plays a role in

removing the signal peptide at the N-terminal of POMC using a signalase enzyme (119). POMC has a specific "heart shaped" conformation at its N-terminal which occurs by the formation of two disulphide bonds formed from Cys_{28}/Cys_{50} and Cys_{34}/Cys_{46} in the region upstream of γ-MSH, sometimes termed the 16K fragment (19, 80). As POMC passes out of the ER it will have had N-linked oligosaccharides added, which can influence processing or have no effect, depending on the region that is glycosylated (17).

B. From the Golgi to the secretory vesicle

In the Golgi apparatus the pro-hormone is moved towards the ends of the cisternae where there is blebbing of the membranes to generate the secretory vesicles (399). During this process, the serine at amino acid 31 in ACTH is phosphorylated by casein kinase and sulphate groups are added to N-linked carbohydrate chains.

The sorting of pro-hormones for processing is dependent on a change in pH between the TGN and the secretory granules. Experiments using chloroquine, which neutralises acidic compartments, resulted in a reduction of newly synthesized ACTH in mature granules (256). As POMC moves through the TGN and into granules, the pH changes from 6.8 (355) to 4.5-5.5 (225) which is coupled with changes in calcium concentrations. This environment provides the optimal conditions for activation of the pro-hormone convertases, so that the initial phases of processing of the pro-hormone precursor can begin. There is data suggesting that POMC is primarily processed in secretory granules (134, 394) although other studies suggest it may begin in the TGN (249, 345, 445). Some of the evidence suggests that the initial cleavage of POMC at the C-terminal of ACTH can occur in the Golgi apparatus but subsequent modifications continue in the secretory vesicles (reviewed in (313)). Therefore the cleavage at the N-terminal of ACTH to generate mature ACTH (1-39) is likely to occur in the secretory vesicles (Figure 4).

Figure 4: Alternative secretory pathways for precursors and POMC-derived peptides

If the initial cleavage between ACTH and β-LPH occurs in the Golgi apparatus, then it is likely that β-LPH (and therefore β-endorphin) could be found in different vesicles to ACTH and α-MSH. If all the processing occurs in the vesicle, then ACTH and β-endorphin will be present in the same vesicles. This is important for understanding whether α-MSH and β-endorphin peptides are released at the same time and at the same site, given that they may have opposing roles in the hypothalamus (See section on β-endorphin in the hypothalamus).

Further processing of ACTH to α-MSH requires not only PC2 but also the enzymes CPE, PAM, and N-AT (see above) which are present in the secretory vesicles in a state ready to be activated. How activation is achieved is not fully understood (100). It is likely that these enzymes have recognition sequences that

direct them to the TGN, but whether all secretory vesicles have this repertoire of enzymes is not clear.

C. What is the regulated secretory pathway?

Gumbiner and Kelly in 1982 recognized that there are classical secretory cells such as those in the adrenal medulla, the exocrine pancreas and the anterior pituitary which have large dense core secretory granules (155). They defined the regulated secretory pathway (RSP) as one where secretagogues controlled the release of the contents of the secretory vesicles. In the absence of secretagogues there is minimal exocytosis of secretory granule contents. The secretory vesicles have an electron dense core and turn over is slow (half life approximately 10 hours), probably because these are the storage organelles for bioactive peptides. Biogenesis of secretory granules was initially thought to require chromogranin A (CGA), a member of the granin family which also includes chromogranin B (CGB, secretogranin I) and chromogranin C (CGC, secretogranin II) (199). However targeted ablation of the chromogranin A (*Chga)* gene indicates that compensatory increases in the expression of other granin family members can compensate for CGA deficiency (163).

D. Pro-hormone sorting

Sorting of peptides to the regulated secretory pathway (RSP) is a pre-requisite for processing of many pro-hormones. Although not fully clarified, it is reasonable to assume that this is also the case for pro-neuropeptides involved in energy balance. These are released from neurons that have their cell bodies in the arcuate nucleus but act at other sites within the hypothalamus. POMC neurons will release α-MSH primarily at the PVN. The molecular mechanisms for sorting pro-hormones to the RSP can involve aggregation of peptides in the presence of high calcium and low pH, as found in the TGN. There is evidence for aggregation of this type for chromogranins A and B (59) however, sorting can occur in the absence of aggregation (316) and other studies have suggested the importance of sorting signal motifs.

POMC has a sorting signal motif at its N-terminal region that is both necessary and sufficient for sorting to the RSP (80-82). This sorting signal in POMC was identified as a result of some of the early structural analysis of the N-terminus of POMC (18, 19). It is thought to involve two acidic residues, Asp_{10} and $Glu_{14,}$ and two amphipathic residues, Leu_{11} and $Leu_{18,}$ which are part of an amphipathic loop at POMC residues 8-20. This sequence was predicted to be a consensus sorting signal which could bind to a sorting receptor and it has also been identified in pro-enkephalin (270) and pro-insulin (99).

For POMC, the sorting receptor was identified as carboxypeptidase E (CPE) (81, 83). This has a ligand binding domain for the POMC sorting motif, which was originally identified by molecular modeling and then disruption of the receptor site by mutation (441). The binding site on CPE, which is distinct from the enzyme active site, also recognizes pro-insulin and pro-enkephalin (441). CPE is known to associate with membranes and this appears to be necessary for its

function in sorting pro-hormones to the RSP (98). This membrane association is with lipid rafts containing glycosphingolipids and cholesterol and is predominantly in the secretory granules, but also in the TGN. Depletion of cholesterol can reduce the association of CPE and its pro-hormone ligand with the membrane (98). Secretogranin III can also have a synergistic role with CPE in the trafficking of POMC and derived peptides (50). RNA silencing of secretogranin III decreases secretion through the RSP in AtT20 cells suggesting that there are several pathways involved in regulated secretion (51).

Much of the work on the membrane association of CPE has used secretory granules and it is not clear at what stage CPE binds to POMC. For CPE to be involved in sorting POMC from the ER to the TGN it would have to bind in the ER in order to transfer it into compartments within the TGN. However, as POMC moves through the TGN, CPE can enable POMC to be selected for immature granules that bud off the TGN. The interaction between CPE and POMC would then retain POMC in the granules and not allow it to move to the constitutive-like pathway (see below).

The relative importance of the roles of CPE in sorting of POMC to the RSP versus its true carboxypeptidase action has not been clearly delineated. Sorting seems to be critical because POMC is not processed but secreted in large amounts from the constitutive pathway in the pituitary of the $Cpe^{fat/fat}$ mice (83, 357).

Another carboxypeptidase, CPD, is present in the TGN and cycles between the TGN and the cell surface. It appears to reside in immature secretory granules, but absent from the mature granules (411). Therefore CPD may be responsible for removal of dibasic amino acids or sorting of pro-hormones in the absence of CPE (102).

E. The movement of vesicles to the cell membrane

For POMC, one of the critical features is the very specific regulation of release of the processed peptides in response to defined signals. The cytoplasmic tail of CPE (i.e. the part of the molecule that remains outside the vesicle) also plays a role in transporting the vesicles containing POMC (or if POMC has been processed then the vesicles which contain ACTH and the other POMC-derived peptides). The secretory vesicles must be transported from the TGN to the cell membrane where they can be stored until there is a stimulus which orchestrates their release. The transport of the vesicles to the secretion sites in pituitary cells occurs along microtubules (205). This involves dynactin being recruited to the cytoplasmic tail of CPE, and dynactin then binding to kinesin 2 and kinesin 3 as part of the secretory process (50, 295). The very specific mechanisms involved in movement of vesicles to the cell membrane have been reviewed by Park and Loh (295).

F. What happens to the mature peptides in the secretory vesicles?

The current working model is one in which the processing of POMC to the smaller peptides continues during the time when the vesicles are trafficking to

the site of secretion. There is evidence that within dense core secretory vesicles a large number of peptide and protein hormones aggregate into insoluble macromolecular complexes (237). These aggregates are crystalline or composed of amyloid fibrils which are cross-β-sheet structures. Interestingly, ACTH was one of the hormones that didn't form amyloid-like aggregates on its own, but when mixed *in vitro* with β-endorphin, in the presence of heparin, the amyloid fibrils were formed. There is the caveat that β-endorphin does not seem to be processed from β-LPH in human pituitary cells so it is not clear if ACTH would form amyloid fibrils in this instance. Nevertheless, there is also evidence for amyloid aggregates in the mouse pituitary cell line AtT20, which is known to secrete ACTH and presumably β-LPH (237).

There is a suggestion that pro-hormones aggregate less than the hormones derived from them (438). Therefore processing of the pro-hormone may be necessary before amyloid aggregation occurs. This would sort the hormone into the granule core and concentrate the molecules, excluding those hormones that don't aggregate which are then constitutively secreted (237). It is thought that the amyloid aggregation begins in the Golgi where the membrane surrounds the aggregates, although for POMC and ACTH this will depend on the degree of processing. The amyloid aggregates are stable and therefore they can be stored, but on stimulation there is a change in pH which is thought to trigger the dissociation of the monomeric hormone from the amyloid allowing its release from the cell (237). Whether this occurs *in vivo* and how it contributes to efficient processing is harder to determine.

G. Release of secretory vesicles from the cell

Once the anterior pituitary cell is stimulated to release ACTH, the vesicles have to dock with the cell membrane. VAMP2, syntaxin 1 and SNAP-25 form a core complex (380) that interacts with NSF and SNAPs. These are termed SNARE proteins and together with synaptotagmin 1 are responsible for synaptic vesicle priming, docking and fusion to the cell membrane. Each of the core complex proteins is related to other similar proteins in their class, which could give rise to specific combinations of these proteins in different complexes (20, 390). For the secretory vesicles to fuse with the plasma membrane, a complex process occurs involving actin and tubulin (399). This enables the secretory vesicles to exude their products into the extra-cellular space.

Exocytosis is coupled to specific extracellular stimuli, such as CRH binding to its receptors on anterior pituitary cells and signaling to evoke secretion (111). How the receptor activation signals to the machinery for release of the secretory vesicles is very relevant, as the whole procedure must occur in milliseconds to release ACTH in times of stress. The release of ACTH from pituitary cells is also stimulated by arginine vasopressin (AVP) and inhibited by glucocorticoids and this process has to synchronise with the mechanisms of release of the secretory vesicles. More details of the regulation of secretion of ACTH are found in Section IV.

H. Constitutive versus regulated secretion

In addition to the regulated secretory pathway, there is also a constitutive pathway of secretion, which is a route allowing the release of peptides from cells which is not regulated by external factors (155); examples of peptides released in this way include lysosomal enzymes secreted by fibroblasts (166), and acetylcholinesterase released from muscle cells (332). This pathway can be inhibited by monensin which is an ionophore that can inhibit the transport of secretory proteins through the TGN.

For secretory cells, there is evidence to suggest they have both constitutive and regulated secretory pathways. Moore *et al.* stably transfected pro-insulin into AtT20 cells, which synthesise and process POMC to ACTH and therefore should have all the secretory components (257). They showed that AtT20 cells rapidly release newly synthesized pro-insulin from a constitutive pathway and store the processed insulin for release after stimulation by a secretagogue. There is evidence that the constitutive pathway releases peptides over about 40 minutes (155). If the regulated pathway is blocked by chloroquine, then newly synthesized ACTH is released from the constitutive pathway, which is further evidence that both pathways exist in secretory cells.

There are two mechanisms proposed for targeting peptides to vesicles. If the targeting occurs in the TGN then it is termed "sorting by entry" (279, 400), but if it occurs in the immature secretory granules (ISGs) then it is termed "sorting by retention" (209). There is evidence for both mechanisms and despite much effort to unravel the processes that target peptides to granules there are still many unanswered questions (100).

I. Release of POMC from the constitutive-like pathway

There is some early evidence to suggest that POMC is released from the constitutive pathway (256) (Figure 4). Analysis of how POMC is processed and how it is trafficked into secretory or constitutive granules utilized radiolabelling of the sulphates on carbohydrate chains linked to POMC in the TGN. POMC processing to convert POMC to ACTH began in the ISGs. However, incompletely processed POMC was also secreted in ISGs by a distinct pathway which has been termed the constitutive-like pathway (110).

With the advent of a specific and sensitive two-site immunoassay for POMC (89), it has become possible to compare direct measurement of POMC and ACTH release from AtT20 cells. When cells are cultured under basal conditions then much higher concentrations of POMC than ACTH are released. After stimulation with corticotropin releasing hormone (CRH) for 2 hours there is a 2-fold increase in secreted ACTH with no change in secretion of ACTH precursors (384), suggesting ACTH is released from the regulated pathway but POMC is released from the constitutive-like pathway.

However there are a number of caveats, the first being that the AtT20 cells release extremely high concentrations of ACTH-related peptides compared with

normal mouse corticotrophs. Therefore, their secretory capacity may be different and the regulatory mechanisms may not reflect "normal" cells. A second caveat is that all ACTH assays recognize ACTH precursors to some degree (255), so the "ACTH" measured may in fact be ACTH precursors. We have calculated that ACTH precursors have <10% cross-reactivity in the ACTH assay we have developed (385). Therefore the concentrations of precursors are contributing only a small amount to the ACTH concentrations measured.

V. RECEPTORS BINDING POMC-DERIVED PEPTIDES

The processed products of POMC bring about their biological actions through melanocortin receptors (MCRs) and the μ-opioid receptor. These will be briefly discussed below, but are reviewed in detail in Cone et al. (77) and Pasternak and Pan (298).

A. Melanocortin Receptors

The five melanocortin receptors (MC1R-MC5R), are differentiated by their tissue localization and ligand affinity (Table 1). They were named in the order they were discovered, rather than any association with their localization or ligands.

1. Melanocortin 1 Receptor (MC1R)

MC1R is located primarily in melanocytes of skin and in hair follicles, but is also expressed in macrophages and adipocytes (169). The main role of melanocortin signaling through MC1R is in regulation of pigmentation in the skin and in hair follicles. Activation of MC1R by its ligand causes a switch from synthesis of the red and yellow, pheomelanin pigments, to the black and brown, eumelanin pigments. Mutations and variants of the MC1R have been found in patients with red hair and fair skin (409). There is also evidence that activation of MC1R can promote cell proliferation, DNA repair and cell survival.

The primary ligand of MC1R is α-MSH, which is endogenously produced in the keratinocytes of skin and hair after exposure to UV light. Additionally, ACTH is also able to activate MC1R and at high concentrations (such as when secreted from tumors) it can cause hyperpigmentation (406). There is also some evidence that MC1R can bind β-MSH and γ-MSH with lower affinity.

2. Melanocortin 2 receptor (MC2R)

The MC2R is also known as the ACTH receptor. It is unique among the MCR family as it only binds ACTH and is unable to bind any of the MSH peptides. The MC2R also has a much lower sequence homology with other melanocortin receptors and in particular, it only has 38% homology with MC4R. This is primarily because MC2R has a different binding pocket compared to the other MCRs (436). MC2R is predominantly expressed in the adrenal cortex and requires the accessory protein, MRAP, to enable it to translocate to the cell surface so it can function. Binding of ACTH to the MC2R activates the cascade for

synthesis of glucocorticoids as part of the HPA axis.

3. Melanocortin 3 receptor (MC3R)

The MC3R has a more minor role in energy homeostasis compared to MC4R, and acts primarily as an inhibitory "auto-receptor" on POMC neurons in the arcuate nucleus, the region associated with energy balance. It binds α-, β- and γ-MSH and ACTH, equipotently (144). The MC3R is expressed in the hypothalamic region of the brain, but also in the limbic regions (331) and in peripheral tissues including the stomach, duodenum, pancreas, heart, testis, ovary, skeletal muscle and kidney (78). However the role of MC3R in these tissues is not as well defined.

4. Melanocortin 4 receptor (MC4R)

Many studies have elucidated the role of the MC4R in regulation of food intake and energy expenditure. MC4R is widely expressed throughout the CNS, but has a very high expression level in the PVN of the hypothalamus (260). Historically, the primary agonist for MC4R has been considered to be α-MSH, although as discussed in this review, and reviewed elsewhere (311), other POMC derived peptide agonists such as des-acetyl α-MSH and β-MSH are likely to have similar physiological relevence. The primary agonist for MC4R is α-MSH, which is released from POMC neurons in the PVN. The antagonist for MC4R, AgRP, is also released in the PVN, from the orexigenic AgRP/NPY neurons. The release of both the agonist and the antagonist at the receptor allows for a complex regulatory mechanism for signaling via MC4R in the PVN.

5. Melanocortin 5 receptor (MC5R)

The function of the MC5R is not as well understood as the other MCRs. It is highly expressed during embryogenesis and is known to be involved in exocrine gland function. Its expression pattern is different to the other MCRs in that it is widely expressed in a large variety of peripheral tissues, however it is not expressed in the CNS (78). The primary ligand at MC5R is α-MSH, but ACTH, β-MSH and γ-MSH are also able to bind.

B. μ-Opioid Receptors

Clearly, β-endorphin is different to other POMC-derived peptides in that it does not have the MSH sequence and therefore does not signal through a melanocortin receptor, but instead binds to the μ-opioid receptor. Although β-endorphin is the only POMC-derived peptide said to bind this type of receptor, it is not clear whether its immediate precursor, β-lipotropin, might also bind the receptor. It is thought that in adult humans, POMC is primarily processed to β-lipotropin and so β-endorphin, would not be released from the pituitary to act on peripheral tissues. There is also the complexity as to how well other endorphins bind the receptors and the implications for morphine as a substrate.

μ-opioid receptors are expressed centrally in regions including the cortex, hippocampus, hypothalamus, and brain stem (292, 293, 301) and are widely expressed in peripherally tissues including pancreas (421), testis (126, 432),

Ovary (432) and kidney (432). These receptors not only mediate analgesic effects, but can also play a role in the regulation of feeding behavior (as described below).

VI. ROLES OF THE COMPONENT PEPTIDES OF POMC

In trying to understand the importance of POMC as the precursor to a number of peptides, the inevitable question arises of why there are several bioactive peptides in one precursor molecule (Figure 5). Is there a survival advantage to having a single mechanism regulating the production of several peptides with different functions? Is it just serendipity that several bioactive peptides are present in the one precursor? If it is serendipitous evolution, then there are very complex events to provide ACTH for its role in the HPA axis and a very different set of mechanisms to generate α-MSH as the key peptide in the melanocortin regulation of energy balance. Alternatively, it may be that researchers working in different fields have focused on specific aspects and not put as much emphasis into investigating how other parts of the precursor may be involved.

For researchers concentrating on the actions of α-MSH in regulation of food intake, it may not occur to them to question how POMC is processed to α-MSH and whether any of the other POMC-derived peptides could be contributing to the effect. For example, POMC is processed to ACTH and then to α-MSH, but processing may not be totally efficient in the hypothalamus and if some ACTH is present it could be acting at the MC4R. POMC itself has the amino acid sequence of α-MSH and could act at the MC4R, although because it is obviously a precursor molecule, we tend to think of it being efficiently processed and therefore not present outside the cell to act at receptors. However POMC is found in relatively high concentrations in human CSF (286, 403) as well as in rat CSF (312), while α-MSH is at least 10-fold lower than POMC and two fold lower than ACTH in rat CSF. The much lower concentrations of α-MSH are most likely due to rapid degradation. Interestingly in hypothalamic extracts, α-MSH is the most abundant of the three POMC peptides and yet its concentrations does not differ between lean and obese rats, while both POMC and ACTH are decreased in hypothalamic extracts in obese animals (312). There is no doubt that it is much harder to measure the different POMC peptides than it is to assess *Pomc* mRNA. The assays for the different peptides require slightly different extraction procedures especially when extracting them from hypothalamic tissue. These procedures can also affect the subsequent immunoassay and careful optimization is required to ensure the molar ratios are not affected by these processes.

Given that these precursors are present, is it the relative affinity at the MC4R that makes α-MSH the only relevant ligand? However α-MSH and ACTH have similar binding affinities at this receptor (311), although POMC is thought to have a lower affinity (White, unpublished data). Therefore, in understanding the dynamic roles of the different peptides, we need to address the relative importance of the processing pathway and the functionality of the different peptides.

A. The Role of ACTH

1. ACTH as an integral part of the HPA axis

The central role of ACTH in the HPA axis is undisputed. Clearly the major function of ACTH in stressful situations is to increase the concentration of glucocorticoids in the blood, enabling them to have their pleiotropic actions. We think of stress being evoked by trauma and pain, but other stressors such as hemorrhage, infection, cold, hypoglycemia, inflammatory reactions, fear, emotional events and exceptional exercise can all stimulate the HPA axis response.

When the HPA axis is stimulated, ACTH is released from the anterior pituitary within minutes, to travel to the adrenal gland and increase glucocorticoids. The most compelling evidence for the rapidity of the release of ACTH in humans, is where patients are investigated for a pituitary tumor by petrosal sinus sampling. In this investigation, patients are given CRH (peripherally) and the resulting increase in ACTH in the petrosal sinuses draining the pituitary occurs within two to three minutes (277). Therefore, this process must be stimulating release of preformed ACTH and this ACTH must be in secretory vesicles, having been processed from POMC and then stored in readiness to respond to stressful stimuli.

ACTH travels in the circulation and acts on the adrenal gland to cause the release of cortisol in humans and corticosterone in rodents. This occurs in the zona fasciculata where ACTH binds to the MC2R. The acute effect of ACTH in the stress response occurs in the mitochondrion, where ACTH stimulates transcription and translation of steroidogenic acute regulatory (StAR) protein, which in turn increases translocation of cholesterol from the outer to the inner mitochondrial membrane (14, 388). Cholesterol is then converted to pregnenolone by the enzyme P450scc and the enzymatic cascade results in cortisol or corticosterone (162, 250). This must occur very rapidly in situations where stress stimulates the HPA axis.

After an initial stressor, there may be a need to respond to another stress in a relatively short timeframe. It has been suggested that one of the reasons for having a precursor molecule is that it can be synthesized and stored in immature secretory granules. Therefore if there is a repeated stressor, it is possible to cleave POMC to ACTH quickly and release the bioactive molecule to provoke the stress response, without the need for stimulation of the POMC gene.

There is also a “basal” secretion of ACTH from the pituitary which has a diurnal rhythm and this in turn evokes a circadian rhythm in cortisol. However there is also a peripheral adrenal clock which modulates the diurnal rhythm of steroidogenesis, leading to the diurnal differences in cortisol release. Thus the basal ACTH secretion has an indirect role in modulating circadian biology, most obviously through initiating the cortisol rhythms (67).

2. Effects of ACTH on Adrenal Growth

The "non-stress" effects of ACTH on the adrenal gland include a role in increasing adrenal growth. This is somewhat controversial in that there are reports that this role is performed by a peptide from the N-terminal region of POMC (N-POMC 1-28) (see below). However ACTH has a role in adrenal cortical development (187, 197) and ACTH replacement in POMC knockout mice is sufficient to cause normal adrenal development (75).

3. Role of ACTH in the skin

There are well-recognized extra-adrenal effects of ACTH in the skin. These are evidenced in some patients with excess secretion of ACTH-related peptides, e.g. Addison's disease and some ACTH secreting tumors, where there is marked excess skin pigmentation, which decreases when ACTH levels are returned to normal (426). This role of ACTH is described below in Section IX.

4. Role of ACTH in adipocytes

Work in the 1970s suggested that ACTH had lipolytic activity in rat and rabbit adipocytes (320) and the effects of ACTH and MSH peptides on adipocytes have been reviewed by Boston (39). In addition to effects on lipolytic activity, ACTH and α-MSH can inhibit leptin expression and decrease insulin-induced glucose uptake, albeit mainly in murine 3T3-L1 cells (reviewed in (143)). Given that α-MSH is not produced by the human anterior pituitary, the relevance of a role for circulating α-MSH in humans is difficult to interpret. However MC2R is expressed in human mesenchymal cells undergoing differentiation into adipocytes (377) and therefore circulating ACTH may be involved.

5. Role of ACTH in lymphocytes

The effect of ACTH synthesis and action in the immune system in an autocrine or paracrine manner is more questionable. It has been shown that POMC is synthesized by lymphocytes (34) and that ACTH is produced, suggesting that the processing of POMC follows a pattern similar to the anterior pituitary, requiring the coordinated expression of PC1/3 and the presence of a regulated secretory pathway. There is also evidence for ACTH receptors on lymphocytes (70), although the functional significance of this remains difficult to ascertain. More recently it has been shown that ACTH controls growth of the thymus and that this is not via stimulation by glucocorticoids (392).

Figure 5: POMC processing generates numerous functional peptides

B. The role of α-MSH

1. α-MSH from the pars intermedia of the pituitary in rodents

While rodents have provided extremely valuable data in the understanding of POMC processing, there are some limitations which are often ignored. This is the

case with POMC expression in the pituitary. In the adult human pituitary, which does not have a pars intermedia (228), POMC is only expressed in corticotroph cells in the anterior lobe. In contrast, rats and mice have a pars intermedia, comprised primarily of melanotrophs. Processing of POMC in the pars intermedia is similar to that in the hypothalamus, and this produces α-MSH and CLIP, rather than ACTH (233). This suggests that these smaller peptides are released into the circulation and must be in high concentrations in the blood of rodents. It is not clear what the functional significance of this is, as α-MSH does not bind with high affinity to the MC2R, so will not affect glucocorticoid release. An important corollary to this is that α-MSH is not produced by human pituitaries and so will not be released from the pituitary into the blood. It is also thought unlikely that α-MSH from the hypothalamus gets into the circulation, given it is not present in CSF in rats (312). However, there are reports of low levels of α-MSH in human blood (172, 190) which may be skin derived (see Section IX).

2. The role of α-MSH in other tissues

With the explosion of research into the role of the melanocortin system in the regulation of energy balance and its implications for obesity, there is no doubt that this is considered the most important function of α-MSH (Figure 4). However as its name suggests, the role of α-melanocyte stimulating factor in darkening of frog skin was recognized many years earlier and this formed the basis of a bioassay for α-MSH (245). Subsequently the role of melanocortin peptides in human skin has led to the suggestion that this evolution of POMC processing in skin is equivalent to a primeval stress axis (361).

3. Relative roles of α-MSH and its precursors: processing is key to function

As described above there is a very well-defined set of intricate processing steps starting from the precursor peptide, POMC, and resulting in α-MSH (314). You could hypothesize that these processing steps have evolved in order to refine the regulation of energy balance. α-MSH certainly binds to the MC4R, but with affinity similar to des-acetyl α-MSH, β-MSH and ACTH (144, 260, 311) and all four peptides have similar potency in stimulating cAMP which is required for MC4R signaling (311).

Central administration of α-MSH to POMC null mice reduced food intake to 35% of sham-treated animals and three days treatment reduced body weight (405). This confirmed earlier studies where administration of α-MSH to rodent brains reduced food intake (1, 247, 251, 310). However other studies also showed that the α-MSH precursors, des-acetyl α-MSH (at high doses) and ACTH, had similar effects (4, 189). This is controversial as there is also evidence that des-acetyl α-MSH injected into the brain had no effect on food intake (1, 261, 404).

However, a recent study has generated a new mouse model where the cleavage site in ACTH, which is necessary to generate α-MSH, has been mutated. By treating these mice with either α-MSH or des-acetyl α-MSH, it has highlighted the

importance of des-acetyl α-MSH, by showing it can have an equivalent effect to α-MSH in reducing body weight (259).

If ACTH can bind to the MC4R and inhibit food intake, what is the purpose of processing ACTH to α-MSH, given this involves cleavage of ACTH to ACTH (1-17), removal of amino acids 14-17, and then amidation and acetylation? Is it more that the key question is which peptides are stable in the POMC neurons in the hypothalamus and which peptides are presented to the MC4R? We have previously shown that ACTH and POMC were present in rat CSF and regulated by fasting, while α-MSH was undetectable (312). However in hypothalamic extracts, we found that α-MSH was present at higher concentrations than POMC or ACTH and the ratios were altered depending on energy requirement (312). Early work suggested that α-MSH's immediate precursor, des-acetyl α-MSH, was the major product in the ARC with lesser amounts of α-MSH and ACTH, while α-MSH predominated in the NTS in the brain stem (113, 114). Other studies also suggest that des-acetyl α-MSH is more abundant than α-MSH in the ARC (97, 156, 182, 201, 296, 328), but not in the brainstem (103). This seems at odds with reports that des-acetyl α-MSH is relatively unstable compared to other POMC-derived peptides (156, 272).

It is difficult to distill a coherent mechanism from the contradictory data. There is evidence that the acetylation of des-acetyl α-MSH to generate α-MSH is regulated by leptin (156) and may be regulated by dopamine (127, 252, 410, 412), although others suggest this is not the case (95). If the final stage in the processing pathway is important for the flux of peptides at the MC4R, this would imply that the N-AT acts on des-acetyl α-MSH at the synapse/bouton/neuronal extremity (Figure 3) (258). Given that the POMC neurons release their peptides in the PVN to act on the MC4R, it is tempting to speculate that future studies should focus on the regulation of whichever peptide is released in proximity to the MC4 receptor.

Although much of the focus on the function of α-MSH relates to suppression of food intake, there is evidence of a role for MC4R in mediating increased energy expenditure (48), oxygen consumption and fuel oxidation. Melanocortin regulation of these metabolic processes appears to occur via the sympathetic nervous system. There is some evidence for this from central injection of MT-II, a very potent synthetic melanocortin peptide analogue, which led to loss of body fat in rats. This was caused by enhanced thermogenesis mediated via sympathetic nervous system outflow to white and brown adipose tissue (359, 430, 444). However the significance of this to in-situ physiological mechanisms is not clear.

C. Role for β-LPH as a precursor of β-endorphin and β-MSH

Early work suggested that β-LPH had a role in mobilizing lipid; hence its name (326) and subsequently that it was the new aldosterone stimulating factor (240). However over the years, it has become established that β-LPH functions primarily as a precursor for β-MSH and β-endorphin. In the human pituitary, β-

LPH is unlikely to be further processed, as the cleavage sites require PC2 which is not present. Therefore β-LPH should be released into the human circulation in molar equivalents to ACTH. We have previously identified β-LPH as the major C-terminal POMC peptide in blood from normal subjects (148, 149). However, several reports suggest that β-endorphin is increased in human plasma with exercise (196). While it may be that exercise specifically changes the processing to give β-endorphin, it could also be explained if it was primarily β-LPH present in the circulation and the β-endorphin immunoassay cross-reacted with β-LPH.

D. The role of β-MSH in energy balance

The impact of β-MSH is somewhat controversial. While β-MSH is present in the human brain, the N-terminal cleavage site to generate β-MSH is not found in rodent POMC (16, 258). Studies have shown that β-MSH binds MC4R with similar affinity to α-MSH and has a similar potency (311). In addition, β-MSH is able to reduce food intake in corticosterone-supplemented *Pomc* null mice, although to a lesser extent than α-MSH (405). Evidence for a role for β-MSH also comes from studies in humans with mutations in β-MSH. Our colleagues in Cambridge have described an obese child with a mutation in POMC that creates a fusion protein of β-MSH and β-endorphin, preventing cleavage of these peptides. One possible hypothesis to explain why α-MSH was not sufficient to prevent the obesity is that the fusion peptide had a dominant negative effect (57). Three subsequent papers (30, 216, 217) describe other mutations in β-MSH that contribute to the evidence that this peptide does have a role in energy balance, which should be considered alongside that of α-MSH. This is described in more detail in Section VII. Intriguingly some Labradors noted for their voracious appetites have loss of the β-MSH sequence. This is caused by a mutation that results in a truncated POMC which loses part of the β-LPH region encompassing β-MSH and β-endorphin (318).

E. The roles of β-endorphin (Figure 5)

1. The opiate activity of β-endorphin

The highest concentration of β-endorphin in the brain is found in the hypothalamus and specifically in the arcuate nucleus, median eminence and ventromedial border of the third ventricle (440). β-endorphin (1-31) is the major form and is active at opioid receptors (see commentary by Loh (223)). As described above, β-LPH is cleaved by PC2 to give γ□LPH and β-endorphin which can be further cleaved by CPE to β-endorphin (1-27) and β-endorphin (1-26), which have much less analgesic activity (269). These enzymes act in secretory granules within cells, so this implies that the cleavage of β-endorphin to the C-terminally truncated β-endorphin peptides is a mechanism to reduce opioid activity in tissues where other POMC peptides are released for non-opioid functions. Acetylation of β-endorphin at its N-terminal is also a mechanism for reduction of opioid activity (92) and this occurs in the pars intermedia of the pituitary and in the brainstem (440). In the NTS, there are POMC expressing neurons that primarily produce β-endorphin, but there is also a considerable

amount of α, N-acetyl β-endorphin (1-27), which would be much less bioactive (103, 440).

The first indication that β-endorphin acts at opiate receptors was in 1976, when it was shown to be 100 times more potent than morphine (132). The sequence of met-enkephalin at its N-terminal is obviously responsible for the opiate activity, but β-endorphin has much longer-lasting effects compared to the transient activity of the enkephalins. This has been attributed to its sequence, which confers resistance to degradation. There is also the suggestion that the more C-terminal region of β-endorphin acts in "an address function", by presenting the peptide to the receptor to aid specificity and potency (378). This could be considered another advantage of the presence of a peptide within a larger pro-hormone structure.

Given that β-endorphin is produced in POMC neurons in the arcuate nucleus of the hypothalamus, it is difficult to rationalize how POMC is stimulated to specifically produce β-endorphin to have its analgesic function in a physiological setting. However immunohistochemical staining for β-endorphin has demonstrated its presence in nerve terminals that extend dorsally and laterally and it can be found in the amygdala, colliculi and hippocampus. While there is evidence for the role of β-endorphin in energy homeostasis (see below), there are very few reports which link how stimulation of POMC expression specifically drives analgesia without releasing the melanocortin peptides, which should have an important role in increasing energy expenditure and inhibiting food intake. It is tempting to speculate that this is where a hormone precursor is providing different peptides with different roles but with a common theme of coordinating a response to pain as a self-preservation mechanism.

In a very elegant study, Rubinstein *et al.* produced mice with a targeted mutation that inserted a premature stop codon in the POMC gene to prevent the synthesis of β-endorphin (334). These mice were not able to mount an analgesic response to a mild swim stress and had a compensatory upregulation of other pain inhibitory pathways. This does suggest that a stress activation of POMC would produce an analgesic response mediated by β-endorphin.

2. Role of β-endorphin in reproductive function

Early work on endogenous opioid peptides, including β-endorphin, indicated that they inhibited gonadotropin secretion (133) and the opioid antagonist, naloxone, stimulated luteinizing hormone release in men and women (122, 315). The mechanism was elucidated in studies in rats and involves the release of hypothalamic β-endorphin into hypophysial portal blood, which is stimulated by ovarian steroids (342) and inhibited by testosterone (418). An interesting aspect of the precursor role of POMC is that in producing both α-MSH and β-endorphin there is the potential to have two peptides which antagonize each other. α-MSH blocks both stress-induced and β-endorphin-stimulated release of prolactin in rats (267). In monkeys, α-MSH has a similar effect on β-endorphin induced prolactin and blocks the β-endorphin mediated decrease in luteinizing hormone

(419).

3. Hypothalamic β-endorphin function and regulation of energy balance

Given that many of the component peptides of POMC have a role in energy balance, it is important to consider whether β-endorphin may also be involved in some capacity. Mechanisms regulating the release of melanocortin peptides from POMC in hypothalamic neurons will generate β-endorphin. However, it is important to consider whether the β-endorphin actions are synergistic with those of the melanocortins, or whether they are not commensurate, implying that they would oppose each other. If it is the latter, then there may be processing mechanisms to inactivate β-endorphin when melanocortins are activated and vice versa. Although inactivation by acetylation of β-endorphin is not thought to occur in the hypothalamus (258), it may be that processing to β-endorphin (1-27) and β-endorphin (1-26) is a mechanism which at least reduces its activity (269). As early as the 1920's there were suggestions that the endogenous opioid system was involved in the regulation of food intake and body weight, with morphine causing a decrease in body weight but a "voracious" appetite. However, there is a lot of contradictory data in both animal and human studies (12). Nevertheless, more recent compelling data from a study of mice with deletion of β-endorphin showed that the male mice were obese and hyperphagic (9). This suggests that loss of β-endorphin results in hyperphagia, highlighting an unexpected anorexigenic effect of endogenous β-endorphin, which parallels the melanocortin actions of the other peptides derived from POMC. Nevertheless, β-endorphin is involved in a motivational reward behavior in non-deprived conditions (227) and other studies have found stimulatory effects on feeding (36), suggesting that there are two different roles for β-endorphin depending on the circumstances. This concept would support the finding that cannabinoid-induced feeding is dependent on β-endorphin (203).

In considering the endogenous POMC activity, it is difficult to rationalize the concept that several peptides are produced simultaneously which have opposing actions. This is nevertheless implied by the fact that α-MSH and β-MSH causes anorexigenic actions while, β-endorphin stimulates feeding. It may be that the regulation of POMC processing events underpins how effective POMC peptides are in coordinately regulating energy balance. Dutia *et al.* gave β-endorphin by intracerebroventricular injection and compared food intake and body weight gain in rats when an analogue of α-MSH (NDP-MSH) was co-administered (112). When β-endorphin was given over 2-6 hours, it stimulated food intake and it reversed the inhibitory effect of NDP-MSH on food intake. However with more chronic dosing over 4-7days, β-endorphin failed to antagonize the effects of NDP-MSH.

This still leaves several questions regarding the mechanisms that balance the effects of melanocortins and β-endorphin on energy balance. Given there are so many regulatory stages in the processing of POMC, it suggests that processing has evolved in such a way to provide subtle regulation of active peptides in the hypothalamic neurons.

4. Role of β-endorphin in skin

It has also been suggested that β-endorphin has very specific roles in the skin and this is described in Section IX.

F. Roles for the N-POMC peptides (Figure 5)

Compared with the other regions of POMC, there are fewer reports on functional roles for the POMC-derived peptides that are linked to the N-terminal of ACTH, at least in the human. It may be that there has been relatively less research in this area, rather than that the peptides do not have physiological roles. To our knowledge, there are relatively few mutations in this region that inform function, and in the human these are involved in obesity (128). However, many of the mutations in this region would also affect the translation of POMC.

1. The role of N-terminal POMC peptides in adrenal growth

There is a wide body of data from the 1980s, described in detail in a review by Bicknell (27), which suggests that a fragment of human N-POMC increases rat adrenal gland weight and mitotic index (124). Previous work had indicated that the full-length N-POMC peptide (1-76 in humans and 1-74 in rats) was not active (123). The most effective fragment was N-POMC (1-28), which had been isolated from human pituitaries as part of the purification of growth hormone (124) but was known to be a purification artefact so presumably didn't exist normally in pituitaries (246). Subsequently in rats, N-POMC (1-28) partially regenerated adrenal glands which had been enucleated (125). Further work provided evidence that the N-POMC (1-28) peptide stimulated cell division in primary bovine adrenal cells, Y1 cells and human adrenal tumor cells (NCI-H295-R) (131). However, when N-POMC (1-28) was given to mice with a null mutation in the *Pomc* gene, there was no effect on adrenal growth, and no change in adrenal morphology, in a setting where ACTH (1-24) caused adrenocortical hypertrophy (75).

Later work with Y1 adrenal cells has extended the analysis of how synthetic N-POMC (1-28) stimulates the pathways involved in cell proliferation (reviewed in (226)). There is evidence that N-POMC (1-28) increases phosphorylation of ERK1/2 as well as activation of MEK and c-RAF (303). This has been complemented with studies in isolated rat adrenal cells showing activation of the ERK pathway by N-POMC (1-28) (241) and *in vivo* in rat adrenal cortex where synthetic N-POMC (1-28) up-regulated proliferation and blocked apoptosis (401).

In parallel with the earlier studies described above, the group led by Phil Lowry injected antisera raised to N-POMC (1-28) and to a synthetic γ_3-MSH peptide into rats. They found different effects on compensatory adrenal growth in the contra-lateral gland, following the removal of the other adrenal gland (229). They suggested that N-POMC (1-48/49) stimulates DNA synthesis and mitogenesis,

while a second region in N-POMC (i.e. γ_3-MSH) increases RNA synthesis and hypertrophy (229).

In essence, the early work showed that full-length N-POMC was not active in stimulating adrenal growth, but that the shorter N-POMC (1-28) was able to stimulate adrenal gland mitogenesis. This led to the hypothesis that N-POMC had to be cleaved to have effects on adrenal growth. N-POMC (also called pro-γ-MSH) can be measured in human plasma (58, 148, 160) and is one of the main products secreted from rat pituitary corticotrope cells (117, 181), indicating that it is likely that this is the major N-terminal POMC peptide in the circulation. Therefore any cleavage of N-POMC would occur at the target cells i.e. at the adrenal cortex. The discovery of a rat adrenal gland derived trypsin-like enzyme called adrenal secretory protein (AsP) is described in detail in Bicknell (27). This enzyme cleaves between valine and methionine and so would generate N-POMC (1-52) which can stimulate adrenal mitogenesis (28). However, there is evidence that the human equivalent of AsP does not have a physiological role in regulation of adrenocortical growth because of low expression of the enzyme in human adrenal tissue (158).

It is difficult to resolve some of the inconsistencies in the understanding of the role of N-POMC peptides, because the large body of data has used different peptides and various models, which are not always comparable. One possibility may be that N-POMC (1-28) is an extraction artefact and there is evidence that N-POMC (1-48/49) may not circulate to get to the adrenals because the O-glycosylation at Thr_{45} inhibits cleavage at Arg_{49}-$Lys_{50,}$ which is a likely site for pro-hormone convertases (348). The presence of full length N-POMC in human plasma substantiates the evidence of a lack of cleavage in human pituitary cells. Therefore, if fragments of the N-POMC peptides play a role in adrenal mitogenesis, it would have to be after cleavage at the adrenal gland. However, it seems that the human equivalent of AsP is not capable of this role.

It may be that stimulation of growth of the adult adrenal cortex by POMC peptides is more physiologically relevant than it is in the fetus. There is evidence for this in *Pomc* null mice where the adrenal glands undergo atrophy after birth. Transplantation of these adrenals into wild-type mice rescues growth and corticosterone production (188). This implies that some POMC-derived peptides restore growth and steroid secretion in mice. However it is not possible to determine which POMC-derived peptides are responsible, although there is evidence for and against ACTH (reviewed in (27, 226)).

2. The role of N-terminal POMC peptides in salt-sensitive hypertension

There is some intriguing evidence about the role of γ-MSH and its effects on natriuresis and control of blood pressure (reviewed in (174)). Several studies have shown that γ-MSH can have a hypertensive effect, acting via a central mechanism. However other studies have indicated the opposite effect. In PC2 knockout mice, where there is decreased γ-MSH, hypertension occurred on a high salt diet and treatment with γ-MSH prevented the increased mean arterial pressure. Absence of the *Mc3r* gene also caused a hypertensive effect (268). In

addition, there is some suggestion that γ-MSH acts directly on MC3R in the kidney to play a role in natriuresis, while other evidence points to a central role acting via sympathetic outflow on the periphery.

Our understanding of these mechanisms is complicated by the fact that in mouse, rat and guinea pig, γ-MSH may not exist as a separate peptide, because the C-terminal region does not have the dibasic amino acids to allow cleavage from the N-POMC region (114). In the studies described above on adrenal growth, it was presumed that the full length N-POMC is released from the anterior pituitary and therefore γ-MSH would only be released from the pars intermedia of the pituitary, which is rudimentary in humans. Therefore, the relevance of these mechanisms in humans needs further clarification. It is tempting to speculate that if there is an enzyme which cleaves N-POMC at the adrenal to produce a peptide which promotes adrenal cortex mitogenesis, then the same enzyme may also be present in the kidney to generate peptides that stimulate natriuresis.

The evolution of POMC as a precursor of peptides with multiple actions leads to the question of whether it would be valuable to have a response that releases stress hormones and a natriuretic hormone that decreases blood pressure. Perhaps this overlooks the subtlety of the system and these two responses have evolved to respond to different stimuli in different tissues.

3. Role of γ-MSH in energy balance

While there is clear evidence that α-MSH plays a role in decreasing food intake, it is more difficult to determine the relative importance of γ-MSH peptides and the net effect of coordinated processing of POMC. It is predicted that γ_3-MSH and γ_2-MSH can be produced in the hypothalamus in humans, but that γ_3-MSH cannot be processed to γ_2-MSH or γ_1-MSH in rats and mice because of the lack of suitable dibasic amino acids (114). It is also difficult to find direct evidence that indicates a role for these peptides in energy balance. γ_2-MSH binds to the mouse MC3R (and MC5R) better than to other MCRs (184) and the MC3R is important for energy homeostasis (reviewed in (258)), although it does not appear to have a role in food intake (1). However α-MSH has comparable binding activity to γ-MSH at the human MC3R (reviewed in (198)) so it is not clear which is the natural ligand at least in the hypothalamus.

G. Does joining peptide have a role?

There is very little evidence for a role for joining peptide. There was a suggestion that a peptide identical to joining peptide (1-18) stimulated production of dihydro-epiandrostenedione (DHEA) from adult human adrenal cells (297) and was therefore designated as the missing cortical androgen-stimulating hormone (CASH). However, other studies have failed to find evidence for this in adult (302) or fetal (330) adrenal cells.

VII. DISORDERED PROCESSING IN THE HYPOTHALAMUS; CHILDREN WITH OBESITY

A. Mutations in *POMC* lead to obesity

The processing of human POMC is very different in the hypothalamus to that in the pituitary. In the hypothalamus it involves the sequential effects of two pro-hormone convertases and numerous post-translational modifications to generate the melanocortin peptides, α-, β- and γ-MSH. Both α- and β-MSH are recognized to have important roles in the regulation of energy balance and either loss of POMC or disruption of pro-hormone processing results in severe obesity. The following examples in children give insights into the importance of the pro-hormone and the requirements for the different melanocortin peptides.

1. Early studies linking mutations in POMC to obesity

The earliest reports suggesting mutations in the POMC gene were associated with obesity came from linkage studies in Mexican Americans. In this analysis, patients with increased leptin levels had a polymorphism which was mapped to chromosome 2p21, where *POMC* is located (76). Another linkage study showed that French subjects had a similar mutation in chromosome 2p21, demonstrating that the mutations were found in other ethnicities and cultural backgrounds (157). These studies were carried out in advance of the *POMC* gene deletion in mice and gave an initial association between mutations in *POMC* and increases in leptin and fat mass.

2. Mutations leading to global loss of POMC peptides

The strongest evidence for a link between mutations in POMC and obesity comes from children who have either homozygous or compound heterozygous mutations in the gene, leading to the absence of all melanocortin peptides. One of the first patients described had a homozygous C → T mutation at 3804 in exon 2, which is in an untranslated region. This created an additional out of frame start codon which abolished the translation of wild-type POMC. The clinical features observed in the patient are linked to the loss of binding of POMC derived peptides to the MCRs in specific tissues. The patients had red hair, indicating lack of binding to MC1R, they were hypocortisolemic due to absence of ACTH binding to MC2R and obese due to deficiency in MSH binding to MC3R and MC4R (207). The same group later described another patient with the same mutation and phenotype (208).

Heterozygous mutations in the non-coding region have also been described and are associated with obesity. By screening obese populations, two patients were found with different heterozygous mutations in exon 2 of the *POMC* gene. These have been implicated in disruption of POMC sorting to the regulatory secretory pathway. Examination of the processing in these patients indicated that the mutations had interfered with the entry of POMC into the normal regulated secretory pathway (86). This disruption to the processing of POMC and the reduction in processed peptides was associated with the development of obesity.

3. Mutations in the N-terminal region of POMC

In the initial paper describing children with a lack of POMC, one of the patients showed two separate mutations in exon 3 of *POMC*, giving a compound heterozygous mutation. The first mutation was a G → T substitution at nucleotide 7013, leading to a premature stop codon at codon 79. The second mutation was a single base pair deletion at nucleotide 7133, predicating a frame shift which would disrupt ACTH and α-MSH binding motifs as well as inserting a stop codon at 131. Similar to the patient with the homozygous mutation in the non-coding region of *POMC*, this patient also had red hair, decreased cortisol and obesity (207). As both α- and β-MSH are disrupted by these mutations, it is difficult to clearly discern their relative importance.

The same research group later characterized two further children who also had mutations in the N-terminal region of *POMC*. They both had compound heterozygote mutations with a frame shift or a premature stop codon, preventing translation of the region with ACTH and the MSH peptides. These patients were obese and also had red hair due to the lack of melanocortin peptides (208).

The first patient to be described without red hair was a Turkish child with a novel homozygous frame shift mutation at nucleotide 6906, though he did have dark red follicles. This mutation would be predicted to lead to a loss of all POMC derived peptides. As with the other patients, this child had severe hyperphagia leading to early onset severe obesity. (129). The association between heterozygous mutations in *POMC* and obesity was strengthened in this study. Of the 12 heterozygous relatives of the child, 11 were overweight or obese (129).

Other novel mutations in the ACTH region of POMC have been described, where the POMC derived peptides are still immunoreactive, but have lower biological activity (339). A more recent study described a patient with red hair who had moderate obesity at an early age, with undetectable plasma ACTH and serum cortisol. This index case was a compound heterozygote with one mutation in the N-terminal region of *POMC* and the second mutation upstream from the coding domain. The latter affected a region involved in translation of the protein such that there was preserved but markedly diminished levels of wild-type POMC transcript (7).

Other patients have been described with mutations in this region. The hair colour phenotype has not been observed in all patients, even when mutations were predicted to lead to an absence in α-, β-, and γ-MSH as well as β-endorphin, (71, 248). However, all patients identified with deletions in the N-terminal of *POMC* have severe obesity (71, 167, 248, 254).

4. Mutations in the α-MSH region

There are very few reports of mutations in this region. Studies examining patients with severe obesity have occasionally identified heterozygous mutations in the α-MSH region of *POMC*. However, these mutations were rare in the obese

population and were also found in the lean control population, indicating that the loss of one allele of α-MSH can be tolerated in the context of energy balance (109, 216), and/or that β-MSH plays a more important role. There is some evidence to substantiate this in the section below.

5. Defects in the β-MSH and β-endorphin regions of the POMC gene

Mutations in the β-MSH region of POMC have strong associations with obesity. During screening studies of patients with early onset obesity, patients have been described with a heterozygous R236G mutation in the highly conserved dibasic processing site between β-MSH and β-endorphin (46, 57, 254). This mutation led to the formation of a fusion protein of the 2 peptides, which was able to bind MC4R, but was less functional (57). These patients have the characteristic hyperphagia and early onset obesity associated with reduced binding to MCRs (57). Interestingly, there were relatives of the index patient who were also heterozygous for the mutation. Although they did not have the severity of obesity observed in the index case, they were more likely to be overweight than a relative without the mutation (57).

Another mutation identified in the β-MSH region is the Y221C mutation. This altered form of β-MSH was able to bind MC4R, but was unable to activate it. This mutation was strongly associated with obesity, as 11 of 13 relatives with the same heterozygous mutation were obese. However, some non-carriers were also found to be overweight (30, 216), indicating that at least in this kindred, the obesity phenotype cannot solely be as a result of the mutation in β-MSH.

6. Variants in the γ-MSH region of POMC

The have been multiple reports of many subjects with 6, 9 and 19 base pair insertions in the γ-MSH region of POMC, in screening studies investigating POMC mutations in obese patients from different ethnic backgrounds. Although these insertions have been found in the obese cohort, they have also been identified in the normal weight participants making it difficult to associate these insertions with obesity (116, 167, 254, 340).

B. Mutations in PC1/3 cause obesity

Many of the early papers characterizing patients with mutations in PC1/3 predate the discovery of leptin and were seminal in defining novel monogenic causes of obesity. As with POMC mutations, homozygous or compound heterozygous mutations in PC1/3 cause severe hyperphagia leading to early onset obesity (130, 179, 180, 239, 274). This is most likely related to the abnormal processing of POMC. These patients have been found to have high levels of POMC (130, 179, 180, 274), but with normal circulating ACTH or normal to low cortisol levels (130, 179, 239, 274). The ACTH has been shown to be authentic, bioactive ACTH (179), which was surprising since PC1/3 mutations would be expected to prevent cleavage of POMC to ACTH. This indicates that in some instances, other enzymes such as PC5A, furin and PACE4 may be able to act in place of PC1/3.

As PC1/3 cleaves numerous pro-peptides, a plethora of other clinical phenotypes were noted in these patients. For example, with an impairment of the cleavage of pro-insulin to insulin, these patients also had abnormal glucose metabolism. (130, 179, 274).

Initial analysis of heterozygous PC1/3 loss was not thought to have any metabolic sequelae, as heterozygous parents of index subjects without a functional copy of PC1/3 were not obese (130, 179, 180). However, further human genetic analysis, both of the *PCSK1* gene (85) and SNPs in this gene (21), suggest this may not be the case. For example, a nonsense mutation in *PCSK1* has been reported to cause dominantly inherited obesity (306) even though *in vitro* bioactivity predicts as little as 20% reduction in enzyme activity (306).

PC1/3 mutations appear to be the only mutations in POMC processing enzymes associated with obesity in humans. Surprisingly, to date, no obese patients have been described with mutations in PC2. A screening study of families with type 2 diabetes found a mutation in carboxypeptidase E, but the authors concluded that the mutation was not a significant cause of the diabetes (63).

VIII. DISORDERED PROCESSNG IN THE HYPOTHALAMUS; MICE WITH OBESITY

A. Global deletion of POMC

To investigate the role of POMC and its processed peptides, mice with a global knockout of POMC have been developed. There have been two separate approaches to removing POMC, both involving the deletion of exon 3. The original model left the possibility that the N-terminal fragments of POMC could still be transcribed (437), but the later version ensured this was not possible (56). Both strains experienced some embryonic lethality (56, 437), indicating the importance of POMC in development and maturation in utero.

Overall, the loss of POMC has a significant impact on the metabolic phenotype of the mouse with much concordance between reports. *Pomc* null mice develop obesity from around 2 months of age, have increased fat and lean mass (56) and an increase in body length (437). The obesity seen in the original model persisted when the mutant allele was backcrossed onto a C57Bl/6 background (371). Both murine models were hyperphagic on low and high fat diets (56, 437) with administration of α-MSH to one of the *Pomc* null models able to ameliorate the hyperphagia and bring about weight loss (437). A lower resting oxygen consumption seen in one model (56) may have an additional role in the development of obesity. *Pomc* null mice have a normal glucose tolerance but they have an increased sensitivity to insulin, likely due to their corticosterone deficiency (170).

Pomc null mouse models have also highlighted the importance of the POMC derived peptides in the maintenance of adrenal gland development. There has

been controversy around which peptides contribute to adrenal gland growth, with evidence for both ACTH and N-POMC peptides as key to the process. At birth, POMC knockout mice have adrenal glands that are morphologically indistinguishable from those of their wild-type littermates (188), but by adulthood, these mice have either no macroscopically determinable (437) or very small but identifiable (56, 371) adrenal glands. The lack of POMC in these mice results in no circulating ACTH, and consequently they lack circulating corticosterone (56, 371, 437), even prior to atrophy of the adrenal glands (188). Acute administration of ACTH appeared insufficient to induce corticosterone production (188), however a longer treatment period normalized adrenal weight and circulating corticosterone (74). In contrast, treatment with POMC (1-28) did not "rescue" the adrenal glands (75). Furthermore, when adrenal glands from knockout mice were transplanted into POMC-intact mice they were able to produce corticosterone (188) showing the importance of POMC derived peptides in maintenance of adrenal gland corticosterone production. Together these results demonstrate that ACTH is required to maintain adrenal gland function.

In these *Pomc* null mouse models, the impact of loss of hypothalamic *Pomc* on body weight may have been tempered by lack of pituitary ACTH and therefore lack of corticosteroids. This has led to an interesting phenotype of obesity in the absence of circulating glucocorticoids. Therefore to investigate the full impact of the loss of POMC in the presence of glucocorticoids, two approaches have been reported: (1) administration of corticosterone in drinking water and (2) restoration of POMC in the pituitary to enable ACTH production and then corticosterone synthesis. In the first approach, corticosterone supplementation normalized the circulating corticosterone in *Pomc* null mice, but significantly increased body fat and body weight further. (73). This was associated with a significant increase in the expression of the MC4R antagonist, AgRP (73). In the second approach, Malcolm Low's lab introduced a POMC transgene into the pituitary of POMC knockout mice to rescue POMC derived peptides in the pituitary (372). In contrast to the global POMC knockout mice, this transgenic line had large adrenal glands and while female mice had a normal corticosterone diurnal rhythm, males had both exaggerated peak and nadir levels leading to overall higher levels of corticosterone, in keeping with a Cushing's type syndrome (373). Compared to POMC knockout mice, these pituitary rescued POMC knockout mice were even more hyperphagic and developed a greater degree of obesity. Additionally, they developed hyperglycaemia and insulin resistance with hepatic steatosis (372), likely to be due to the excess pituitary ACTH increasing glucocorticoids.

To elucidate the role of hypothalamic POMC, and in particular α-MSH, at different stages in the evolving obesity seen in global POMC deficiency, another murine model was established that allowed for re-expression of hypothalamic POMC at different ages in global *Pomc* null mice. As one might expect, restoration of neuronal POMC and α-MSH expression at all ages effectively normalized the hyperphagia in *Pomc* null mice. However, the effectiveness of this treatment to normalize body weight and diminish adipose mass declined progressively as the age at which *Pomc* was inducted increased, with a diminished impact on body fat reduction in older, and hence fatter, mice (45). Finally, in yet another mouse

model, re-expression of *Pomc* solely in hypothalamic neurons expressing the leptin receptor was sufficient not only to normalize the increased body weight and food intake observed in the global *Pomc* null mice but also to correct alterations in glucose homeostasis and locomotor function (212).

Together, a range of mouse models with genetically altered POMC have helped to elucidate the roles of POMC in many aspects of adrenal development and metabolic homeostasis. Perhaps surprisingly however a distinct coat color phenotype was only clearly seen in POMC null mice on a 129 background (56).

B. Loss of PC1/3: implications for POMC

1. PC1/3 null mice

The importance of POMC as a precursor compared to the derived peptides should be determined by the knockout of PC1/3, as this has the potential to produce POMC *in vivo* without any of the peptides derived from it. However, the reality has proved much more complex, because of concomitant lack of processing of other peptides and the potential for cleavage of POMC by other peptidases.

The role of PC1/3 in the cleavage of POMC *in vivo* was first elucidated in PC1/3 null mice developed in 2002. These mice have increased unprocessed POMC in the pituitary and a lack of processing to ACTH (291, 449). Surprisingly, even though there was an absence of ACTH, there was no difference in corticosterone (449), suggesting that perhaps the higher levels of POMC could compensate for the lack of ACTH. However, this has not been confirmed by other studies (387). Relative levels of other POMC-derived peptides were not altered in PC1/3 null mice (291), indicating some adaptation or compensation. Either PC2 or another enzyme must be in place to maintain the levels of other POMC-derived peptides.

The first PC1/3 null mice were not obese, unlike patients with mutations in the gene (see Section VII). This may not be as surprising as it first seems, because the mice have unaltered levels of POMC cleavage products including αMSH. PC1/3 null mice also have other metabolic abnormalities, including undetectable levels of insulin in pancreatic islets as they are unable to cleave pro-insulin to insulin (448).Intriguingly, despite this marked hyperproinsulinemia the mice appear not to have an impairment of glucose tolerance. (449).

A second PC1/3 null mouse was developed by Seidah and Chrétien in 2007. However this mouse was embryonic lethal and therefore could not be used in further experiments (243).

2. PCSK1-N222D hypomorph mouse

Interestingly, a single point mutation in the *Psck1* gene led to a mouse with an obese phenotype, similar to that seen in patients with these mutations. This Pcsk1-N222D hypomorph mouse had a 60% reduction in PC1/3 activity (221). Unlike the PC1/3 knockout mouse, this strain was a normal size due to its ability

to process pro-GHRH (386). These mice developed obesity and by 6 months, males were 32% heavier and females 68% heavier then their wild-type littermates as a result of increased fat mass (221).

In the hypothalamus, the expression of the *Pomc* gene in Pcsk1-N222D hypomorph mice was similar to wild-type mice, but they had a 45% reduction in α-MSH, which may have a played a role in the observed hyperphagia and could have contributed to the obesity (221). There was also impaired processing in the pituitary, in that they had increased pro-ACTH levels compared to wild-type mice (386). Surprisingly the Pcsk1-N222D hypomorph mice had a slight elevation in ACTH which supports the theory that processing of POMC to ACTH may not be completely dependent on PC1/3 (221).

C. PC2 knockout mice: Implications for POMC processing

The PC2 knockout strain was developed in 1997 by deletion of exon 3. The mice appeared normal at birth, but grew at a slightly slower rate and had normal fat distribution and mass (140). In addition, PC2 null mice had high circulating ACTH, but normal circulating corticosterone (300). Abnormalities in the processing of POMC in both the pituitary and hypothalamus were noted. The pituitary had reduced *Pomc* mRNA levels, but both the glycosylated and unglycosylated forms of POMC protein were increased (213). This was accompanied by increased pituitary ACTH concentrations (213, 300) and higher numbers of secretory granules (213), which was consistent with the elevated POMC and ACTH concentrations. The pituitaries from PC2 knockout mice also contain increased amounts of β-LPH, and reduced amounts of its cleavage products γ-LPH and β-endorphin due to the lack of processing (213). Depending on the method of detection, α-MSH was found to be either absent (213) or very diminished (161). Furthermore, des-acetyl α-MSH, di-acetyl α-MSH forms and CLIP were also found at much lower levels than in wild-type mice (161).

In the hypothalamus, the levels of POMC were not altered. Again, similar to the pituitary, there was a large reduction in the cleavage of β-LPH to γ-LPH and β-endorphin, but with still about a third of the normal conversion (6), indicating that although PC2 is the primary processing enzyme, other pathways are possible. Of the β-endorphin (1-31) present, there was a reduced amount of processing to β-endorphin (1-27) and β-endorphin (1-26) (6). Like the pituitary, α-MSH, des-acetyl α-MSH and CLIP were all absent in the hypothalamus (290, 443). It would be interesting to investigate the effects of deletion of both PC1/3 and PC2 on POMC processing, however the double knockout strain was lethal (420).

D. CPE gene deletion: implications for POMC

$CPE^{fat/fat}$ mice have a missense mutation in the gene for CPE at Ser202. Investigation of this identified a problem with the translation of CPE, as the mRNA levels were normal, but the protein was absent (263). Phenotypically the mice had late onset obesity and were hyperglycemic, but responded to exogenous insulin, demonstrating that pro-insulin processing was defective

(263). Although CPE was completely absent in CPE$^{fat/fat}$ mice, there was other carboxypeptidase activity in some tissues. In the pituitary, it was at about 6%, in brain at 50-57%, but in heart and duodenum there was no reduction in activity. This was most likely due to the activity of CPD, CPN and/or CPM (137).

The studies carried out on POMC in CPE$^{fat/fat}$ mice have helped elucidate the role of CPE as a sorting enzyme, controlling the release of POMC and its processed products between constitutive and regulated pathways. CPE$^{fat/fat}$ mice had increased constitutive POMC and ACTH release from their pituitaries (83, 356, 357). They also had very few of the small cleavage products of POMC and, as most of this processing occurs in regulated secretory granules, this is consistent with these mice not being able to sort POMC into these secretory granules. Therefore in CPE$^{fat/fat}$ mice, due to the lack of CPE, POMC is mis-sorted and mainly released constitutively.

Additionally, many studies have examined the processing of POMC in the CPE$^{fat/fat}$ mice. POMC accumulated in the pituitary in these mice at a level of 24-fold greater than WT controls (357), but it was poorly processed to ACTH, with only 30% of the expected amount (83, 357). There were also reductions in the levels of α-MSH, β-endorphin, β-LPH and CLIP (23). This may be because there is mis-sorting or because of altered levels of PC1 and PC2 in different brain regions of CPE$^{fat/fat}$ mice (23, 220). These changes in peptide levels in the hypothalamus had a functional effect on the body weight phenotype. There was a reduction in peptides like α-MSH, which could lead to an increase in body weight, but no change in the hypothalamic levels of those known to do the opposite, such as β-endorphin (1-31) (442). Overall this may enhance the obesity phenotype.

More recently the Loh group generated a CPE global knockout mouse. This strain is similar to the CPE$^{fat/fat}$ mice, in that they had late onset obesity, hyperglycaemia and higher levels of pro-insulin than insulin (53). Very little work has been carried out in these mice in relation to POMC processing. However, they were found to have reduced hypothalamic α-MSH. In addition, the pituitary levels of ACTH and α-MSH were also reduced, with higher levels of unprocessed POMC in the pituitary (52). Overall it appears that the global deletion of CPE gives a very similar phenotype because of the same reduction in protein expression as seen with the single point mutation in the CPE$^{fat/fat}$ mice.

IX. POMC PROCESSING IN THE SKIN

Given that the MSH peptides were named melanocyte stimulating hormones after their role in skin (55, 358), it is not surprising that there is a long history concerning the production and the roles of POMC and constituent peptides. The POMC peptides were detected in the skin before it was obvious that they came from a common precursor (26, 364, 366, 397, 414) and some of the work underpinned the evolution of the links between the different peptides (228). Subsequently, the identification of children with loss of function of the *POMC* gene, who have red hair and pale skin, is clear evidence of the importance of POMC-derived peptides in skin and hair pigmentation (207).

Early work detected α-MSH and β-endorphin, in addition to ACTH, in cultured human keratinocytes (343, 431) and human epidermal melanocytes (191, 343, 362, 363, 414, 431). This suggests that POMC is processed in skin in a manner similar to the hypothalamus, rather than the human pituitary. The more extensive processing of POMC is substantiated by evidence that PC2 as well as PC1/3 is expressed in human and rodent skin (242, 305), in cultured epidermal melanocytes (305) and human keratinocytes (333). Interestingly, even human dermal fibroblasts express the POMC processing enzymes (344). UV-irradiation increases POMC and α-MSH-like immunoreactivity (α-MSH-LI) in auricular skin from mice, but interestingly the α-MSH-LI was found to be ACTH (1-8), formed by tryptase digestion in the extracellular space. The ACTH (1-8) was shown to stimulate melanin production via the MC1R (435). This is an unusual processing step which has not been reported in other tissues.

A. POMC derived peptides and melanogenesis

The action of α-MSH was shown dramatically in an *in vitro* assay using skin from frogs, because the α-MSH stimulated melanin production and therefore the darkening of the skin cells (55, 358). We and others have subsequently used the darkening of human melanoma cells, which is visible in the cell pellet, as a bioassay to show that although POMC is a precursor of α-MSH it is still bioactive itself (333).

Early work provided evidence that α-MSH stimulated melanogenesis in human melanocytes (2, 175), but there was also evidence that the immediate precursor of α-MSH, i.e. ACTH, could also stimulate melanogenesis (175, 414). This is also evidenced by the pigmentation of some patients, particularly those with Nelson's syndrome, who have excessively high concentrations of ACTH in their blood (323). However there is always the question as to whether the tumors undergo abnormal processing of POMC and produce α-MSH. We identified one ectopic tumor where the patient had enhanced pigmentation which disappeared after removal of the tumor. There was elevated POMC and ACTH in the blood, but no excess α-MSH (426). This led us to question the relative release of POMC, ACTH and α-MSH by normal human epidermal keratinocytes, melanocytes and hair follicle cells and their relative bioactivity in skin (333). The subtlety lies in the concentrations of the respective peptides, as POMC has a low potency so will only be bioactive if present at the MC1R at high concentrations. In patients with tumors, which are secreting grossly elevated concentrations of POMC, it is likely that these precursors of α-MSH can cause pigmentation. However, under normal conditions the processing of POMC and the regulation of release of the MSH peptides allows for paracrine (and maybe autocrine) activity at the melanocytes in skin.

It seems plausible that keratinocytes would secrete α-MSH related peptides that act on cell surface MCRs on melanocytes to stimulate melanogenesis and proliferation (186). However it is less clear why epidermal melanocytes secrete these peptides. It may be that there is a necessity for an autocrine pathway, or

that they act on surrounding keratinocytes and dermal fibroblasts where they have a different role, perhaps in differentiation or proliferation.

Both β-endorphin and the μ-opiate receptor have been identified in human epidermal melanocytes, using immunohistochemistry, again suggesting that there is an autocrine mechanism operating in these cells (191). The role of β-endorphin in stimulating melanogenesis, mitogenesis and dendrite outgrowth suggests its function is very similar to that of α-MSH (191).

B. The skin equivalent of the HPA axis: implications for processing (Figure 1)

It was somewhat surprising to learn that all the hormonal components of the HPA axis exist in the skin (360, 370). CRH is expressed in the skin (362, 365) and can act to stimulate POMC activity and corticosterone synthesis in dermal fibroblasts (367-369). Differentiation of human keratinocytes alters expression of the components of this skin "HPA axis" indicating marked integration of the pathways (428). It has been suggested that the HPA axis represents an evolutionary development from the skin "HPA axis" (361). In the skin, the "HPA axis" interacts with the innate immune system to protect against pathogens and other stressors and then forms an inhibitory loop giving anti-inflammatory effects (361). In this model, CRH acts to stimulate *POMC* gene expression in situations where the POMC peptides have an immunoregulatory role (37) and where corticosteroids can act to suppress the skin-immune mechanisms.

C. Hair follicles and POMC processing

Hair follicles also produce POMC and process it in a manner analogous to the skin (194). This provides the POMC-derived peptides in the hair follicles which can modulate pigment formation, activate differentiation and have an immunoregulatory role (37, 193). The hair follicles are also regulated by CRH (192) and have an equivalent to the HPA axis with synthesis of cortisol (178).

D. Assessment of POMC peptides in skin: implications for interpretation

The evidence is compelling for the presence of the POMC peptides and the importance of their role in skin. However, we must accept that while dispersing and culturing the cells allows better quantitation of specific peptides, it may mask the true endogenous peptide networks between the cells and cause abnormal function. On the other hand, analysis of the peptides in tissues by immunohistochemistry is only as good as the knowledge of the specificity of the antibodies. We know that antibodies produced with specificity for specific peptides such as ACTH, may detect POMC or pro-ACTH as well as ACTH when used in immunohistochemistry. Others may be unaware of this, because they do not have purified forms of POMC and pro-ACTH to test on their antibodies. Another consideration is that some of our knowledge comes from rodents and

this might be difficult to extrapolate, for example because they don't get the same exposure to sunlight (361).

The skin can be considered one of the largest organs in the body because of its surface area. Therefore, in extrapolating the concentrations of POMC-derived peptides in skin to what might appear in blood, some calculations suggest that the levels will be so high as to be compatible with causing Cushing's syndrome. Clearly this is not the case and it is thought that the MSH and ACTH peptides are degraded locally (346).

X. PITUITARY PROCESSING OF POMC: A KEY FACET IN REGULATION OF THE HPA AXIS

The importance of this axis in managing the response to stress is well known. However, it is sometimes hard to believe that the intricacy of the production of *POMC* and its processing to ACTH is designed primarily to regulate the release of glucocorticoids. In studying the role of ACTH, it is apparent that its effects are mainly via glucocorticoids, which act on most tissues in the body to modulate homeostatic processes. This is evidenced by the many clinical features that occur as a result of glucocorticoid excess as in Cushing's syndrome.

Secretion of a hormone is almost always regulated by a series of mechanisms to tightly control release into the circulation. When there is a hormone precursor this adds another layer of complexity. For POMC, the three key stages are regulation of (1) the gene (2) the processing enzymes and (3) the secretion from cells, as well as some cell-specific post-translational processing, such as glycosylation. Unfortunately, we rarely consider all the stages together, so it is difficult to understand which of the regulatory mechanisms or which stage in the pathway dominates the outcome.

From the perspective of POMC processing, the different stages regulating the *POMC* gene, the enzymes for cleavage of POMC and the secretory vesicle release of ACTH have to be coordinated. This is needed so that ACTH is secreted in a pulsatile manner, which underpins the circadian rhythm, creating the diurnal changes. This "basal" production of ACTH is distinct from the stress-related stimulation of ACTH secretion.

A. Ultradian Rhythm and Pulsatile Secretion

The complexity of the rhythms of the HPA axis is still unfolding as new techniques give us greater understanding. The pulsatile pattern of secretion of ACTH and cortisol has been difficult to assess in humans, because of the stress of repetitive blood collection. However the use of automated sampling techniques (164) has uncovered the very dynamic nature of these hormones (338). The pulses of ACTH occur every 60-90 minutes and have a higher amplitude and greater frequency at the circadian peak. Pioneering studies by Stafford Lightman and colleagues used mathematical modelling (416) and subsequent *in vivo* experiments to show that the ultradian pattern of ACTH and cortisol derives

from a feed forward and a feedback system, involving the pituitary and adrenal (415). This rejects the long-held view that pulsatility is caused by a pulse-generator in a higher centre such as the hypothalamus or hippocampus. Their research highlighted the timing of this loop: (1) ACTH secretion, (2) its action on the MC2R in the adrenal gland, (3) the *de novo* synthesis of cortisol and (4) its rapid non-genomic negative feedback on ACTH secretion. Given the relatively short half-life of ACTH and cortisol, this loop continues with the degradation of cortisol, which then removes the glucocorticoid inhibition, so that constant CRH stimulation can then increase the ACTH as part of the rising phase of the next pulse. The details of this system and the studies that underpin these hypotheses are amply described in the review by Russell et al (338). The biological significance of the ultradian pulsatility is highlighted by studies showing that there are different effects on target genes if glucocorticoids are given constantly or in pulses (79, 381).

What is less clear is how POMC processing contributes to this pulsatility, if at all. POMC is released into the human circulation (89, 148) and in our study of HPA ultradian activity in humans, where POMC was measured in blood, there was no evidence for POMC pulsatility (337). Our hypothesis is that POMC is released from cells via a constitutive pathway (162, 314) which is separate from the regulated release of ACTH. Therefore the rapid glucocorticoid feedback proposed for the ultradian pulses could act at secretory vesicles containing ACTH. This may occur via cortisol acting on membrane glucocorticoid receptors (389, 395) which would provide a non-genomic pathway of feedback inhibition. This mechanism is supported by early studies in rodents which showed that a rapid glucocorticoid inhibition of ACTH secretion is independent of protein synthesis (195) and of POMC processing (115).

B. Circadian rhythm

The concentrations of ACTH in the human circulation show a distinct circadian rhythm, with highest levels just before wakening and then a decline throughout the day to a nadir between 11pm and 3am. Interestingly, the peak and trough values for ACTH differ by two- to three-fold, while those for cortisol can be four- to six-fold in healthy individuals. This may be because the adrenal gland has sympathetic innervation that is regulated by the PVN or because it has an independent clock. Whichever mechanism prevails in the adrenal gland, it impacts on the cortisol circadian rhythm to generate the greater magnitude in cortisol diurnal rhythm (reviewed in (338)).

This rhythm is under the control of the suprachiasmatic nucleus which stimulates release of CRH and AVP from the PVN in the hypothalamus (reviewed in (44)). These neuropeptides can stimulate both synthesis of POMC and release of ACTH and it is not entirely clear whether one or both mechanisms primarily generate the diurnal rhythm. These mechanisms are explored more fully in stress-related stimulation of POMC and ACTH below.

C. Acute Stress

In the physiological context, stress which stimulates the HPA axis encompasses acute illness, haemorrhage, hypoglycaemia and flight from predators requiring extreme activation of muscles.

1. CRH stimulation of ACTH release from secretory vesicles (Figure 6)

The classical stressor requires that the hypothalamus releases CRH to cause very fast secretion of ACTH into the circulation in order to stimulate cortisol release. The mechanism by which CRH stimulates release of secretory vesicles containing ACTH involves extracellular calcium influx and release from intracellular pools (379). The immediate release of ACTH from secretory vesicles combined with the stimulation of POMC synthesis leads to a biphasic response in humans (93). It is difficult to assess the immediate release of ACTH and POMC after CRH in normal subjects, but this has been documented in patients who undergo petrosal sinus sampling for a suspected ACTH-secreting pituitary tumor. After CRH stimulation, ACTH released into the petrosal sinus capillaries can be measured within minutes. The stimulated release usually results in a peak of ACTH within 5-15 minutes. POMC release from the pituitary can be detected but it does not mimic the marked increase in ACTH (Figure 6)(148). This has led us to hypothesize that POMC is released from the corticotropes via a different mechanism to ACTH. It could be that in the steady state when there are sufficient ACTH vesicles, the excess POMC exits the cells by a constitutive pathway representing an "overflow" mechanism (384). This is substantiated in normal subjects where CRH caused an increase in circulating ACTH but no change in ACTH precursors (337).

Figure 6: Regulatory processes for the secretion of POMC and its peptides

2. CRH stimulation of the POMC gene in the anterior pituitary (Figure 6)

It has long been recognized that the binding of CRH to a corticotropic cell results in CRH activation of *POMC* transcription (142), presumably to replenish stores of ACTH peptide in the secretory vesicles. It is possible that stimulation of the *POMC* gene involves the same intermediary factors which act on the channels to cause ACTH secretion. CRH receptor activation seems to have effects on a number of pathways (overview in (162); reviewed in detail in (104)). Early work defined the effect of CRH on cAMP pathways both *in vitro* and *in vivo* (231). CRH is known to increase cAMP, calcium and MAPK in *POMC* expressing cells (204, 236). There is also evidence that CRH stimulates transcription of JunB, c-fos, and FosB, transcription factors that bind to the AP-1 transcription factor binding site in exon 1 of the *POMC* promoter, activating *POMC* transcription (13, 42).

More recent data has delineated a MAPK pathway which activates nuclear receptors related to NGFI-B (Nur77) and these bind to a Nur response element in a regulatory element at -404bp of the rat *POMC* promoter (reviewed in (104)). MAPK signaling enables the Nur factors to bind SRC co-activators which enhance

POMC transcription. CRH signaling also activates Tif1β which is synergistic with SRC2 action (321).

3. CRH regulation of processing

There is very little evidence in the literature to suggest that that the processing of POMC to ACTH is regulated or that the pro-hormone convertase, PC1, is stimulated by CRH. However there is always the caveat that "this is an experiment waiting to be done".

4. Stimulation of ACTH by other factors acting on CRH

Many other factors have been reported to stimulate release of ACTH, such as catecholamines, angiotensin II, interleukins (24, 341), ghrelin, vasoactive intestinal polypeptide (VIP) (271), serotonin and oxytocin. However, they mostly act via CRH and there is little evidence for direct effects on *POMC* gene expression. Opioid peptides also affect the HPA axis, but in differing ways depending on the species studied and whether the actions are acute or chronic. It has also been suggested that opioids are acting at the level of CRH release (396, 402).

5. Stimulation of ACTH by argenine vasopressin

Early work outlined the potentiation of CRH-stimulated secretion of POMC-derived peptides by arginine vasopressin (AVP) (408) and this is often stated as a key regulatory role in the HPA axis. There seems to be a clear distinction, because while AVP can synergize with CRH to stimulate ACTH release, it does not appear to act on transcription of the gene. In fact, AVP alone decreases levels of the *POMC* primary transcript and does not act in a synergistic manner with CRH on *POMC* gene expression in rat anterior pituitary primary cultures (219).

6. Other factors which stimulate POMC gene expression

Given the physiological importance of the interactions between the immune system and the HPA axis, it is not surprising that leukemia inhibitory factor (LIF), which is a pro-inflammatory cytokine, activates *POMC* gene expression (41, 324, 325). LIF binding activates the Jak-STAT pathway and there is a STAT binding site in the proximal *POMC* promoter close to the Nur response element (262). This suggests that the HPA axis role in toning-down the cytokine response requires increased *POMC* gene expression, which may provide a greater or prolonged effect on glucocorticoid release compared to the stress response that is set up to deliver fast release of ACTH into the circulation.

D. Feedback inhibition of the HPA axis by glucocorticoids (Figure 6)

The classical hormonal axes involving the hypothalamus and pituitary have the ability to generate a loop, whereby stimulation at several stages leads to a hormone, which feeds back and switches off the cascade. Glucocorticoid inhibition of the HPA axis is one of the best examples of this tightly regulated

feedback system. Stress activation of the HPA axis must incorporate a mechanism to switch off glucocorticoid release, which if unrestrained would lead to not only prolonged immune suppression, but also a very adverse profile of effects in many tissues. The inhibition by glucocorticoids is complex and some reports highlight the importance of regulation at the level of CRH in the hypothalamus, while others suggest that inhibition of *POMC* gene expression and ACTH release are the critical components (96). There have been some elegant studies addressing the issues of the effects of acute glucocorticoid feedback on stress-related activation of the HPA axis, considering the timing of glucocorticoid feedback particularly in *in vivo* paradigms (90, 282).

1. Glucocorticoid inhibition of ACTH release

After a stressor activates the HPA axis, the surge in cortisol feeds back at the pituitary and inhibits ACTH release. This is rapid and is thought to be a non-genomic mechanism, with glucocorticoids acting on secretory vesicle release (96). Early research suggested that glucocorticoids inhibit the calcium signaling, which triggers release of ACTH from the plasma membrane (8).

Another mechanism involves Annexin 1 (ANXA1) which was originally identified as an anti-inflammatory protein. ANXA1 is released from folliculostellate cells in the pituitary in response to glucocorticoid stimulation and this causes translocation of ANXA1 to the outside of the cell by a mechanism which doesn't involve exocytosis. ANXA1 then inhibits CRH-stimulated ACTH secretion (43). Given the steps involved, it would seem that this feedback would take longer to have its effects on ACTH.

2. Glucocorticoid inhibition of the POMC gene

Over the longer term, glucocorticoids can inhibit *POMC* gene expression. They access the pituitary because it is outside the blood-brain barrier and then diffuse into the corticotropes to bind the intracellular glucocorticoid receptors (GRs). These receptors are part of the nuclear hormone receptor family and on binding of ligand they are released from heat shock proteins in the cytoplasm, allowing them to translocate to the nucleus. There they bind to negative glucocorticoid response elements (nGREs) in the promoter region of the *POMC* gene to inhibit transcription. The regulation of the *POMC* gene by glucocorticoids was first explored in the 1980s (33, 141). A region necessary for repression was identified at -77 to -50 relative to the transcription start site of *POMC* (107, 108) and a second site between -480 and -320 was subsequently mapped (327). This site involves the NurRE at -395 bps from the start site (307, 308). GRs interact with Nur factors by protein/protein interactions and this requires BRG1, part of the SW1/SNF remodeling complex, and HDAC2, a histone deacetylase (31). Both these sites are necessary to effect transcriptional inhibition. What is unusual about the nGRE at -63bp in the rat *Pomc* promoter is that it binds a GR homodimer as found in positive GREs but then a GR monomer binds to the opposite side of the helix in the promoter (106).

3. Glucocorticoid inhibition of POMC processing enzymes

It seems logical that the regulation of expression of the processing enzyme that cleaves POMC i.e. PC1/3 parallels that of POMC in corticotropes. Indeed studies in rats showed that adrenalectomy increased the mRNA levels of PC1/3 and that dexamethasone treatment of the adrenalectomized animals reversed this. This suggests that endogenous glucocorticoids would inhibit the expression of the processing enzymes in the corticotropic cells (101).

E. Stress recovery mechanisms: the role of Cannabinoids

The endocannabinoids are involved in stress recovery mechanisms and homeostasis, therefore, it is not surprising that they have effects on the HPA axis. However, the literature suggests that the effects are very dependent on the context. Several studies have reported that cannabinoid agonists increase circulating ACTH in animal models (reviewed in (288)). There is some suggestion that these agonists act by increasing CRH although, the cannabinoid receptor CB1, is present on ACTH secreting cells (289), indicating that cannabinoids are having a direct effect at the level of the pituitary. Interestingly, mice with knockdown of CB1 have increased levels of corticosterone and a generalized upregulation of the HPA axis (84), which would indicate that endocannabinoids also have the potential to inhibit the HPA axis. This fits with the proposal that endocannabinoids can inhibit stress-induced HPA axis activation and therefore may be of value in treatment of anxiety-related disorders (299).

XI. POMC PROCESSING BY TUMORS

Cushing's Syndrome is defined by excess cortisol secretion which can be caused by pituitary tumors that secrete ACTH or non-pituitary or ectopic tumors, which we believe secrete predominantly ACTH precursors (423) (Figure 7). The latter is referred to as ectopic ACTH syndrome but we have suggested it should be renamed ectopic ACTH precursor syndrome (385). The tumors are often small cell lung carcinomas (SCLC) but can also be pancreatic, thyroid, or carcinoid tumors or phaeochromocytomas.

Much of what we know now about POMC as the precursor of ACTH arose from observations of tumors producing "abnormal" ACTH molecules. This was often investigated because the patient would have symptoms of Cushing's syndrome which were suggestive of high ACTH concentrations in the patient's blood, but the results would be inconsistent. We now know this is most often because some of these tumors were producing ACTH precursors. These precursors seem to have a lower bioactivity, as only relatively high concentrations stimulate cortisol production and are associated with clinical symptoms of cortisol excess. In addition, although ACTH assays used in the clinic have some cross reactivity for ACTH precursors, they only measure approximately 2% of the total precursors (255). This can result in a "normal" ACTH and only slightly elevated cortisol but because there is no diurnal rhythm, this change in the HPA axis can give

symptoms of Cushing's syndrome. With more specific assays and more sensitive imaging techniques it is now easier to get a diagnosis, although there are still some patients who present with a confusing set of diagnostic results, indicating we still have more to discover.

We developed a two-site immunoradiometric assay for ACTH precursors in 1988 (89), using a pair of monoclonal antibodies. One antibody binds to the ACTH region of POMC and the other to the γ-MSH region (see section XII). Binding of both antibodies is required to generate a signal and this only occurs when POMC or pro-ACTH are present. Importantly, this assay for ACTH precursors does not detect ACTH. In contrast, an assay for ACTH will always recognize ACTH precursors to some degree, because the ACTH sequence is present in both pro-ACTH and POMC. This is very important in diagnostic ACTH assays, as they need to identify any peptides with ACTH-like activity. However as the antibodies cross-react 100% with ACTH but only <5% with POMC, (255, 385) this can lead to the discrepancies described above.

A. ACTH precursor secretion in ectopic ACTH syndrome

High molecular weight forms of ACTH were first found in an ectopic tumor extract using chromatographic separation and then radioimmunoassay (433). These high molecular weight forms were subsequently found in patients' blood (159, 322), but it required large volumes of plasma for the procedure and took several days, so it was not a suitable approach to use routinely. Most reported chromatograms show a major elution peak at the position for POMC and a shoulder to the peak, suggesting some pro-ACTH, but the resolution was not usually specific enough to determine relative amounts.

Figure 7: ACTH precursor secretion in ectopic ACTH syndrome

Quantifying ACTH-precursors, using the two-site immunoradiometric assay, revealed that most of the patients with ectopic ACTH syndrome had elevated circulating concentrations (385) (Figure 8). It is very difficult to prove whether the ACTH precursors or bonafide ACTH cause the clinical symptoms in these patients. Low concentrations of ACTH (around 1.0 pmol/L) secreted continuously from tumors, and therefore not subject to a diurnal rhythm, are thought to be able to cause elevated cortisol, which can result in Cushing's syndrome. We did not detect ACTH in the chromatographed plasma from a patient with ectopic ACTH syndrome, where we measured high levels of ACTH precursors. This suggests that ACTH precursors were bioactive in this case, but we cannot completely rule out the possibility that the lack of detection of ACTH may be due to sensitivity limitations of the chromatography (385).

Carcinoid tumors can also secrete ACTH precursors and produce features of the ectopic ACTH syndrome, even though they are often much smaller tumors (423). However other work using an assay specific for POMC, which did not detect pro-ACTH, suggested POMC was not present in the bronchial carcinoids they studied (319). To add to the confusion, this group detected CLIP (the C-terminal fragment of ACTH) in four carcinoid tumor extracts (413). Unfortunately the

concentrations of precursors, ACTH and CLIP were not measured in the same patients in any of the studies and it is not clear if the antibody to CLIP recognized POMC. If CLIP is present in a selection of tumors, this suggests that these tumors have the processing enzymes, PC1/3 and PC2, to cleave POMC to these smaller fragments. Indeed PC2 has been detected in the majority of carcinoid tumors studied (347). However, more recently, it has become clear that patients with less aggressive Cushing's syndrome caused by carcinoid tumors have elevated ACTH precursors (285) (Figure 8).

Figure 8: Concentrations of ACTH precursors in different patient groups

B. POMC processing in pituitary microadenomas

Patients with small pituitary microadenomas causing Cushing's disease process POMC to ACTH, seemingly in a similar way to normal subjects. Therefore, while ACTH precursors are detectable (as they are in normal subjects), the concentrations range from low normal to approximately 100pmol/L (278). However patients with ectopic tumors causing Cushing's syndrome have ACTH precursors in the range 100-20,000 pmol/L (425). This gives virtually 100% discrimination between patients with pituitary dependent Cushing's syndrome and ectopic ACTH syndrome (Figure 8).

In addition to ACTH, the precursors can be detected in samples taken from the inferior petrosal sinuses, draining the pituitary, in patients with pituitary microadenomas. However, when CRH is given as part of this procedure, while the ACTH concentrations increase, the ACTH precursors do not seem to respond to CRH to the same degree, suggesting that the mechanisms for regulation of release of ACTH and ACTH precursors may differ (148).

C. POMC processing in large invasive pituitary tumors

There is a small subset of patients who have much larger tumors, which tend to be invasive (11), and they may present with vague symptoms of Cushing's syndrome and abnormally low ACTH results considering the clinical features. Investigating a small group of these tumors we found that they also have high concentrations of ACTH precursors in the blood (150) and a POMC specific assay has identified elevated POMC in 7/8 patients (319).

There are also "silent" tumors in patients who do not appear to have elevated ACTH in the circulation, but their tumors stain positively for "ACTH". In cases we have studied, this is because the tumors produce ACTH precursors, which can be detected by the ACTH antibody used in immunohistochemistry. If the tumors have not been completely removed at surgery and there is recurrence, the ACTH precursors can be detected in the circulation.

There is also some evidence for large invasive pituitary adenomas producing α-MSH and most of these were immunopositive for PC2 (176). Unfortunately, ACTH precursors were not measured in these patients and so it is not possible to speculate on the molar ratios of the POMC peptides produced by these tumors.

D. POMC processing in Nelson's syndrome

Nelson's syndrome is relatively rare, but has highlighted some interesting aspects of POMC processing which are still not fully understood. Nelson's syndrome occurs after bilateral adrenalectomy which is used as a means of treating some cases of Cushing's syndrome. Subsequently, a pituitary adenoma, usually not detected as the cause of the Cushing's syndrome, then expands and secretes high concentrations of ACTH, often resulting in pigmentation.

These pituitary tumors are often invasive and this led us to investigate whether they secreted ACTH precursors in a similar fashion to the group of large invasive pituitary tumors we had studied previously (150). The ACTH precursors were elevated in 11 of the 24 patients (median 97.5pmol/L, range 26 to 647pmol/L), compared to untreated Cushing's disease where the range was 9-104pmol/L (Figure 7) However, the processing of POMC to ACTH appeared to be enhanced as evidenced by the ratio of precursors to ACTH (323). This seemed unusual, but suggests that the lack of endogenous cortisol and the presence of oral hydrocortisone for only part of the 24h period may have affected the processing of POMC to ACTH.

E. Processing of POMC in tumor cells

There is ample evidence of POMC production and secretion by pituitary and ectopic tumors (276, 278, 285, 319). Why this occurs is still a matter of speculation (423). The processing pathway to produce ACTH is complex and requires the presence of PC1/3 and mature secretory vesicles, to provide the correct calcium and pH optimal for the processing. Therefore it seems reasonable to predict that some tumors (particularly non-pituitary tumors) may not have differentiated sufficiently to generate this pathway. However, these ectopic tumors are often characterized by large dense core secretory vesicles, which is the location for processing precursor hormones. It may be that these tumors are less differentiated and not able to synthesize PC1/3. This is supported by a study of 13 SCLC cell lines which had restricted expression of PC1/3 (87). We have also found high levels of precursors and undetectable ACTH in SCLC cell lines (88, 385). The fact that large invasive pituitary tumors can produce ACTH precursors at higher concentrations than ACTH also supports the suggestion that aggressive, less differentiated tumors may not fully process POMC to ACTH. However, the increased processing in those pituitary tumors associated with Nelson's syndrome suggests that the lack of "natural" glucocorticoid feedback inhibition may be influencing processing.

XII. MEASUREMENT OF POMC DERIVED PEPTIDES – WHAT ARE WE REALLY MEASURING?

Measurement of ACTH initially involved a bioassay using rat adrenal cells that secreted corticosterone. This was very sensitive and could detect circulating ACTH but was also very variable due to the unpredictability in responsiveness of

different adrenal preparations (61). Subsequently a few research groups, largely based within hospital laboratories, began to produce polyclonal antisera and develop immunoassays to measure ACTH. With these assays it was possible to identify discordance between the clinical features in some patients with tumors and the low levels of ACTH detected. This led to the concept that some tumors might be producing abnormal molecules with ACTH activity (see section XI above). This set the context for the development of methods to accurately assess the POMC peptides.

A. The value of pulse-chase analysis

In trying to understand the relevance of pro-hormone processing, we rely heavily on the methodology used to address the questions. Without pulse-chase analysis it may have been many years before pro-insulin was discovered. Similarly much of the early work on POMC, as the precursor of ACTH, relied on pulse-chase analysis of POMC peptides from the AtT20 mouse pituitary adenoma cell line (119, 232). These cells were incubated with a radiolabeled amino acid and then after a set time "chased" with unlabeled amino acid. This provides a profile of labeled peptides over time. Antibodies are used to identify and concentrate the specific peptides and then SDS-gel electrophoresis determines the size of the peptides. This is a dynamic process studying the timing of the appearance and disappearance of the labeled peptides. The information on the relative amounts of each of the peptides in the processing pathway depends on the ability of the antibody to recognize a particular epitope in ACTH, pro-ACTH and POMC. From immunoassay data, we are aware that antibodies may recognize ACTH to a greater degree than the precursors. There is also the possibility that the different conditions used in immunoprecipitation can affect the relative recognition of the three peptides, so it is important to consider antibody specificity for the different peptides under these conditions, in order to interpret the data.

Much of the data proving that ACTH and β-endorphin come from POMC was derived from extensive and very methodical pulse-chase analysis (119). This biochemical analysis preceded the identification of the gene structure and provided invaluable information on POMC processing.

B. Immunoassays for ACTH

The clinical need for measurement of ACTH became apparent with identification of tumors secreting ACTH as a cause of Cushing's syndrome (281, 434). Many immunoassays for clinically relevant hormones were developed shortly after the initial immunoassay for insulin had been described. However, development of polyclonal antisera to ACTH proved difficult, as the ACTH peptide is not very immunogenic. In addition, there were problems with radiolabeling ACTH for the radioimmunoassays, as it was very labile. At this time, extraction of ACTH from plasma was necessary to improve the detection of low normal concentrations and laboratories used the knowledge that ACTH sticks to ground glass or silica for this purpose. This process concentrated the ACTH, to allow for the lack of

sensitivity of the immunoassays, while at the same time removing the plasma, which interfered in many of the immunoassays.

The advent of a two-site immunoradiometric assay based on polyclonal antibodies to ACTH provided significant advantages (171). However, the ability to generate monoclonal antibodies to ACTH (424) (Figure 9) enabled the characterization of a monoclonal antibody-based immunoradiometric assay (427). Having hybrid cell lines secreting large quantities of monoclonal antibodies led the way for development of commercial diagnostic assays, which opened up ACTH measurement to a much wider clinical community. However, it was also known that some tumors produced high molecular weight forms of ACTH, while other tumors were thought to produce ACTH fragments. The immunoradiometric assays were considered very specific for ACTH (135) and the assay based on the paper by Hodgkinson et al (171) was found not to detect the "big ACTH" produced by tumors (139). Similarly ACTH fragments not detected in the immunoradiometric assays can cause problems (317). In essence, it is important that the ACTH assays do detect ACTH precursors or fragments produced by tumors, but only if the precursors or fragments are bioactive and responsible for the clinical symptoms.

C. Immunometric assays for ACTH precursors (Figure 9)

Many immunoassays for ACTH can also detect the high molecular weight forms of ACTH, such as POMC and pro-ACTH. In this instance, the antibodies which bind ACTH can also recognize this sequence in POMC. However, the antibody may not recognize the ACTH sequence to the same degree in the larger precursor molecule. Therefore, the ACTH assay may underestimate the concentration of POMC, because of its low cross-reactivity with the antibodies. This has been accentuated in the two-site immunometric assays for ACTH with many of them only detecting 2% of the POMC precursors present (255).

Figure 9: Monoclonal antibody based assays to POMC derived peptides

The development of an immunometric assay for POMC and pro-ACTH (89), provided the opportunity to specifically quantitate these precursors without the problem of trying to accurately measure them in the ACTH assay. In the precursor assay we developed, one antibody detects an epitope in ACTH and the other antibody detects an epitope in γ-MSH. Since both antibodies are required to generate a signal, only peptides containing both epitopes (i.e. POMC and pro-ACTH) are measured. Therefore the smaller peptides, including ACTH, are not recognized by the assay (Figure 9). The second factor which made this assay possible was that we were able to use culture medium from a pituitary tumor growing *in vitro* as a source of POMC and subsequently to prepare standards by purifying POMC from a human small cell lung cancer cell line (89).

This assay for ACTH precursors confirmed the early work on high molecular weight ACTH, ie POMC and pro-ACTH, in tumors. It has enabled analysis of much larger numbers of patients and proved that high levels of ACTH precursors can be found in the blood of patients with ectopic ACTH syndrome (385). The greater

sensitivity of this approach allows ACTH precursors to be measured directly, without the need for chromatography, greatly enhancing our understanding of the processing in ACTH-related disorders (150, 278, 285, 323). Another immunometric assay for POMC based on antibodies to epitopes in ACTH and β-endorphin showed greater heterogeneity, but still detected elevated POMC levels associated with more aggressive tumors in patients with ACTH-related disorders (319).

The immunometric assay technology enables lower concentrations to be detected. This has made it possible to measure POMC in plasma (148, 285, 337) and in CSF (286, 403) from normal subjects.

D. Immunometric assays for β-LPH and β-endorphin

By developing two-site assays similar to those for ACTH and ACTH precursors, it has been possible to generate assays that distinguish β-LPH and β-endorphin (149). This provided evidence that there is very little β-endorphin in the human circulation and its precursor, β-LPH, is more prevalent. It is likely that some of the original radioimmunoassays for β-endorphin actually detected its precursor, β-LPH.

E. Which POMC peptide are you measuring by immunohistochemistry?

Accurate detection of POMC and the smaller melanocortin peptides in tissues by immunohistochemistry remains complex. Antibodies raised to α-MSH, for example, may be wholly specific for that peptide or may recognize the amino acid sequence in ACTH, pro-ACTH and/or POMC. It is challenging to use single antibodies in immunohistochemistry to detect fully processed peptides as they may be identifying the larger POMC precursor. This is made more relevant as the precursors are thought to be less biologically active and therefore a tissue or tumor may have a bioactive smaller peptide or a less bioactive precursor. The specificity of the antibody can be assessed by competing with increasing concentrations of the precursors, but these are not generally available.

We have an antibody that recognizes the C-terminal of ACTH and therefore detects ACTH and pro-ACTH but not POMC. This has been proven in immunoassays and has also been used in immunohistochemistry to show that a tumor was producing POMC but not ACTH, which helped explain the clinical symptoms in relation to the POMC derived peptides in the circulation (146).

XVIII. BIOACTIVITY OF POMC AND DERIVED PEPTIDES

A. Bioactivity of ACTH Precursors

The perceived role of a precursor in relation to its peptide products would suggest that the precursor is not biologically active and that the reason for regulating the processing steps is to provide bioactive end products. The

situation is slightly more complex with POMC and ACTH and much less is known about other POMC derived peptides such as α-MSH and β-endorphin.

The relative bioactivity of POMC and ACTH was addressed in the 1970's using POMC (then called pro-ACTH/endorphin) isolated primarily from AtT20 mouse pituitary adenoma cells. The peptides were purified by gel chromatography and SDS gel electrophoresis, then measured using an ACTH radioimmunoassay and tested on rat adrenocortical cells, which produced corticosterone as the evidence of bioactivity. Initially this approach provided proof of the relative position of the different peptides within the POMC precursor, in that it had not previously been known that N-POMC was N-terminal to ACTH and ACTH was N-terminal to β-LPH. These studies also showed that POMC and pro-ACTH were two orders of magnitude less bioactive than ACTH (1-39) (145). This data does depend on the accuracy of the quantitation of the precursor peptides used in the bioassay. It is clear that this was recognized as an issue at that stage because Eipper and Mains (119) commented "it has been known for some time that radioimmunoassays for ACTH may only detect a few percent of the high molecular weight forms". They indicate that this will bias the ratio of bioactive to immunoactive peptide measured.

This careful study of bioactivity provided evidence that the precursors of ACTH were able to stimulate corticosterone production without a time lag, indicating that it did not require proteolysis for the precursors to act at the MCRs on the rat adrenocortical cell membranes (145). Nevertheless, much higher concentrations of precursors were needed to have an effect.

This work underpinned the concept that POMC is a precursor with relatively low biological activity (119, 276). However, pro-ACTH has 8-33% the potency of ACTH in a cytochemical bioassay (322), suggesting that having the ACTH sequence at the C-terminal end of this precursor makes it more bioactive than when ACTH is flanked at both ends by other peptides. This makes the interpretation of which peptides are present in the circulation and how they are measured very relevant (423).

To analyze bioactivity, research groups primarily used tumor extracts as the source of POMC. The "big" ACTH in human non-pituitary tumor extracts was found to be relatively biologically inactive (168) or had less than 4% bioactivity (147). It was also shown that trypsin can convert the "big" ACTH peptide to a biologically active ACTH (147). Other groups isolated "big" ACTH, from a human pituitary tumor, and found it to have 30% of the bioactivity of ACTH (118, 206) , suggesting that the peptides isolated may have been a mixture of POMC and pro-ACTH.

Using the ACTH precursor assay to quantitate POMC and pro-ACTH purified from the plasma of a patient with an ectopic tumor, provided evidence that the ACTH precursors, rather than ACTH, might be responsible for the clinical symptoms (385). It was suggested that although they have low bioactivity, they may still act with low potency if they are present in the circulation at very high concentrations. Another option is that the high concentrations of ACTH

precursors are cleaved at the adrenal cells and, even if this cleavage is very inefficient, the concentrations of ACTH generated may be sufficient to stimulate excess cortisol, especially at the diurnal nadir.

B. Relative bioactivity of α-MSH and its precursors ACTH and POMC

For some reason, very little has been done to consider if the precursors of α-MSH act in the hypothalamus at MC4R or in the skin at MC1R, although we have tried to address this. ACTH is able to act at the MC4R, found in the hypothalamus, with a similar potency to α-MSH (311). POMC is less bioactive, but may still act if present at 100 fold higher concentrations and it is intriguing that this level of excess is found in the CSF (287, 403). Similarly, ACTH can act at the MC1R found in skin with a similar potency to α-MSH (333) where again POMC has low bioactivity. Therefore, it is important to understand the relative concentrations of the precursors as well as their derived peptides in the vicinity of their receptors, particularly if acetylation of α-MSH is so tightly regulated (156).

XIV. CONUNDRUMS AND FUTURE PERSEPECTIVES

The wealth of data presented in this review is testament to the essential roles played by POMC-derived peptides in a vast array of tissues and in many diverse physiological systems. In many research arenas there is an inevitable tendency to focus in on one particular tissue or cell type. Hopefully this review will encourage those working, for example, on hypothalamic signaling to also look at the complexity of regulation of POMC processing in the skin and vice versa. Only by grappling with the subtlety of homeostatic control mechanisms in all relevant tissues, can one appreciate the full power of hormone processing vital for physiological processes in many biological systems.

In presenting POMC as the archetypal polypeptide precursor, this review has addressed processing to generate the smaller peptide fragments at the molecular and cellular level. Understanding the processing steps responsible for cleavage of POMC and how they differ in certain tissues, sets the context for recognition of how mutations lead to such widespread phenotypes in both humans and mice. By considering the processing pathway from the TGN to the cell surface, it is possible to address questions about how the regulated secretion of ACTH from the pituitary occurs so rapidly in response to stress. This is obviously necessary in order to stimulate the glucocorticoid concentrations needed for metabolic support in the “fight and flight” mechanisms. However, a complete understanding of the regulation of the *POMC* gene in the hypothalamus remains more elusive and much less is known about how processing in the secretory granules proceeds within relevant hypothalamic neurons. For example, this review has provided evidence for regulation of the many enzymes involved in generating bioactive α-MSH. Because this needs to occur in secretory vesicles rather than in the extra-cellular space, it remains to be determined how the length of the neuronal projections affects the various stages in acetylation and amidation of α-MSH.

Our gathering of evidence for the complexity of POMC processing in all of the many tissues where it is expressed has again raised issues about which POMC peptides have biological activity and highlighted continuing uncertainty of the unique versus overlapping roles of melanocortins. Where a block in the post-translational mechanisms affects processing and there is a build up of POMC precursors, it is important to understand if the biological activity of these precursors is contributing, even in part, to changes in physiological processes normally ascribed to the smaller, more highly processed peptides like ACTH, α-MSH or β-endorphin. This phenomenon has been accepted for many years by endocrinologists studying tumors secreting ACTH-related peptides, but the more recent identification of children with mutations in *POMC* or with mutations in the enzymes involved in processing POMC, has shone a light into another biological theatre in which precursors could have important actions.

One of the major stumbling blocks to a more complete knowledge of which POMC peptides are involved in particular physiological processes, is the problem of attempting to measure one peptide specifically without inadvertently also measuring its larger precursor or a smaller peptide derived from it. This is a particular issue for immunoassays that rely on the specificity of the antibody. For example, in the case of ACTH assays their recognition of POMC or pro-ACTH is rarely understood. There is now evidence that most immunometric assays for ACTH only detect about 2% of the precursors present. If the aim is to use this approach to measure POMC and pro-ACTH, then it massively underestimates their true concentrations. This has undoubtedly hampered the understanding of some cell-based studies.

The sensitivity of the detection system is also critical. Some techniques to concentrate the various peptides prior to analysis are recognized to recover the larger precursors in different proportions to the smaller peptides, thereby introducing error. This is especially an issue for mass-spectrometry or gel chromatography. Similarly, there is no tradition of checking the antibodies used in immunohistochemistry to determine if they are recognizing POMC precursors to the same degree as the peptide to which they have been raised. Much of the literature makes statements about the peptides detected, but rarely do reports qualify this with mention or measure of other POMC peptides which might also be present.

A. Future perspectives on POMC processing in the hypothalamus

Given the significant amount of knowledge gained in the last 20 years about the role of POMC in regulating energy balance, it may seem that there is little more to unravel. However, this review has highlighted the uncertainty around the respective roles of α- and β-MSH. There is no doubt that loss of the complete *POMC* gene is associated with obesity, however it is more difficult to understand the contribution of α- and β-MSH in patients with mutations in these regions. To date, evidence indicates that loss of β-MSH rather than α-MSH is more likely to be associated with an increased risk of obesity, but the mutations reported have been in the heterozygous state and number of affected probands remains small. The loss of active β-MSH in ravenously hungry and overweight Labradors

provides intriguing evidence for its function. On the other hand, the inability to produce β-MSH in rodents points to a redundancy. The comparable potency of the two peptides at the MC4R suggests that either peptide could regulate energy balance. Therefore it may be that discrimination lies at the level of post-translational modifications which might generate bioactive α-MSH but inactive β-MSH or vice versa. An ability to measure the relative concentrations of each of the bioactive peptides in the vicinity of the receptors *in vivo* would be invaluable but, to date, this remains a very technically challenging procedure.

In addition to the contention around which species of MSH may predominate at the MC4R, there still remains uncertainty around the acetylation of α-MSH. There is conflicting data about whether α-MSH or des-acetyl α-MSH represents the more relevant form in the hypothalamus. N-terminal acetylation is thought to increase the stability of peptides, although other reports indicate it depends on the type of N-terminal acetylase and may target peptides for degradation. Early literature suggests des-acetyl α-MSH is the major form in the ARC of the hypothalamus. There is a suggestion that the des-acetyl α-MSH peptide travels within the POMC neurons from the ARC to the PVN and then the N-acetyl transferase acts at the neuronal terminals in the PVN just prior to release from the neuron. Nevertheless, it is the acetylated form that is thought to be biologically active in terms of food intake and the process of acetylation, which is regulated by leptin, suggesting that this is a critical step. However, there is also controversy about the relative concentrations of its precursors. While α-MSH is detected at higher concentrations than POMC and ACTH in rat hypothalamic extracts, its levels are not regulated by fasting, in contrast to those of its precursors. This again highlights some gaps in our understanding of POMC processing.

B. Why is POMC present in the circulation?

It is often assumed that hormone precursor molecules will be efficiently processed within the cell before release of the small active peptide, but like pro-insulin, POMC is released into the circulation. There is now good evidence for POMC in the circulation, both from normal human subjects and particularly in patients with tumors secreting ACTH-related peptides. It is tempting to speculate that this is an "overflow" mechanism, occurring in the pituitary corticotrophs. As ACTH has to be present in secretory vesicles ready for release at times of acute stress, it may be that POMC is produced continuously to supply ACTH, but when there is sufficient ACTH, POMC is routed to immature secretory granules and released from the corticotrophs in an "overflow" pathway. This would explain the data suggesting that the precursors may not be regulated to the same degree as ACTH.

C. Are ACTH precursors responsible for the clinical symptoms of ectopic ACTH syndrome?

Increased ACTH precursors are frequently used in our lab as a diagnostic tool to identify patients with ectopic ACTH syndrome (and those with large pituitary corticotroph macroadenomas). In addition, as stated above, most ACTH assays

detect the ACTH precursors, but underestimate their true concentrations. Therefore it would seem tempting to speculate that the ACTH precursors are the cause, at least in part, of the clinical symptoms.

On the other hand, this review has highlighted several reasons why it is difficult to make these assumptions. The early studies assessing the bioactivity of POMC and pro-ACTH have suggested that these precursors may only have low bioactivity at the MC2R. However, with newer approaches to measuring the precursors and with the discovery of MRAP, it may be that this evidence needs to be revisited. It is also likely that the higher molecular weight precursors will have a longer half-life and this might increase their ability to stimulate the receptors at the adrenal gland.

In contrast, it is difficult to completely rule out ACTH as the causative agent. This is particularly true in those cases of ectopic ACTH syndrome where ACTH precursors are high, but ACTH concentrations are normal or slightly elevated. It is known that these levels of ACTH, if continuously secreted by a tumor, so that they remain elevated at night, can give rise to Cushing's syndrome. Therefore, given these reservations, it is important to continue to improve our understanding of the role of ACTH precursors and their processing in Cushing's syndrome.

D. Summary

POMC represents a conundrum in many ways. Is it just an inactive precursor? Does it have a role as a relatively stable protein, binding with low affinity to receptors? Does the secretion of unprocessed POMC by tumors reflect a relative lack of differentiation of the malignant cells? How important is regulation of *POMC* gene expression when the enzymes generating the smaller bioactive peptides are also tightly regulated? POMC is certainly an archetypal hormone precursor, delivering exquisite physiological control to complex multi-organ processes and we need to learn more about it.

ACKNOWLEGMENTS

We thank all the members of our research group for valuable discussions and helpful proof reading. Special thanks to Charlotte Sefton for help with the figures.

Address for reprint requests and other correspondence: Professor A. White, Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, 3.016 AV Hill Building, Manchester, M13 9PT, UK (e-mail: anne.white@manchester.ac.uk)

GRANTS

This work was supported by the Barbara Mawer-Fitzgerald endowment fund, University of Manchester. APC is supported by the Medical Research Council (MRC Metabolic Diseases Unit [MRC_MC_UU_12012.1])

DISCLOSURES

No conflicts of interest, financial or otherwise are declared by the authors. Monoclonal antibodies to ACTH have been license by A White to a number of companies for diagnostic kits.

FIGURE LEGENDS

Figure 1: Processing of human POMC in different tissues
Pro-hormone convertase 1/3 (PC1/3) sequentially cleaves Pro-opiomelanocortin (POMC) → pro-ACTH → adrenocorticotropic hormone (ACTH). In hypothalamus, skin, and pars intermedia of the pituitary ACTH is further cleaved by PC2 to produce ACTH (1-17) and corticotropin-like intermediate peptide (CLIP). Carboxypeptidase E (CPE) then cleaves basic amino acid residues from the C terminal, allowing amidation by peptidyl α-amidating monooxygenase (PAM) to form des-acetyl α-MSH (DA-α-MSH). N-acetyltransferase (N-AT) finally acetylates DA-α-MSH to produce α-MSH. PC2 cleaves β–lipotropic hormone (β-LPH) to β-endorphin (β-EP) and γ-LPH, which is further cleaved to β-MSH. The N-terminal peptide, N-POMC, has dibasic amino acids at the N-terminal of γ-MSH which are thought to be cleaved by PC2.

Figure 2: Species differences in the cleavage sites of POMC
The *Pomc* gene has three exons with the translation start site in exon 2. Prohormone convertases (PC) cleave at dibasic sites comprising lysine (K) and arginine (R). These sites are generally well conserved, but occur at different amino acid numbers in the human, mouse/rat and dog sequences. The absence of pairs of dibasic amino acids at the relevant sites in the rat/mouse POMC sequence predicts that γ-MSH and β-MSH will not be produced.

Figure 3: POMC processing in neurons
POMC processing begins in the TGN which is based in the cell body in the ARC. Very little is known about the sites of processing as the peptides move to the neuronal terminals in the PVN. There is some suggestion that N-terminal acetylase (N-AT) converts des-acetyl α-MSH (des-α-MSH) to α-MSH at the neuronal terminal such that α-MSH is released to activate MC4R and decrease food intake (258, 312). POMC can also be processed in the NTS, where less is known about the processing and des-acetyl α-MSH and acetylated β-endorphin are the prominent peptides generated. *ARC is arcuate nucleus, PVN is the paraventricular nucleus, 3V is third ventricle, NTS is Nucleus Tractus Solitarius.*

Figure 4: Alternative secretory pathways for precursors and POMC-derived peptides.
POMC is either stored in immature secretory granules (ISG) and released by constitutive secretion or processed and peptides stored in mature secretory vesicles (MSG) before release by regulated secretion. The anterior pituitary has PC1/3 and therefore processing is more limited than in the hypothalamus and skin which have both PC1/3 and PC2, and other enzymes, giving rise to further post-translational processing that results in the MSH peptides.

Figure 5: POMC processing generates numerous functional peptides.
The primary roles of the different functional peptides cleaved from POMC are shown

Figure 6: Regulatory processes for secretion of POMC and its peptides.
(A) POMC moves from the TGN to immature secretory granules (ISG) and is secreted from cells by constitutive secretion. PC1 processing cleaves POMC to produce ACTH which is stored in dense core secretory granules (DCSGs) before secretion is stimulated. **(B)** On stimulation, α-MSH and possibly ACTH is released from the cells in the hypothalamus/skin/pars intermedia of the anterior lobe of the pituitary. **(C)** Acute CRH stimulation in the anterior pituitary causes the release of ACTH. POMC is also released but not subject to stimulation. **(D)** Long-term CRH stimulation upregulates the *Pomc* gene and release of ACTH. **(E)** Glucocorticoids can inhibit ACTH secretion in an acute, non-genomic manner in the anterior pituitary. **(F)** Chronic exposure to glucocorticoids inhibits POMC transcription and ACTH release. Adapted from (384)

Figure 7: ACTH precursor secretion in ectopic ACTH syndrome
Pituitary tumors have excess production of ACTH while ACTH precursors are released from ectopic (non-pituitary) tumors. The increased ACTH related peptides lead to increased cortisol production

Figure 8: Concentrations of ACTH precursors in different patient groups.
The ranges relate to concentrations of ACTH precursors in blood samples from different groups of patients. The superscript numbers indicate the following references [1](89), [2](385), [3](150)), [4](278), [5](337), [6](285).

Figure 9: Monoclonal antibody based assays to POMC derived peptides.
(a) The monoclonal antibodies (MAbs) bind to specific epitopes on the peptides. A pair of antibodies is required for a two-site assay. This gives specificity. **(b)** The ACTH precursor assay has one MAb specific for the ACTH region and one within the N-POMC region. **(c)** The ACTH assay uses a pair of MAbs which recognise the N- and C-regions of ACTH. They can recognise these epitopes in POMC but only bind about 2% of the precursors

Table 1: Melanocortin receptors and ligand selectivity

REFERENCES

1. **Abbott CR, Rossi M, Kim M, AlAhmed SH, Taylor GM, Ghatei MA, Smith DM, and Bloom SR**. Investigation of the melanocyte stimulating hormones on food intake. Lack Of evidence to support a role for the melanocortin-3-receptor. *Brain research* 869: 203-210, 2000.
2. **Abdel-Malek Z, Swope VB, Suzuki I, Akcali C, Harriger MD, Boyce ST, Urabe K, and Hearing VJ**. Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. *Proc Natl Acad Sci U S A* 92: 1789-1793, 1995.
3. **Akil H, Young E, Watson SJ, and Coy DH**. Opiate binding properties of naturally occurring N- and C-terminus modified beta-endorphins. *Peptides* 2: 289-292, 1981.
4. **Al-Barazanji KA, Miller JE, Rice SQ, Arch JR, and Chambers JK**. C-terminal fragments of ACTH stimulate feeding in fasted rats. *Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme* 33: 480-485, 2001.
5. **Allen BM**. Extirpation experiments in Rana pipiens larvae. *Science* 44: 755-757, 1916.
6. **Allen RG, Peng B, Pellegrino MJ, Miller ED, Grandy DK, Lundblad JR, Washburn CL, and Pintar JE**. Altered processing of pro-orphanin FQ/nociceptin and pro-opiomelanocortin-derived peptides in the brains of mice expressing defective prohormone convertase 2. *J Neurosci* 21: 5864-5870, 2001.
7. **Anisimova AS, Rubtsov PM, Akulich KA, Dmitriev SE, Frolova E, and Tiulpakov A**. Late Diagnosis of POMC Deficiency and In Vitro Evidence of Residual Translation From Allele With c.-11C>A Mutation. *J Clin Endocrinol Metab* 102: 359-362, 2017.
8. **Antoni FA**. Mortyn Jones Memorial Lecture--1995. Calcium checks cyclic AMP--corticosteroid feedback in adenohypophysial corticotrophs. *J Neuroendocrinol* 8: 659-672, 1996.
9. **Appleyard SM, Hayward M, Young JI, Butler AA, Cone RD, Rubinstein M, and Low MJ**. A role for the endogenous opioid beta-endorphin in energy homeostasis. *Endocrinology* 144: 1753-1760, 2003.
10. **Arnaoutova I, Smith AM, Coates LC, Sharpe JC, Dhanvantari S, Snell CR, Birch NP, and Loh YP**. The prohormone processing enzyme PC3 is a lipid raft-associated transmembrane protein. *Biochemistry* 42: 10445-10455, 2003.
11. **Aron DC, Findling JW, Fitzgerald PA, Forsham PH, Wilson CB, and Tyrrell JB**. Cushing's syndrome: problems in management. *Endocr Rev* 3: 229-244, 1982.
12. **Atkinson RL**. Opioid regulation of food intake and body weight in humans. *Federation proceedings* 46: 178-182, 1987.
13. **Autelitano DJ**. Stress-induced stimulation of pituitary POMC gene expression is associated with activation of transcription factor AP-1 in hypothalamus and pituitary. *Brain Res Bull* 45: 75-82, 1998.
14. **Begeot M, and Saez JM**. Melanocortins and Adrenocortical Funcion. In: *The Melanocortin Receptors*, edited by Cone RD. New Jersey: Humana Press, 2000, p. 75-107.
15. **Benjannet S, Rondeau N, Day R, Chretien M, and Seidah NG**. PC1 and PC2 are proprotein convertases capable of cleaving proopiomelanocortin at distinct pairs of basic residues. *Proc Natl Acad Sci U S A* 88: 3564-3568, 1991.
16. **Bennett HP**. Biosynthetic fate of the amino-terminal fragment of pro-opiomelanocortin within the intermediate lobe of the mouse pituitary. *Peptides* 7: 615-622, 1986.
17. **Bennett HP**. Glycosylation, phosphorylation and sulphation of peptide hormones and their precursors. In: *Peptide Biosynthesis and Processing*, edited by Fricker LD. Boca Raton: CRC Press, 1991, p. 111-140.

18. **Bennett HP**. Isolation and characterization of the 1 to 49 amino-terminal sequence of pro-opiomelanocortin from bovine posterior pituitaries. *Biochem Biophys Res Commun* 125: 229-236, 1984.
19. **Bennett HP, Seidah NG, Benjannet S, Solomon S, and Chretien M**. Reinvestigation of the disulfide bridge arrangement in human pro-opiomelanocortin N-terminal segment (hNT 1-76). *International journal of peptide and protein research* 27: 306-313, 1986.
20. **Bennett MK**. SNAREs and the specificity of transport vesicle targeting. *Current opinion in cell biology* 7: 581-586, 1995.
21. **Benzinou M, Creemers JW, Choquet H, Lobbens S, Dina C, Durand E, Guerardel A, Boutin P, Jouret B, Heude B, Balkau B, Tichet J, Marre M, Potoczna N, Horber F, Le Stunff C, Czernichow S, Sandbaek A, Lauritzen T, Borch-Johnsen K, Andersen G, Kiess W, Korner A, Kovacs P, Jacobson P, Carlsson LM, Walley AJ, Jorgensen T, Hansen T, Pedersen O, Meyre D, and Froguel P**. Common nonsynonymous variants in PCSK1 confer risk of obesity. *Nature genetics* 40: 943-945, 2008.
22. **Bergeron F, Leduc R, and Day R**. Subtilase-like pro-protein convertases: from molecular specificity to therapeutic applications. *J Mol Endocrinol* 24: 1-22, 2000.
23. **Berman Y, Mzhavia N, Polonskaia A, and Devi LA**. Impaired prohormone convertases in Cpe(fat)/Cpe(fat) mice. *J Biol Chem* 276: 1466-1473, 2001.
24. **Bernton EW, Beach JE, Holaday JW, Smallridge RC, and Fein HG**. Release of multiple hormones by a direct action of interleukin-1 on pituitary cells. *Science* 238: 519-521, 1987.
25. **Bertagna X, Camus F, Lenne F, Girard F, and Luton JP**. Human joining peptide: a proopiomelanocortin product secreted as a homodimer. *Mol Endocrinol* 2: 1108-1114, 1988.
26. **Bhardwaj RS, and Luger TA**. Proopiomelanocortin production by epidermal cells: evidence for an immune neuroendocrine network in the epidermis. *Arch Dermatol Res* 287: 85-90, 1994.
27. **Bicknell AB**. N-terminal POMC peptides and adrenal growth. *J Mol Endocrinol* 2016.
28. **Bicknell AB, Lomthaisong K, Woods RJ, Hutchinson EG, Bennett HP, Gladwell RT, and Lowry PJ**. Characterization of a serine protease that cleaves pro-gamma-melanotropin at the adrenal to stimulate growth. *Cell* 105: 903-912, 2001.
29. **Bicknell KA, Harmer SC, Yiangson S, Lockwood W, and Bicknell AB**. Lys-gamma3-MSH: a global regulator of hormone sensitive lipase activity? *Mol Cell Endocrinol* 300: 71-76, 2009.
30. **Biebermann H, Castaneda TR, van Landeghem F, von Deimling A, Escher F, Brabant G, Hebebrand J, Hinney A, Tschop MH, Gruters A, and Krude H**. A role for beta-melanocyte-stimulating hormone in human body-weight regulation. *Cell metabolism* 3: 141-146, 2006.
31. **Bilodeau S, Vallette-Kasic S, Gauthier Y, Figarella-Branger D, Brue T, Berthelet F, Lacroix A, Batista D, Stratakis C, Hanson J, Meij B, and Drouin J**. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. *Genes Dev* 20: 2871-2886, 2006.
32. **Birch NP, Estivariz FE, Bennett HP, and Loh YP**. Differential glycosylation of N-POMC1-77 regulates the production of gamma 3-MSH by purified pro-opiomelanocortin converting enzyme. A possible mechanism for tissue-specific processing. *FEBS Lett* 290: 191-194, 1991.
33. **Birnberg NC, Lissitzky JC, Hinman M, and Herbert E**. Glucocorticoids regulate proopiomelanocortin gene expression in vivo at the levels of transcription and secretion. *Proc Natl Acad Sci U S A* 80: 6982-6986, 1983.
34. **Blalock JE**. Proopiomelanocortin and the immune-neuroendocrine connection. *Ann N Y Acad Sci* 885: 161-172, 1999.

35. **Blazquez M, Docherty K, and Shennan KI**. Association of prohormone convertase 3 with membrane lipid rafts. *J Mol Endocrinol* 27: 107-116, 2001.
36. **Bodnar RJ**. Endogenous opioids and feeding behavior: a 30-year historical perspective. *Peptides* 25: 697-725, 2004.
37. **Bohm M, Eickelmann M, Li Z, Schneider SW, Oji V, Diederichs S, Barsh GS, Vogt A, Stieler K, Blume-Peytavi U, and Luger TA**. Detection of functionally active melanocortin receptors and evidence for an immunoregulatory activity of alpha-melanocyte-stimulating hormone in human dermal papilla cells. *Endocrinology* 146: 4635-4646, 2005.
38. **Boileau G, Barbeau C, Jeannotte L, Chretien M, and Drouin J**. Complete structure of the porcine pro-opiomelanocortin mRNA derived from the nucleotide sequence of cloned cDNA. *Nucleic acids research* 11: 8063-8071, 1983.
39. **Boston BA**. The role of melanocortins in adipocyte function. *Ann N Y Acad Sci* 885: 75-84, 1999.
40. **Boudreault A, Gauthier D, and Lazure C**. Proprotein convertase PC1/3-related peptides are potent slow tight-binding inhibitors of murine PC1/3 and Hfurin. *J Biol Chem* 273: 31574-31580, 1998.
41. **Bousquet C, Zatelli MC, and Melmed S**. Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing. *J Clin Invest* 106: 1417-1425, 2000.
42. **Boutillier AL, Monnier D, Lorang D, Lundblad JR, Roberts JL, and Loeffler JP**. Corticotropin-releasing hormone stimulates proopiomelanocortin transcription by cFos-dependent and -independent pathways: characterization of an AP1 site in exon 1. *Mol Endocrinol* 9: 745-755, 1995.
43. **Buckingham JC**. Glucocorticoids: exemplars of multi-tasking. *Brit J Pharmacol* 147: S258-S268, 2006.
44. **Buijs RM, and Kalsbeek A**. Hypothalamic integration of central and peripheral clocks. *Nat Rev Neurosci* 2: 521-526, 2001.
45. **Bumaschny VF, Yamashita M, Casas-Cordero R, Otero-Corchon V, de Souza FS, Rubinstein M, and Low MJ**. Obesity-programmed mice are rescued by early genetic intervention. *J Clin Invest* 122: 4203-4212, 2012.
46. **Buono P, Pasanisi F, Nardelli C, Ieno L, Capone S, Liguori R, Finelli C, Oriani G, Contaldo F, and Sacchetti L**. Six novel mutations in the proopiomelanocortin and melanocortin receptor 4 genes in severely obese adults living in southern Italy. *Clin Chem* 51: 1358-1364, 2005.
47. **Burbach JP, Lebouille JL, and Wang X**. Metabolic conversion of pro-opiomelanocortin peptides by brain peptidases: ACTH, a-MSH and b-Endorphin. In: *Central actions of ACTH and related peptides*, edited by De Wied D, and Ferrari W. Padova: Liviana Press, 1986, p. 53-67.
48. **Butler AA, Marks DL, Fan W, Kuhn CM, Bartolome M, and Cone RD**. Melanocortin-4 receptor is required for acute homeostatic responses to increased dietary fat. *Nature neuroscience* 4: 605-611, 2001.
49. **Cangemi L, Adage T, Morabito A, and Portaleone P**. N-Acetyltransferase mechanism for alpha-melanocyte stimulating hormone regulation in rat ageing. *Neuroscience letters* 201: 65-68, 1995.
50. **Cawley NX, Li Z, and Loh YP**. 60 YEARS OF POMC: Biosynthesis, trafficking, and secretion of pro-opiomelanocortin-derived peptides. *J Mol Endocrinol* 56: T77-97, 2016.
51. **Cawley NX, Rathod T, Young S, Lou H, Birch N, and Loh YP**. Carboxypeptidase E and Secretogranin III coordinately facilitate efficient sorting of pro-opiomelanocortin to the regulated secretory pathway in AtT20 cells. *Mol Endocrinol* me20151166, 2015.
52. **Cawley NX, Yanik T, Woronowicz A, Chang W, Marini JC, and Loh YP**. Obese carboxypeptidase E knockout mice exhibit multiple defects in peptide hormone processing contributing to low bone mineral density. *Am J Physiol Endocrinol Metab* 299: E189-197, 2010.

53. **Cawley NX, Zhou J, Hill JM, Abebe D, Romboz S, Yanik T, Rodriguiz RM, Wetsel WC, and Loh YP**. The carboxypeptidase E knockout mouse exhibits endocrinological and behavioral deficits. *Endocrinology* 145: 5807-5819, 2004.
54. **Cerritelli S, Hirschberg S, Hill R, Balthasar N, and Pickering AE**. Activation of Brainstem Pro-opiomelanocortin Neurons Produces Opioidergic Analgesia, Bradycardia and Bradypnoea. *PloS one* 11: e0153187, 2016.
55. **Chadwick A, and Lowry PJ**. In vitro assay of MSH using skin from the frog Hyla arborea. *Gen Comp Endocrinol* 15: 493-495, 1970.
56. **Challis BG, Coll AP, Yeo GS, Pinnock SB, Dickson SL, Thresher RR, Dixon J, Zahn D, Rochford JJ, White A, Oliver RL, Millington G, Aparicio SA, Colledge WH, Russ AP, Carlton MB, and O'Rahilly S**. Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). *Proc Natl Acad Sci U S A* 101: 4695-4700, 2004.
57. **Challis BG, Pritchard LE, Creemers JW, Delplanque J, Keogh JM, Luan J, Wareham NJ, Yeo GS, Bhattacharyya S, Froguel P, White A, Farooqi IS, and O'Rahilly S**. A missense mutation disrupting a dibasic prohormone processing site in pro-opiomelanocortin (POMC) increases susceptibility to early-onset obesity through a novel molecular mechanism. *Human molecular genetics* 11: 1997-2004, 2002.
58. **Chan JS, Seidah NG, and Chretien M**. Measurement of N-terminal (1-76) of human proopiomelanocortin in human plasma: correlation with adrenocorticotropin. *J Clin Endocrinol Metab* 56: 791-796, 1983.
59. **Chanat E, and Huttner WB**. Milieu-induced, selective aggregation of regulated secretory proteins in the trans-Golgi network. *J Cell Biol* 115: 1505-1519, 1991.
60. **Chance RE, Ellis RM, and Bromer WW**. Porcine proinsulin: characterization and amino acid sequence. *Science* 161: 165-167, 1968.
61. **Chayen J, Loveridge N, and Daly JR**. A sensitive bioassay for adrenocorticotrophic hormone in human plasma. *Clin Endocrinol (Oxf)* 1: 219-233, 1972.
62. **Chen CL, Chang CC, Krieger DT, and Bardin CW**. Expression and regulation of proopiomelanocortin-like gene in the ovary and placenta: comparison with the testis. *Endocrinology* 118: 2382-2389, 1986.
63. **Chen H, Jawahar S, Qian Y, Duong Q, Chan G, Parker A, Meyer JM, Moore KJ, Chayen S, Gross DJ, Glaser B, Permutt MA, and Fricker LD**. Missense polymorphism in the human carboxypeptidase E gene alters enzymatic activity. *Human mutation* 18: 120-131, 2001.
64. **Chretien M, Benjannet S, Gossard F, Gianoulakis C, Crine P, Lis M, and Seidah NG**. From beta-lipotropin to beta-endorphin and 'pro-opio-melanocortin'. *Canadian journal of biochemistry* 57: 1111-1121, 1979.
65. **Chretien M, and Li CH**. Isolation, purification, and characterization of gamma-lipotropic hormone from sheep pituitary glands. *Canadian journal of biochemistry* 45: 1163-1174, 1967.
66. **Chretien M, and Mbikay M**. 60 YEARS OF POMC: From the prohormone theory to pro-opiomelanocortin and to proprotein convertases (PCSK1 to PCSK9). *J Mol Endocrinol* 56: T49-62, 2016.
67. **Chung S, Son GH, and Kim K**. Circadian rhythm of adrenal glucocorticoid: its regulation and clinical implications. *Biochim Biophys Acta* 1812: 581-591, 2011.
68. **Ciccotosto GD, Schiller MR, Eipper BA, and Mains RE**. Induction of integral membrane PAM expression in AtT-20 cells alters the storage and trafficking of POMC and PC1. *J Cell Biol* 144: 459-471, 1999.
69. **Clark AJ**. 60 YEARS OF POMC: The proopiomelanocortin gene: discovery, deletion and disease. *J Mol Endocrinol* 56: T27-37, 2016.
70. **Clarke BL, and Bost KL**. Differential expression of functional adrenocorticotropic hormone receptors by subpopulations of lymphocytes. *Journal of immunology* 143: 464-469, 1989.

71. **Clement K, Dubern B, Mencarelli M, Czernichow P, Ito S, Wakamatsu K, Barsh GS, Vaisse C, and Leger J**. Unexpected endocrine features and normal pigmentation in a young adult patient carrying a novel homozygous mutation in the POMC gene. *J Clin Endocrinol Metab* 93: 4955-4962, 2008.
72. **Cochet M, Chang AC, and Cohen SN**. Characterization of the structural gene and putative 5'-regulatory sequences for human proopiomelanocortin. *Nature* 297: 335-339, 1982.
73. **Coll AP, Challis BG, Lopez M, Piper S, Yeo GS, and O'Rahilly S**. Proopiomelanocortin-deficient mice are hypersensitive to the adverse metabolic effects of glucocorticoids. *Diabetes* 54: 2269-2276, 2005.
74. **Coll AP, Challis BG, Yeo GS, Snell K, Piper SJ, Halsall D, Thresher RR, and O'Rahilly S**. The effects of proopiomelanocortin deficiency on murine adrenal development and responsiveness to adrenocorticotropin. *Endocrinology* 145: 4721-4727, 2004.
75. **Coll AP, Fassnacht M, Klammer S, Hahner S, Schulte DM, Piper S, Tung YC, Challis BG, Weinstein Y, Allolio B, O'Rahilly S, and Beuschlein F**. Peripheral administration of the N-terminal pro-opiomelanocortin fragment 1-28 to Pomc-/- mice reduces food intake and weight but does not affect adrenal growth or corticosterone production. *J Endocrinol* 190: 515-525, 2006.
76. **Comuzzie AG, Hixson JE, Almasy L, Mitchell BD, Mahaney MC, Dyer TD, Stern MP, MacCluer JW, and Blangero J**. A major quantitative trait locus determining serum leptin levels and fat mass is located on human chromosome 2. *Nature genetics* 15: 273-276, 1997.
77. **Cone RD**. *The Melanocortin Receptors*. Totoaw, New Jersey: Humana Press, 2000.
78. **Cone RD**. Studies on the physiological functions of the melanocortin system. *Endocr Rev* 27: 736-749, 2006.
79. **Conway-Campbell BL, Sarabdjitsingh RA, McKenna MA, Pooley JR, Kershaw YM, Meijer OC, De Kloet ER, and Lightman SL**. Glucocorticoid ultradian rhythmicity directs cyclical gene pulsing of the clock gene period 1 in rat hippocampus. *J Neuroendocrinol* 22: 1093-1100, 2010.
80. **Cool DR, Fenger M, Snell CR, and Loh YP**. Identification of the sorting signal motif within pro-opiomelanocortin for the regulated secretory pathway. *J Biol Chem* 270: 8723-8729, 1995.
81. **Cool DR, and Loh YP**. Carboxypeptidase E is a sorting receptor for prohormones: binding and kinetic studies. *Mol Cell Endocrinol* 139: 7-13, 1998.
82. **Cool DR, and Loh YP**. Identification of a sorting signal for the regulated secretory pathway at the N-terminus of pro-opiomelanocortin. *Biochimie* 76: 265-270, 1994.
83. **Cool DR, Normant E, Shen F, Chen HC, Pannell L, Zhang Y, and Loh YP**. Carboxypeptidase E is a regulated secretory pathway sorting receptor: genetic obliteration leads to endocrine disorders in Cpe(fat) mice. *Cell* 88: 73-83, 1997.
84. **Cota D, Steiner MA, Marsicano G, Cervino C, Herman JP, Grubler Y, Stalla J, Pasquali R, Lutz B, Stalla GK, and Pagotto U**. Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. *Endocrinology* 148: 1574-1581, 2007.
85. **Creemers JW, Choquet H, Stijnen P, Vatin V, Pigeyre M, Beckers S, Meulemans S, Than ME, Yengo L, Tauber M, Balkau B, Elliott P, Jarvelin MR, Van Hul W, Van Gaal L, Horber F, Pattou F, Froguel P, and Meyre D**. Heterozygous mutations causing partial prohormone convertase 1 deficiency contribute to human obesity. *Diabetes* 61: 383-390, 2012.
86. **Creemers JW, Lee YS, Oliver RL, Bahceci M, Tuzcu A, Gokalp D, Keogh J, Herber S, White A, O'Rahilly S, and Farooqi IS**. Mutations in the amino-terminal region of proopiomelanocortin (POMC) in patients with early-onset obesity impair

POMC sorting to the regulated secretory pathway. *J Clin Endocrinol Metab* 93: 4494-4499, 2008.
87. **Creemers JW, Roebroek AJ, and Van de Ven WJ**. Expression in human lung tumor cells of the proprotein processing enzyme PC1/PC3. Cloning and primary sequence of a 5 kb cDNA. *FEBS Lett* 300: 82-88, 1992.
88. **Crosby SR, Stewart MF, Farrell WE, Gibson S, and White A**. Comparison of ACTH and ACTH precursor peptides secreted by human pituitary and lung tumour cells in vitro. *J Endocrinol* 125: 147-152, 1990.
89. **Crosby SR, Stewart MF, Ratcliffe JG, and White A**. Direct measurement of the precursors of adrenocorticotropin in human plasma by two-site immunoradiometric assay. *J Clin Endocrinol Metab* 67: 1272-1277, 1988.
90. **Dallman MF, Akana SF, Scribner KA, Bradbury MJ, Walker CD, Strack AM, and Cascio CS**. Stress, feedback and facilitation in the hypothalamo-pituitary-adrenal axis. *J Neuroendocrinol* 4: 517-526, 1992.
91. **Day R, Schafer MK, Watson SJ, Chretien M, and Seidah NG**. Distribution and regulation of the prohormone convertases PC1 and PC2 in the rat pituitary. *Mol Endocrinol* 6: 485-497, 1992.
92. **Deakin JF, Dostrovsky JO, and Smyth DG**. Influence of N-terminal acetylation and C-terminal proteolysis on the analgesic activity of beta-endorphin. *Biochem J* 189: 501-506, 1980.
93. **DeBold CR, DeCherney GS, Jackson RV, Sheldon WR, Alexander AN, Island DP, Rivier J, Vale W, and Orth DN**. Effect of synthetic ovine corticotropin-releasing factor: prolonged duration of action and biphasic response of plasma adrenocorticotropin and cortisol. *J Clin Endocrinol Metab* 57: 294-298, 1983.
94. **DeBold CR, Menefee JK, Nicholson WE, and Orth DN**. Proopiomelanocortin gene is expressed in many normal human tissues and in tumors not associated with ectopic adrenocorticotropin syndrome. *Mol Endocrinol* 2: 862-870, 1988.
95. **Delbende C, Jegou S, Tranchand-Bunel D, Pelletier G, and Vaudry H**. Hypothalamic alpha-melanocyte-stimulating hormone (alpha-MSH) is not under dopaminergic control. *Brain research* 423: 203-212, 1987.
96. **Deng Q, Riquelme D, Trinh L, Low MJ, Tomic M, Stojilkovic S, and Aguilera G**. Rapid Glucocorticoid Feedback Inhibition of ACTH Secretion Involves Ligand-Dependent Membrane Association of Glucocorticoid Receptors. *Endocrinology* 156: 3215-3227, 2015.
97. **Dennis M, Seidah NG, and Chretien M**. Regional heterogeneity in the processing of pro-opiomelanocortin in rat brain. *Life sciences* 33 Suppl 1: 49-52, 1983.
98. **Dhanvantari S, and Loh YP**. Lipid raft association of carboxypeptidase E is necessary for its function as a regulated secretory pathway sorting receptor. *J Biol Chem* 275: 29887-29893, 2000.
99. **Dhanvantari S, Shen FS, Adams T, Snell CR, Zhang C, Mackin RB, Morris SJ, and Loh YP**. Disruption of a receptor-mediated mechanism for intracellular sorting of proinsulin in familial hyperproinsulinemia. *Mol Endocrinol* 17: 1856-1867, 2003.
100. **Dikeakos JD, and Reudelhuber TL**. Sending proteins to dense core secretory granules: still a lot to sort out. *J Cell Biol* 177: 191-196, 2007.
101. **Dong W, and Day R**. Gene expression of proprotein convertases in individual rat anterior pituitary cells and their regulation in corticotrophs mediated by glucocorticoids. *Endocrinology* 143: 254-262, 2002.
102. **Dong W, Fricker LD, and Day R**. Carboxypeptidase D is a potential candidate to carry out redundant processing functions of carboxypeptidase E based on comparative distribution studies in the rat central nervous system. *Neuroscience* 89: 1301-1317, 1999.
103. **Dores RM, Jain M, and Akil H**. Characterization of the forms of beta-endorphin and alpha-MSH in the caudal medulla of the rat and guinea pig. *Brain research* 377: 251-260, 1986.

104. **Drouin J**. 60 YEARS OF POMC: Transcriptional and epigenetic regulation of POMC gene expression. *J Mol Endocrinol* 56: T99-T112, 2016.
105. **Drouin J, and Goodman HM**. Most of the coding region of rat ACTH beta--LPH precursor gene lacks intervening sequences. *Nature* 288: 610-613, 1980.
106. **Drouin J, Sun YL, Chamberland M, Gauthier Y, De Lean A, Nemer M, and Schmidt TJ**. Novel glucocorticoid receptor complex with DNA element of the hormone-repressed POMC gene. *EMBO J* 12: 145-156, 1993.
107. **Drouin J, Sun YL, and Nemer M**. Glucocorticoid repression of pro-opiomelanocortin gene transcription. *J Steroid Biochem* 34: 63-69, 1989.
108. **Drouin J, Trifiro MA, Plante RK, Nemer M, Eriksson P, and Wrange O**. Glucocorticoid receptor binding to a specific DNA sequence is required for hormone-dependent repression of pro-opiomelanocortin gene transcription. *Mol Cell Biol* 9: 5305-5314, 1989.
109. **Dubern B, Lubrano-Berthelier C, Mencarelli M, Ersoy B, Frelut ML, Bougle D, Costes B, Simon C, Tounian P, Vaisse C, and Clement K**. Mutational analysis of the pro-opiomelanocortin gene in French obese children led to the identification of a novel deleterious heterozygous mutation located in the alpha-melanocyte stimulating hormone domain. *Pediatr Res* 63: 211-216, 2008.
110. **Dumermuth E, and Moore HP**. Analysis of constitutive and constitutive-like secretion in semi-intact pituitary cells. *Methods* 16: 188-197, 1998.
111. **Duncan PJ, Sengul S, Tabak J, Ruth P, Bertram R, and Shipston MJ**. Large conductance Ca(2)(+)-activated K(+) (BK) channels promote secretagogue-induced transition from spiking to bursting in murine anterior pituitary corticotrophs. *J Physiol* 593: 1197-1211, 2015.
112. **Dutia R, Meece K, Dighe S, Kim AJ, and Wardlaw SL**. beta-Endorphin antagonizes the effects of alpha-MSH on food intake and body weight. *Endocrinology* 153: 4246-4255, 2012.
113. **Eberle AN**. *The Melanotropins: Chemistry, Physiology and Mechanisms of Action*. Basel: Karger, 1988.
114. **Eberle AN**. Proopiomelanocortin and the Melanocortin Peptides. In: *The Melanocortin Receptors*, edited by Cone RD. Totowa: Humana Press, 2000.
115. **Eberwine JH, and Roberts JL**. Glucocorticoid regulation of pro-opiomelanocortin gene transcription in the rat pituitary. *J Biol Chem* 259: 2166-2170, 1984.
116. **Echwald SM, Sorensen TI, Andersen T, Tybjaerg-Hansen A, Clausen JO, and Pedersen O**. Mutational analysis of the proopiomelanocortin gene in Caucasians with early onset obesity. *Int J Obes Relat Metab Disord* 23: 293-298, 1999.
117. **Eipper BA, and Mains RE**. Analysis of the common precursor to corticotropin and endorphin. *J Biol Chem* 253: 5732-5744, 1978.
118. **Eipper BA, and Mains RE**. High molecular weight forms of adrenocorticotropic hormone in the mouse pituitary and in a mouse pituitary tumor cell line. *Biochemistry* 14: 3836-3844, 1975.
119. **Eipper BA, and Mains RE**. Structure and biosynthesis of pro-adrenocorticotropin/endorphin and related peptides. *Endocr Rev* 1: 1-27, 1980.
120. **Eipper BA, Milgram SL, Husten EJ, Yun HY, and Mains RE**. Peptidylglycine alpha-amidating monooxygenase: a multifunctional protein with catalytic, processing, and routing domains. *Protein science : a publication of the Protein Society* 2: 489-497, 1993.
121. **El Meskini R, Galano GJ, Marx R, Mains RE, and Eipper BA**. Targeting of membrane proteins to the regulated secretory pathway in anterior pituitary endocrine cells. *J Biol Chem* 276: 3384-3393, 2001.
122. **Ellingboe J, Veldhuis JD, Mendelson JH, Kuehnle JC, and Mello NK**. Effect of endogenous opioid blockade on the amplitude and frequency of pulsatile luteinizing hormone secretion in normal men. *J Clin Endocrinol Metab* 54: 854-857, 1982.

123. **Estivariz FE, Hope J, McLean C, and Lowry PJ**. Purification and characterization of a gamma-melanotropin precursor from frozen human pituitary glands. *Biochem J* 191: 125-132, 1980.
124. **Estivariz FE, Iturriza F, McLean C, Hope J, and Lowry PJ**. Stimulation of adrenal mitogenesis by N-terminal proopiocortin peptides. *Nature* 297: 419-422, 1982.
125. **Estivariz FE, Morano MI, Carino M, Jackson S, and Lowry PJ**. Adrenal regeneration in the rat is mediated by mitogenic N-terminal pro-opiomelanocortin peptides generated by changes in precursor processing in the anterior pituitary. *J Endocrinol* 116: 207-216, 1988.
126. **Estomba H, Munoa-Hoyos I, Gianzo M, Urizar-Arenaza I, Casis L, Irazusta J, and Subiran N**. Expression and Localization of Opioid Receptors in Male Germ Cells and the Implication for Mouse Spermatogenesis. *PloS one* 11: e0152162, 2016.
127. **Facchinetti F, Perez-Fernandez R, Toma MO, Gaudiero GJ, Lechuga MJ, Devesa J, and Genazzani AR**. Dopamine acts on acetylation of proopiomelanocortin-derived products in dog pituitary. *Acta endocrinologica* 117: 33-38, 1988.
128. **Farooqi IS**. Monogenic human obesity. *Frontiers of hormone research* 36: 1-11, 2008.
129. **Farooqi IS, Drop S, Clements A, Keogh JM, Biernacka J, Lowenbein S, Challis BG, and O'Rahilly S**. Heterozygosity for a POMC-null mutation and increased obesity risk in humans. *Diabetes* 55: 2549-2553, 2006.
130. **Farooqi IS, Volders K, Stanhope R, Heuschkel R, White A, Lank E, Keogh J, O'Rahilly S, and Creemers JW**. Hyperphagia and early-onset obesity due to a novel homozygous missense mutation in prohormone convertase 1/3. *J Clin Endocrinol Metab* 92: 3369-3373, 2007.
131. **Fassnacht M, Hahner S, Hansen IA, Kreutzberger T, Zink M, Adermann K, Jakob F, Troppmair J, and Allolio B**. N-terminal proopiomelanocortin acts as a mitogen in adrenocortical tumor cells and decreases adrenal steroidogenesis. *J Clin Endocrinol Metab* 88: 2171-2179, 2003.
132. **Feldberg W, and Smyth DG**. The C-fragment of lipotropin - a potent analgesic [proceedings]. *J Physiol* 260: 30P-31P, 1976.
133. **Ferin M, Van Vugt D, and Wardlaw S**. The hypothalamic control of the menstrual cycle and the role of endogenous opioid peptides. *Recent progress in hormone research* 40: 441-485, 1984.
134. **Fernandez CJ, Haugwitz M, Eaton B, and Moore HP**. Distinct molecular events during secretory granule biogenesis revealed by sensitivities to brefeldin A. *Molecular biology of the cell* 8: 2171-2185, 1997.
135. **Findling JW, Engeland WC, and Raff H**. The use of immunoradiometric assay for the measurement of ACTH in human plasma. *Trends Endocrinol Metab* 1: 283-287, 1990.
136. **Fortenberry Y, Liu J, and Lindberg I**. The role of the 7B2 CT peptide in the inhibition of prohormone convertase 2 in endocrine cell lines. *Journal of neurochemistry* 73: 994-1003, 1999.
137. **Fricker LD, Berman YL, Leiter EH, and Devi LA**. Carboxypeptidase E activity is deficient in mice with the fat mutation. Effect on peptide processing. *J Biol Chem* 271: 30619-30624, 1996.
138. **Fricker LD, McKinzie AA, Sun J, Curran E, Qian Y, Yan L, Patterson SD, Courchesne PL, Richards B, Levin N, Mzhavia N, Devi LA, and Douglass J**. Identification and characterization of proSAAS, a granin-like neuroendocrine peptide precursor that inhibits prohormone processing. *J Neurosci* 20: 639-648, 2000.
139. **Fukata J, Naitoh Y, Usui T, Nakaishi S, Nakai Y, and Imura H**. Two-site immunoradiometric assay for adrenocorticotrophin: a cautionary study about the reactivity to its precursor molecules. *Endocrinol Jpn* 36: 155-161, 1989.
140. **Furuta M, Yano H, Zhou A, Rouille Y, Holst JJ, Carroll R, Ravazzola M, Orci L, Furuta H, and Steiner DF**. Defective prohormone processing and altered pancreatic

islet morphology in mice lacking active SPC2. *Proc Natl Acad Sci U S A* 94: 6646-6651, 1997.
141. **Gagner JP, and Drouin J**. Opposite regulation of pro-opiomelanocortin gene transcription by glucocorticoids and CRH. *Mol Cell Endocrinol* 40: 25-32, 1985.
142. **Gagner JP, and Drouin J**. Tissue-specific regulation of pituitary proopiomelanocortin gene transcription by corticotropin-releasing hormone, 3',5'-cyclic adenosine monophosphate, and glucocorticoids. *Mol Endocrinol* 1: 677-682, 1987.
143. **Gallo-Payet N**. 60 YEARS OF POMC: Adrenal and extra-adrenal functions of ACTH. *J Mol Endocrinol* 56: T135-156, 2016.
144. **Gantz I, Miwa H, Konda Y, Shimoto Y, Tashiro T, Watson SJ, DelValle J, and Yamada T**. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. *J Biol Chem* 268: 15174-15179, 1993.
145. **Gasson JC**. Steroidogenic activity of high molecular weight forms of corticotropin. *Biochemistry* 18: 4215-4224, 1979.
146. **Gevers E, Meredith S, Shah P, Torpiano J, Peters C, Sebire N, Slater O, White A, and Datani M**. Cushing Syndrome in a child due to Pro-opiomelanocortin (POMC) secretion from a yolk sac tumor. *Eur J Endocrinol* 2016.
147. **Gewirtz G, Schneider B, Krieger DT, and Yalow RS**. Big ACTH: conversion to biologically active ACTH by trypsin. *J Clin Endocrinol Metab* 38: 227-230, 1974.
148. **Gibson S, Crosby SR, Stewart MF, Jennings AM, McCall E, and White A**. Differential release of proopiomelanocortin-derived peptides from the human pituitary: evidence from a panel of two-site immunoradiometric assays. *J Clin Endocrinol Metab* 78: 835-841, 1994.
149. **Gibson S, Crosby SR, and White A**. Discrimination between beta-endorphin and beta-lipotrophin in human plasma using two-site immunoradiometric assays. *Clin Endocrinol (Oxf)* 39: 445-453, 1993.
150. **Gibson S, Ray DW, Crosby SR, Dornan TL, Jennings AM, Bevan JS, Davis JR, and White A**. Impaired processing of proopiomelanocortin in corticotroph macroadenomas. *J Clin Endocrinol Metab* 81: 497-502, 1996.
151. **Gizang-Ginsberg E, and Wolgemuth DJ**. Expression of the proopiomelanocortin gene is developmentally regulated and affected by germ cells in the male mouse reproductive system. *Proc Natl Acad Sci U S A* 84: 1600-1604, 1987.
152. **Glauder J, Ragg H, Rauch J, and Engels JW**. Human peptidylglycine alpha-amidating monooxygenase: cDNA, cloning and functional expression of a truncated form in COS cells. *Biochem Biophys Res Commun* 169: 551-558, 1990.
153. **Goodman LJ, and Gorman CM**. Autoproteolytic activation of the mouse prohormone convertase mPC1. *Biochem Biophys Res Commun* 201: 795-804, 1994.
154. **Guillemin R**. Peptides in the brain: the new endocrinology of the neuron. *Science* 202: 390-402, 1978.
155. **Gumbiner B, and Kelly RB**. Two distinct intracellular pathways transport secretory and membrane glycoproteins to the surface of pituitary tumor cells. *Cell* 28: 51-59, 1982.
156. **Guo L, Munzberg H, Stuart RC, Nillni EA, and Bjorbaek C**. N-acetylation of hypothalamic alpha-melanocyte-stimulating hormone and regulation by leptin. *Proc Natl Acad Sci U S A* 101: 11797-11802, 2004.
157. **Hager J, Dina C, Francke S, Dubois S, Houari M, Vatin V, Vaillant E, Lorentz N, Basdevant A, Clement K, Guy-Grand B, and Froguel P**. A genome-wide scan for human obesity genes reveals a major susceptibility locus on chromosome 10. *Nature genetics* 20: 304-308, 1998.
158. **Hahner S, Fassnacht M, Hammer F, Schammann M, Weismann D, Hansen IA, and Allolio B**. Evidence against a role of human airway trypsin-like protease--the human analogue of the growth-promoting rat adrenal secretory protease--in adrenal tumourigenesis. *Eur J Endocrinol* 152: 143-153, 2005.

159. **Hale AC, Besser GM, and Rees LH**. Characterization of pro-opiomelanocortin-derived peptides in pituitary and ectopic adrenocorticotrophin-secreting tumours. *J Endocrinol* 108: 49-56, 1986.
160. **Hale AC, Ratter SJ, Tomlin SJ, Lytras N, Besser GM, and Rees LH**. Measurement of immunoreactive gamma-MSH in human plasma. *Clin Endocrinol (Oxf)* 21: 139-148, 1984.
161. **Hardiman A, Friedman TC, Grunwald WC, Jr., Furuta M, Zhu Z, Steiner DF, and Cool DR**. Endocrinomic profile of neurointermediate lobe pituitary prohormone processing in PC1/3- and PC2-Null mice using SELDI-TOF mass spectrometry. *J Mol Endocrinol* 34: 739-751, 2005.
162. **Harno E, and White A**. Adrenocorticotropic Hormone. In: *Endocrinology: Adult and Pediatric*, edited by Jameson JL, De Groot LJ, de Kretser DM, Giudice LC, Grossman AB, Melmed S, Potts J, J.T., and Weir GC. Philadelphia: Elsevier, 2015, p. 129-146.
163. **Hendy GN, Li T, Girard M, Feldstein RC, Mulay S, Desjardins R, Day R, Karaplis AC, Tremblay ML, and Canaff L**. Targeted ablation of the chromogranin a (Chga) gene: normal neuroendocrine dense-core secretory granules and increased expression of other granins. *Mol Endocrinol* 20: 1935-1947, 2006.
164. **Henley DE, Leendertz JA, Russell GM, Wood SA, Taheri S, Woltersdorf WW, and Lightman SL**. Development of an automated blood sampling system for use in humans. *J Med Eng Technol* 33: 199-208, 2009.
165. **Herbert E, Comb M, Thomas G, Liston D, Civelli O, Martin MG, and Birnberg NC**. Biosynthesis of ACTH and related peptides. In: *Hormonal Proteins and Peptides*, edited by Li CH. Orlando, FL, USA: Academic Press, Inc., 1987, p. 59-87.
166. **Hickman S, Shapiro LJ, and Neufeld EF**. A recognition marker required for uptake of a lysosomal enzyme by cultured fibroblasts. *Biochem Biophys Res Commun* 57: 55-61, 1974.
167. **Hinney A, Becker I, Heibult O, Nottebom K, Schmidt A, Ziegler A, Mayer H, Siegfried W, Blum WF, Remschmidt H, and Hebebrand J**. Systematic mutation screening of the pro-opiomelanocortin gene: identification of several genetic variants including three different insertions, one nonsense and two missense point mutations in probands of different weight extremes. *J Clin Endocrinol Metab* 83: 3737-3741, 1998.
168. **Hirata Y, Yamamoto H, Matsukura S, and Imura H**. In vitro release and biosynthesis of tumor ACTH in ectopic ACTH producing tumors. *J Clin Endocrinol Metab* 41: 106-114, 1975.
169. **Hoch M, Hirzel E, Lindinger P, Eberle AN, Linscheid P, Martin I, Peters T, and Peterli R**. Weak functional coupling of the melanocortin-1 receptor expressed in human adipocytes. *Journal of receptor and signal transduction research* 28: 485-504, 2008.
170. **Hochgeschwender U, Costa JL, Reed P, Bui S, and Brennan MB**. Altered glucose homeostasis in proopiomelanocortin-null mouse mutants lacking central and peripheral melanocortin. *Endocrinology* 144: 5194-5202, 2003.
171. **Hodgkinson SC, Allolio B, Landon J, and Lowry PJ**. Development of a non-extracted 'two-site' immunoradiometric assay for corticotropin utilizing extreme amino- and carboxy-terminally directed antibodies. *Biochem J* 218: 703-711, 1984.
172. **Hoggard N, Johnstone AM, Faber P, Gibney ER, Elia M, Lobley G, Rayner V, Horgan G, Hunter L, Bashir S, and Stubbs RJ**. Plasma concentrations of alpha-MSH, AgRP and leptin in lean and obese men and their relationship to differing states of energy balance perturbation. *Clin Endocrinol (Oxf)* 61: 31-39, 2004.
173. **Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, and Morris HR**. Identification of two related pentapeptides from the brain with potent opiate agonist activity. *Nature* 258: 577-580, 1975.
174. **Humphreys MH**. Gamma-MSH, sodium metabolism, and salt-sensitive hypertension. *Am J Physiol Regul Integr Comp Physiol* 286: R417-430, 2004.

175. **Hunt G, Todd C, Cresswell JE, and Thody AJ**. Alpha-melanocyte stimulating hormone and its analogue Nle4DPhe7 alpha-MSH affect morphology, tyrosinase activity and melanogenesis in cultured human melanocytes. *J Cell Sci* 107 (Pt 1): 205-211, 1994.
176. **Iino K, Oki Y, Yamashita M, Matsushita F, Hayashi C, Yogo K, Nishizawa S, Yamada S, Maekawa M, Sasano H, and Nakamura H**. Possible relevance between prohormone convertase 2 expression and tumor growth in human adrenocorticotropin-producing pituitary adenoma. *J Clin Endocrinol Metab* 95: 4003-4011, 2010.
177. **Ingle DJ, and Kendall EC**. Atrophy of the Adrenal Cortex of the Rat Produced by the Administration of Large Amounts of Cortin. *Science* 86: 245, 1937.
178. **Ito N, Ito T, Kromminga A, Bettermann A, Takigawa M, Kees F, Straub RH, and Paus R**. Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal axis and synthesize cortisol. *FASEB J* 19: 1332-1334, 2005.
179. **Jackson RS, Creemers JW, Farooqi IS, Raffin-Sanson ML, Varro A, Dockray GJ, Holst JJ, Brubaker PL, Corvol P, Polonsky KS, Ostrega D, Becker KL, Bertagna X, Hutton JC, White A, Dattani MT, Hussain K, Middleton SJ, Nicole TM, Milla PJ, Lindley KJ, and O'Rahilly S**. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. *J Clin Invest* 112: 1550-1560, 2003.
180. **Jackson RS, Creemers JW, Ohagi S, Raffin-Sanson ML, Sanders L, Montague CT, Hutton JC, and O'Rahilly S**. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. *Nature genetics* 16: 303-306, 1997.
181. **Jackson S, Salacinski P, Hope J, and Lowry PJ**. An investigation of N-terminal pro-opiocortin peptides in the rat pituitary. *Peptides* 4: 431-438, 1983.
182. **Jegou S, Tranchand-Bunel D, Delbende C, Blasquez C, and Vaudry H**. Characterization of alpha-MSH-related peptides released from rat hypothalamic neurons in vitro. *Brain research Molecular brain research* 5: 219-226, 1989.
183. **Jingami H, Nakanishi S, Imura H, and Numa S**. Tissue distribution of messenger RNAs coding for opioid peptide precursors and related RNA. *European journal of biochemistry* 142: 441-447, 1984.
184. **Joseph CG, Yao H, Scott JW, Sorensen NB, Marnane RN, Mountjoy KG, and Haskell-Luevano C**. gamma(2)-Melanocyte stimulation hormone (gamma(2)-MSH) truncation studies results in the cautionary note that gamma(2)-MSH is not selective for the mouse MC3R over the mouse MC5R. *Peptides* 31: 2304-2313, 2010.
185. **Jutras I, Seidah NG, Reudelhuber TL, and Brechler V**. Two activation states of the prohormone convertase PC1 in the secretory pathway. *J Biol Chem* 272: 15184-15188, 1997.
186. **Kadekaro AL, Kanto H, Kavanagh R, and Abdel-Malek Z**. Significance of the melanocortin 1 receptor in regulating human melanocyte pigmentation, proliferation, and survival. *Ann N Y Acad Sci* 994: 359-365, 2003.
187. **Karpac J, Kern A, and Hochgeschwender U**. Pro-opiomelanocortin peptides and the adrenal gland. *Mol Cell Endocrinol* 265-266: 29-33, 2007.
188. **Karpac J, Ostwald D, Bui S, Hunnewell P, Shankar M, and Hochgeschwender U**. Development, maintenance, and function of the adrenal gland in early postnatal proopiomelanocortin-null mutant mice. *Endocrinology* 146: 2555-2562, 2005.
189. **Kask A, Rago L, Wikberg JE, and Schioth HB**. Differential effects of melanocortin peptides on ingestive behaviour in rats: evidence against the involvement of MC(3) receptor in the regulation of food intake. *Neuroscience letters* 283: 1-4, 2000.
190. **Katsuki A, Sumida Y, Murashima S, Furuta M, Araki-Sasaki R, Tsuchihashi K, Hori Y, Yano Y, and Adachi Y**. Elevated plasma levels of alpha-melanocyte stimulating hormone (alpha-MSH) are correlated with insulin resistance in obese men. *Int J Obes Relat Metab Disord* 24: 1260-1264, 2000.

191. **Kauser S, Schallreuter KU, Thody AJ, Gummer C, and Tobin DJ**. Regulation of human epidermal melanocyte biology by beta-endorphin. *J Invest Dermatol* 120: 1073-1080, 2003.
192. **Kauser S, Slominski A, Wei ET, and Tobin DJ**. Modulation of the human hair follicle pigmentary unit by corticotropin-releasing hormone and urocortin peptides. *FASEB J* 20: 882-895, 2006.
193. **Kauser S, Thody AJ, Schallreuter KU, Gummer CL, and Tobin DJ**. beta-Endorphin as a regulator of human hair follicle melanocyte biology. *J Invest Dermatol* 123: 184-195, 2004.
194. **Kauser S, Thody AJ, Schallreuter KU, Gummer CL, and Tobin DJ**. A fully functional proopiomelanocortin/melanocortin-1 receptor system regulates the differentiation of human scalp hair follicle melanocytes. *Endocrinology* 146: 532-543, 2005.
195. **Keller-Wood ME, and Dallman MF**. Corticosteroid inhibition of ACTH secretion. *Endocr Rev* 5: 1-24, 1984.
196. **Kelso TB, Herbert WG, Gwazdauskas FC, Goss FL, and Hess JL**. Exercise-thermoregulatory stress and increased plasma beta-endorphin/beta-lipotropin in humans. *J Appl Physiol Respir Environ Exerc Physiol* 57: 444-449, 1984.
197. **Kempna P, and Fluck CE**. Adrenal gland development and defects. *Best practice & research Clinical endocrinology & metabolism* 22: 77-93, 2008.
198. **Kesterson RA**. The Melanocortin-3 Receptor. In: *The Melanocortin Receptors*, edited by Cone RD. New Jersey, USA: Humana Press, 2000, p. 385-404.
199. **Kim T, Tao-Cheng JH, Eiden LE, and Loh YP**. Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis. *Cell* 106: 499-509, 2001.
200. **Kimura S, Lewis RV, Gerber LD, Brink L, Rubinstein M, Stein S, and Udenfriend S**. Purification to homogeneity of camel pituitary pro-opiocortin, the common precursor of opioid peptides and corticotropin. *Proc Natl Acad Sci U S A* 76: 1756-1759, 1979.
201. **Kishida M, Baker BI, and Bird DJ**. Localisation and identification of melanocyte-stimulating hormones in the fish brain. *Gen Comp Endocrinol* 71: 229-242, 1988.
202. **Kitabchi AE**. The biological and immunological properties of pork and beef insulin, proinsulin, and connecting peptides. *J Clin Invest* 49: 979-987, 1970.
203. **Koch M, Varela L, Kim JG, Kim JD, Hernandez-Nuno F, Simonds SE, Castorena CM, Vianna CR, Elmquist JK, Morozov YM, Rakic P, Bechmann I, Cowley MA, Szigeti-Buck K, Dietrich MO, Gao XB, Diano S, and Horvath TL**. Hypothalamic POMC neurons promote cannabinoid-induced feeding. *Nature* 519: 45-50, 2015.
204. **Kovalovsky D, Refojo D, Liberman AC, Hochbaum D, Pereda MP, Coso OA, Stalla GK, Holsboer F, and Arzt E**. Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. *Mol Endocrinol* 16: 1638-1651, 2002.
205. **Kreis TE, Matteoni R, Hollinshead M, and Tooze J**. Secretory granules and endosomes show saltatory movement biased to the anterograde and retrograde directions, respectively, along microtubules in AtT20 cells. *European journal of cell biology* 49: 128-139, 1989.
206. **Krieger DT, Choi HS, and Anderson PJ**. The characterization of the ACTH produced by a primary pituitary tumour in a patient with Cushing's disease. *Clin Endocrinol (Oxf)* 5: 455-472, 1976.
207. **Krude H, Biebermann H, Luck W, Horn R, Brabant G, and Gruters A**. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. *Nature genetics* 19: 155-157, 1998.
208. **Krude H, Biebermann H, Schnabel D, Tansek MZ, Theunissen P, Mullis PE, and Gruters A**. Obesity due to proopiomelanocortin deficiency: three new cases and

treatment trials with thyroid hormone and ACTH4-10. *J Clin Endocrinol Metab* 88: 4633-4640, 2003.
209. **Kuliawat R, and Arvan P**. Protein targeting via the "constitutive-like" secretory pathway in isolated pancreatic islets: passive sorting in the immature granule compartment. *J Cell Biol* 118: 521-529, 1992.
210. **Kumar D, Mains RE, and Eipper BA**. 60 YEARS OF POMC: From POMC and alpha-MSH to PAM, molecular oxygen, copper, and vitamin C. *J Mol Endocrinol* 56: T63-76, 2016.
211. **Lacaze-Masmonteil T, de Keyzer Y, Luton JP, Kahn A, and Bertagna X**. Characterization of proopiomelanocortin transcripts in human nonpituitary tissues. *Proc Natl Acad Sci U S A* 84: 7261-7265, 1987.
212. **Lam DD, Attard CA, Mercer AJ, Myers MG, Jr., Rubinstein M, and Low MJ**. Conditional expression of Pomc in the Lepr-positive subpopulation of POMC neurons is sufficient for normal energy homeostasis and metabolism. *Endocrinology* 156: 1292-1302, 2015.
213. **Laurent V, Jaubert-Miazza L, Desjardins R, Day R, and Lindberg I**. Biosynthesis of proopiomelanocortin-derived peptides in prohormone convertase 2 and 7B2 null mice. *Endocrinology* 145: 519-528, 2004.
214. **Laurent V, Kimble A, Peng B, Zhu P, Pintar JE, Steiner DF, and Lindberg I**. Mortality in 7B2 null mice can be rescued by adrenalectomy: involvement of dopamine in ACTH hypersecretion. *Proc Natl Acad Sci U S A* 99: 3087-3092, 2002.
215. **Lee SN, Prodhomme E, and Lindberg I**. Prohormone convertase 1 (PC1) processing and sorting: effect of PC1 propeptide and proSAAS. *J Endocrinol* 182: 353-364, 2004.
216. **Lee YS, Challis BG, Thompson DA, Yeo GS, Keogh JM, Madonna ME, Wraight V, Sims M, Vatin V, Meyre D, Shield J, Burren C, Ibrahim Z, Cheetham T, Swift P, Blackwood A, Hung CC, Wareham NJ, Froguel P, Millhauser GL, O'Rahilly S, and Farooqi IS**. A POMC variant implicates beta-melanocyte-stimulating hormone in the control of human energy balance. *Cell metabolism* 3: 135-140, 2006.
217. **Leibel RL**. The molecular genetics of the melanocortin pathway and energy homeostasis. *Cell metabolism* 3: 79-81, 2006.
218. **Lerner AB, Shizume K, and Bunding I**. The mechanism of endocrine control of melanin pigmentation. *J Clin Endocrinol Metab* 14: 1463-1490, 1954.
219. **Levin N, Blum M, and Roberts JL**. Modulation of basal and corticotropin-releasing factor-stimulated proopiomelanocortin gene expression by vasopressin in rat anterior pituitary. *Endocrinology* 125: 2957-2966, 1989.
220. **Lim J, Berezniuk I, Che FY, Parikh R, Biswas R, Pan H, and Fricker LD**. Altered neuropeptide processing in prefrontal cortex of Cpe (fat/fat) mice: implications for neuropeptide discovery. *Journal of neurochemistry* 96: 1169-1181, 2006.
221. **Lloyd DJ, Bohan S, and Gekakis N**. Obesity, hyperphagia and increased metabolic efficiency in Pc1 mutant mice. *Human molecular genetics* 15: 1884-1893, 2006.
222. **Loh YP**. Kinetic studies on the processing of human beta-lipotropin by bovine pituitary intermediate lobe pro-opiomelanocortin-converting enzyme. *J Biol Chem* 261: 11949-11955, 1986.
223. **Loh YP**. Molecular mechanisms of beta-endorphin biosynthesis. *Biochem Pharmacol* 44: 843-849, 1992.
224. **Loh YP, Parish DC, and Tuteja R**. Purification and characterization of a paired basic residue-specific pro-opiomelanocortin converting enzyme from bovine pituitary intermediate lobe secretory vesicles. *J Biol Chem* 260: 7194-7205, 1985.
225. **Loh YP, Tam WW, and Russell JT**. Measurement of delta pH and membrane potential in secretory vesicles isolated from bovine pituitary intermediate lobe. *J Biol Chem* 259: 8238-8245, 1984.

226. **Lotfi CF, and de Mendonca PO**. Comparative Effect of ACTH and Related Peptides on Proliferation and Growth of Rat Adrenal Gland. *Front Endocrinol (Lausanne)* 7: 39, 2016.
227. **Low MJ, Hayward MD, Appleyard SM, and Rubinstein M**. State-dependent modulation of feeding behavior by proopiomelanocortin-derived beta-endorphin. *Ann N Y Acad Sci* 994: 192-201, 2003.
228. **Lowry P**. 60 YEARS OF POMC: Purification and biological characterisation of melanotrophins and corticotrophins. *J Mol Endocrinol* 56: T1-T12, 2016.
229. **Lowry PJ, Silas L, McLean C, Linton EA, and Estivariz FE**. Pro-gamma-melanocyte-stimulating hormone cleavage in adrenal gland undergoing compensatory growth. *Nature* 306: 70-73, 1983.
230. **Lowry PJ, Silman RE, Hope J, and Scott AP**. Structure and biosynthesis of peptides related to corticotropins and beta-melanotropins. *Ann N Y Acad Sci* 297: 49-62, 1977.
231. **Lundblad JR, and Roberts JL**. Regulation of proopiomelanocortin gene expression in pituitary. *Endocr Rev* 9: 135-158, 1988.
232. **Mains RE, and Eipper BA**. Biosynthesis of adrenocorticotropic hormone in mouse pituitary tumor cells. *J Biol Chem* 251: 4115-4120, 1976.
233. **Mains RE, and Eipper BA**. Comparison of rat anterior and intermediate pituitary in tissue culture: corticotropin (ACTH) and beta-endorphin. *Ciba Foundation symposium* 81: 32-54, 1981.
234. **Mains RE, and Eipper BA**. Coordinate synthesis of corticotropins and endorphins by mouse pituitary tumor cells. *J Biol Chem* 253: 651-655, 1978.
235. **Mains RE, Eipper BA, and Ling N**. Common precursor to corticotropins and endorphins. *Proc Natl Acad Sci U S A* 74: 3014-3018, 1977.
236. **Maira M, Couture C, Le Martelot G, Pulichino AM, Bilodeau S, and Drouin J**. The T-box factor Tpit recruits SRC/p160 co-activators and mediates hormone action. *J Biol Chem* 278: 46523-46532, 2003.
237. **Maji SK, Perrin MH, Sawaya MR, Jessberger S, Vadodaria K, Rissman RA, Singru PS, Nilsson KP, Simon R, Schubert D, Eisenberg D, Rivier J, Sawchenko P, Vale W, and Riek R**. Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. *Science* 325: 328-332, 2009.
238. **Malide D, Seidah NG, Chretien M, and Bendayan M**. Electron microscopic immunocytochemical evidence for the involvement of the convertases PC1 and PC2 in the processing of proinsulin in pancreatic beta-cells. *The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society* 43: 11-19, 1995.
239. **Martin MG, Lindberg I, Solorzano-Vargas RS, Wang J, Avitzur Y, Bandsma R, Sokollik C, Lawrence S, Pickett LA, Chen Z, Egritas O, Dalgic B, Albornoz V, de Ridder L, Hulst J, Gok F, Aydogan A, Al-Hussaini A, Gok DE, Yourshaw M, Wu SV, Cortina G, Stanford S, and Georgia S**. Congenital proprotein convertase 1/3 deficiency causes malabsorptive diarrhea and other endocrinopathies in a pediatric cohort. *Gastroenterology* 145: 138-148, 2013.
240. **Matsuoka H, Mulrow PJ, and Li CH**. Beta-lipotropin: a new aldosterone-stimulating factor. *Science* 209: 307-308, 1980.
241. **Mattos GE, Jacysyn JF, Amarante-Mendes GP, and Lotfi CF**. Comparative effect of FGF2, synthetic peptides 1-28 N-POMC and ACTH on proliferation in rat adrenal cell primary cultures. *Cell Tissue Res* 345: 343-356, 2011.
242. **Mazurkiewicz JE, Corliss D, and Slominski A**. Spatiotemporal expression, distribution, and processing of POMC and POMC-derived peptides in murine skin. *J Histochem Cytochem* 48: 905-914, 2000.
243. **Mbikay M, Croissandeau G, Sirois F, Anini Y, Mayne J, Seidah NG, and Chretien M**. A targeted deletion/insertion in the mouse Pcsk1 locus is associated with homozygous embryo preimplantation lethality, mutant allele preferential transmission

and heterozygous female susceptibility to dietary fat. *Developmental biology* 306: 584-598, 2007.
244. **Mbikay M, Seidah NG, and Chretien M**. Neuroendocrine secretory protein 7B2: structure, expression and functions. *Biochem J* 357: 329-342, 2001.
245. **McGuire J**. Melanin granule dispersion in epidermal melanocytes. *J Invest Dermatol* 45: 547-548, 1965.
246. **McLean C, Hope J, Salacinski P, Estivariz F, and Lowry PJ**. Purification and characterization of amino-terminal pro-opiocortin peptides from human pituitary glands. *Biosci Rep* 1: 843-849, 1981.
247. **McMinn JE, Wilkinson CW, Havel PJ, Woods SC, and Schwartz MW**. Effect of intracerebroventricular alpha-MSH on food intake, adiposity, c-Fos induction, and neuropeptide expression. *Am J Physiol Regul Integr Comp Physiol* 279: R695-703, 2000.
248. **Mendiratta MS, Yang Y, Balazs AE, Willis AS, Eng CM, Karaviti LP, and Potocki L**. Early onset obesity and adrenal insufficiency associated with a homozygous POMC mutation. *International journal of pediatric endocrinology* 2011: 5, 2011.
249. **Milgram SL, and Mains RE**. Differential effects of temperature blockade on the proteolytic processing of three secretory granule-associated proteins. *J Cell Sci* 107 (Pt 3): 737-745, 1994.
250. **Miller WL**. Molecular biology of steroid hormone synthesis. *Endocr Rev* 9: 295-318, 1988.
251. **Millington GW, Tung YC, Hewson AK, O'Rahilly S, and Dickson SL**. Differential effects of alpha-, beta- and gamma(2)-melanocyte-stimulating hormones on hypothalamic neuronal activation and feeding in the fasted rat. *Neuroscience* 108: 437-445, 2001.
252. **Millington WR, O'Donohue TL, Chappell MC, Roberts JL, and Mueller GP**. Coordinate regulation of peptide acetyltransferase activity and proopiomelanocortin gene expression in the intermediate lobe of the rat pituitary. *Endocrinology* 118: 2024-2033, 1986.
253. **Millington WR, Rosenthal DW, Unal CB, and Nyquist-Battie C**. Localization of pro-opiomelanocortin mRNA transcripts and peptide immunoreactivity in rat heart. *Cardiovascular research* 43: 107-116, 1999.
254. **Miraglia del Giudice E, Cirillo G, Santoro N, D'Urso L, Carbone MT, Di Toro R, and Perrone L**. Molecular screening of the proopiomelanocortin (POMC) gene in Italian obese children: report of three new mutations. *Int J Obes Relat Metab Disord* 25: 61-67, 2001.
255. **Monaghan PJ, Kyriacou A, Sturgeon C, Davies A, Trainer PJ, White A, and Higham CE**. Proopiomelanocortin interference in the measurement of adrenocorticotrophic hormone: a United Kingdom National External Quality Assessment Service study. *Clin Endocrinol (Oxf)* 85: 569-574, 2016.
256. **Moore HP, Gumbiner B, and Kelly RB**. Chloroquine diverts ACTH from a regulated to a constitutive secretory pathway in AtT-20 cells. *Nature* 302: 434-436, 1983.
257. **Moore HP, Walker MD, Lee F, and Kelly RB**. Expressing a human proinsulin cDNA in a mouse ACTH-secreting cell. Intracellular storage, proteolytic processing, and secretion on stimulation. *Cell* 35: 531-538, 1983.
258. **Mountjoy KG**. Functions for pro-opiomelanocortin-derived peptides in obesity and diabetes. *Biochem J* 428: 305-324, 2010.
259. **Mountjoy KG, Caron A, Hubbard K, Shome A, Grey AC, Sun B, Bould S, Middleditch M, Pontre B, McGregor A, Harris PWR, Kowalczyk R, Brimble MA, Botha R, Tan KML, Piper SJ, Buchanan C, Lee S, Coll AP, and Elmquist JK**. Desacetyl-alpha-melanocyte stimulating hormone and alpha-melanocyte stimulating hormone are required to regulate energy balance. *Molecular metabolism* 2017.

260. **Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, and Cone RD**. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. *Mol Endocrinol* 8: 1298-1308, 1994.
261. **Mountjoy KG, Wu CS, Cornish J, and Callon KE**. alpha-MSH and desacetyl-alpha-MSH signaling through melanocortin receptors. *Ann N Y Acad Sci* 994: 58-65, 2003.
262. **Mynard V, Guignat L, Devin-Leclerc J, Bertagna X, and Catelli MG**. Different mechanisms for leukemia inhibitory factor-dependent activation of two proopiomelanocortin promoter regions. *Endocrinology* 143: 3916-3924, 2002.
263. **Naggert JK, Fricker LD, Varlamov O, Nishina PM, Rouille Y, Steiner DF, Carroll RJ, Paigen BJ, and Leiter EH**. Hyperproinsulinaemia in obese fat/fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity. *Nature genetics* 10: 135-142, 1995.
264. **Nakamura M, Inoue A, Nakanishi S, and Numa S**. Partial amino-terminal sequence of cell-free translation product encoded by bovine corticotropin-beta-lipotropin precursor messenger RNA. *FEBS Lett* 105: 357-359, 1979.
265. **Nakanishi S, Inoue A, Kita T, Nakamura M, Chang AC, Cohen SN, and Numa S**. Nucleotide sequence of cloned cDNA for bovine corticotropin-beta-lipotropin precursor. *Nature* 278: 423-427, 1979.
266. **Navarro S, Soletto L, Puchol S, Rotllant J, Soengas JL, and Cerda-Reverter JM**. 60 YEARS OF POMC: POMC: an evolutionary perspective. *J Mol Endocrinol* 56: T113-118, 2016.
267. **Newman CB, Wardlaw SL, and Frantz AG**. Suppression of basal and stress-induced prolactin release and stimulation of luteinizing hormone secretion by alpha-melanocyte-stimulating hormone. *Life sciences* 36: 1661-1668, 1985.
268. **Ni XP, Pearce D, Butler AA, Cone RD, and Humphreys MH**. Genetic disruption of gamma-melanocyte-stimulating hormone signaling leads to salt-sensitive hypertension in the mouse. *J Clin Invest* 111: 1251-1258, 2003.
269. **Nicolas P, and Li CH**. Beta-endorphin-(1-27) is a naturally occurring antagonist to etorphine-induced analgesia. *Proc Natl Acad Sci U S A* 82: 3178-3181, 1985.
270. **Normant E, and Loh YP**. Depletion of carboxypeptidase E, a regulated secretory pathway sorting receptor, causes misrouting and constitutive secretion of proinsulin and proenkephalin, but not chromogranin A. *Endocrinology* 139: 2137-2145, 1998.
271. **Nussdorfer GG, and Malendowicz LK**. Role of VIP, PACAP, and related peptides in the regulation of the hypothalamo-pituitary-adrenal axis. *Peptides* 19: 1443-1467, 1998.
272. **O'Donohue TL, Handelmann GE, Chaconas T, Miller RL, and Jacobowitz DM**. Evidence that N-acetylation regulates the behavioral activity of alpha-MSH in the rat and human central nervous system. *Peptides* 2: 333-344, 1981.
273. **O'Donohue TL, Handelmann GE, Miller RL, and Jacobowitz DM**. N-acetylation regulates the behavioral activity of alpha-melanotropin in a multineurotransmitter neuron. *Science* 215: 1125-1127, 1982.
274. **O'Rahilly S, Gray H, Humphreys PJ, Krook A, Polonsky KS, White A, Gibson S, Taylor K, and Carr C**. Brief report: impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. *The New England journal of medicine* 333: 1386-1390, 1995.
275. **Oates EL, Allaway GP, and Prabhakar BS**. A potential for mutual regulation of proopiomelanocortin gene and Epstein-Barr virus expression in human lymphocytes. *Ann N Y Acad Sci* 594: 60-65, 1990.
276. **Odell WD**. Ectopic ACTH secretion. A misnomer. *Endocrinol Metab Clin North Am* 20: 371-379, 1991.
277. **Oldfield EH, Doppman JL, Nieman LK, Chrousos GP, Miller DL, Katz DA, Cutler GB, Jr., and Loriaux DL**. Petrosal sinus sampling with and without corticotropin-

releasing hormone for the differential diagnosis of Cushing's syndrome. *The New England journal of medicine* 325: 897-905, 1991.
278. **Oliver RL, Davis JR, and White A**. Characterisation of ACTH related peptides in ectopic Cushing's syndrome. *Pituitary* 6: 119-126, 2003.
279. **Orci L, Ravazzola M, Amherdt M, Perrelet A, Powell SK, Quinn DL, and Moore HP**. The trans-most cisternae of the Golgi complex: a compartment for sorting of secretory and plasma membrane proteins. *Cell* 51: 1039-1051, 1987.
280. **Orth D, Nicholson W, Shapiro M, and Byyny R**. Adrenocorticotropic hormone (ACTH) and malanocyte-stimulating hormone (MSH) production by a single cell. *Program Endocr Soc* 52nd Meet. St Louis: 140, 1970.
281. **Orth DN, Nicholson WE, Mitchell WM, Island DP, Shapiro M, and Byyny RL**. ACTH and MSH production by a single cloned mouse pituitary tumor cell line. *Endocrinology* 92: 385-393, 1973.
282. **Osterlund CD, Rodriguez-Santiago M, Woodruff ER, Newsom RJ, Chadayammuri AP, and Spencer RL**. Glucocorticoid Fast Feedback Inhibition of Stress Induced ACTH Secretion in the Male Rat: Rate Independence and Stress-State Resistance. *Endocrinology* 157: 2785-2798, 2016.
283. **Padilla SL, Carmody JS, and Zeltser LM**. Pomc-expressing progenitors give rise to antagonistic neuronal populations in hypothalamic feeding circuits. *Nat Med* 16: 403-405, 2010.
284. **Padilla SL, Reef D, and Zeltser LM**. Defining POMC neurons using transgenic reagents: impact of transient Pomc expression in diverse immature neuronal populations. *Endocrinology* 153: 1219-1231, 2012.
285. **Page-Wilson G, Freda PU, Jacobs TP, Khandji AG, Bruce JN, Foo ST, Meece K, White A, and Wardlaw SL**. Clinical Utility of Plasma POMC and AgRP Measurements in the Differential Diagnosis of ACTH-Dependent Cushing's Syndrome. *J Clin Endocr Metab* 99: E1838-E1845, 2014.
286. **Page-Wilson G, Meece K, White A, Rosenbaum M, Leibel RL, Smiley R, and Wardlaw SL**. Proopiomelanocortin, agouti-related protein, and leptin in human cerebrospinal fluid: correlations with body weight and adiposity. *Am J Physiol Endocrinol Metab* 309: E458-465, 2015.
287. **Page-Wilson G, Reitman-Ivashkov E, Meece K, White A, Rosenbaum M, Smiley RM, and Wardlaw SL**. Cerebrospinal fluid levels of leptin, proopiomelanocortin, and agouti-related protein in human pregnancy: evidence for leptin resistance. *J Clin Endocrinol Metab* 98: 264-271, 2013.
288. **Pagotto U, Marsicano G, Cota D, Lutz B, and Pasquali R**. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. *Endocr Rev* 27: 73-100, 2006.
289. **Pagotto U, Marsicano G, Fezza F, Theodoropoulou M, Grubler Y, Stalla J, Arzberger T, Milone A, Losa M, Di Marzo V, Lutz B, and Stalla GK**. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. *J Clin Endocrinol Metab* 86: 2687-2696, 2001.
290. **Pan H, Che FY, Peng B, Steiner DF, Pintar JE, and Fricker LD**. The role of prohormone convertase-2 in hypothalamic neuropeptide processing: a quantitative neuropeptidomic study. *Journal of neurochemistry* 98: 1763-1777, 2006.
291. **Pan H, Nanno D, Che FY, Zhu X, Salton SR, Steiner DF, Fricker LD, and Devi LA**. Neuropeptide processing profile in mice lacking prohormone convertase-1. *Biochemistry* 44: 4939-4948, 2005.
292. **Pan YX, Xu J, Bolan E, Abbadie C, Chang A, Zuckerman A, Rossi G, and Pasternak GW**. Identification and characterization of three new alternatively spliced mu-opioid receptor isoforms. *Molecular pharmacology* 56: 396-403, 1999.

293. **Pan YX, Xu J, Mahurter L, Bolan E, Xu M, and Pasternak GW**. Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene. *Proc Natl Acad Sci U S A* 98: 14084-14089, 2001.
294. **Panskepp J, Reilly P, Bishop P, Meeker RB, Vilberg TR, and Kastin AJ**. Effects of alpha-MSH on motivation, vigilance and brain respiration. *Pharmacology, biochemistry, and behavior* 5: 59-64, 1976.
295. **Park JJ, Cawley NX, and Loh YP**. Carboxypeptidase E cytoplasmic tail-driven vesicle transport is key for activity-dependent secretion of peptide hormones. *Mol Endocrinol* 22: 989-1005, 2008.
296. **Parker CR, Jr., Barnea A, Tilders FJ, and Porter JC**. Characterization of immunoreactive alpha-melanocyte stimulating hormone (alpha-MSHi) in human brain tissue. *Brain Res Bull* 6: 275-280, 1981.
297. **Parker LN, and Odell WD**. Evidence for existence of cortical androgen-stimulating hormone. *The American journal of physiology* 236: E616-620, 1979.
298. **Pasternak GW, and Pan YX**. Mu opioids and their receptors: evolution of a concept. *Pharmacological reviews* 65: 1257-1317, 2013.
299. **Patel S, Roelke CT, Rademacher DJ, Cullinan WE, and Hillard CJ**. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. *Endocrinology* 145: 5431-5438, 2004.
300. **Peinado JR, Laurent V, Lee SN, Peng BW, Pintar JE, Steiner DF, and Lindberg I**. Strain-dependent influences on the hypothalamo-pituitary-adrenal axis profoundly affect the 7B2 and PC2 null phenotypes. *Endocrinology* 146: 3438-3444, 2005.
301. **Peng J, Sarkar S, and Chang SL**. Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR. *Drug and alcohol dependence* 124: 223-228, 2012.
302. **Penhoat A, Sanchez P, Jaillard C, Langlois D, Begeot M, and Saez JM**. Human proopiomelanocortin-(79-96), a proposed cortical androgen-stimulating hormone, does not affect steroidogenesis in cultured human adult adrenal cells. *J Clin Endocrinol Metab* 72: 23-26, 1991.
303. **Pepper DJ, and Bicknell AB**. The stimulation of mitogenic signaling pathways by N-POMC peptides. *Mol Cell Endocrinol* 300: 77-82, 2009.
304. **Perroud B, Alvarado RJ, Espinal GM, Morado AR, Phinney BS, and Warden CH**. In vivo multiplex quantitative analysis of 3 forms of alpha melanocyte stimulating hormone in pituitary of prolyl endopeptidase deficient mice. *Molecular brain* 2: 14, 2009.
305. **Peters EMJ, Tobin DJ, Seidah NG, and Schallreuter KU**. Pro-opiomelanocortin-related peptides, prohormone convertases 1 and 2 and the regulatory peptide 7B2 are present in melanosomes of human melanocytes. *J Invest Dermatol* 114: 430-437, 2000.
306. **Philippe J, Stijnen P, Meyre D, De Graeve F, Thuillier D, Delplanque J, Gyapay G, Sand O, Creemers JW, Froguel P, and Bonnefond A**. A nonsense loss-of-function mutation in PCSK1 contributes to dominantly inherited human obesity. *International journal of obesity* 39: 295-302, 2015.
307. **Philips A, Lesage S, Gingras R, Maira MH, Gauthier Y, Hugo P, and Drouin J**. Novel dimeric Nur77 signaling mechanism in endocrine and lymphoid cells. *Mol Cell Biol* 17: 5946-5951, 1997.
308. **Philips A, Maira M, Mullick A, Chamberland M, Lesage S, Hugo P, and Drouin J**. Antagonism between Nur77 and glucocorticoid receptor for control of transcription. *Mol Cell Biol* 17: 5952-5959, 1997.
309. **Pintar JE, Schachter BS, Herman AB, Durgerian S, and Krieger DT**. Characterization and localization of proopiomelanocortin messenger RNA in the adult rat testis. *Science* 225: 632-634, 1984.
310. **Poggioli R, Vergoni AV, and Bertolini A**. ACTH-(1-24) and alpha-MSH antagonize feeding behavior stimulated by kappa opiate agonists. *Peptides* 7: 843-848, 1986.

311. **Pritchard LE, Armstrong D, Davies N, Oliver RL, Schmitz CA, Brennand JC, Wilkinson GF, and White A**. Agouti-related protein (83-132) is a competitive antagonist at the human melanocortin-4 receptor: no evidence for differential interactions with pro-opiomelanocortin-derived ligands. *J Endocrinol* 180: 183-191, 2004.
312. **Pritchard LE, Oliver RL, McLoughlin JD, Birtles S, Lawrence CB, Turnbull AV, and White A**. Proopiomelanocortin-derived peptides in rat cerebrospinal fluid and hypothalamic extracts: evidence that secretion is regulated with respect to energy balance. *Endocrinology* 144: 760-766, 2003.
313. **Pritchard LE, Turnbull AV, and White A**. Pro-opiomelanocortin processing in the hypothalamus: impact on melanocortin signalling and obesity. *J Endocrinol* 172: 411-421, 2002.
314. **Pritchard LE, and White A**. Neuropeptide processing and its impact on melanocortin pathways. *Endocrinology* 148: 4201-4207, 2007.
315. **Quigley ME, and Yen SS**. The role of endogenous opiates in LH secretion during the menstrual cycle. *J Clin Endocrinol Metab* 51: 179-181, 1980.
316. **Quinn D, Orci L, Ravazzola M, and Moore HP**. Intracellular transport and sorting of mutant human proinsulins that fail to form hexamers. *J Cell Biol* 113: 987-996, 1991.
317. **Raff H, and Findling JW**. A new immunoradiometric assay for corticotropin evaluated in normal subjects and patients with Cushing's syndrome. *Clin Chem* 35: 596-600, 1989.
318. **Raffan E, Dennis RJ, O'Donovan CJ, Becker JM, Scott RA, Smith SP, Withers DJ, Wood CJ, Conci E, Clements DN, Summers KM, German AJ, Mellersh CS, Arendt ML, Iyemere VP, Withers E, Soder J, Wernersson S, Andersson G, Lindblad-Toh K, Yeo GS, and O'Rahilly S**. A Deletion in the Canine POMC Gene Is Associated with Weight and Appetite in Obesity-Prone Labrador Retriever Dogs. *Cell metabolism* 23: 893-900, 2016.
319. **Raffin-Sanson ML, Massias JF, Dumont C, Raux-Demay MC, Proeschel MF, Luton JP, and Bertagna X**. High plasma proopiomelanocortin in aggressive adrenocorticotropin-secreting tumors. *J Clin Endocrinol Metab* 81: 4272-4277, 1996.
320. **Ramachandran J, Farmer SW, Liles S, and Li CH**. Comparison of the steroidogenic and melanotropic activities of corticotropin, alpha-melanotropin and analogs with their lipolytic activities in rat and rabbit adipocytes. *Biochim Biophys Acta* 428: 347-354, 1976.
321. **Rambaud J, Desroches J, Balsalobre A, and Drouin J**. TIF1beta/KAP-1 is a coactivator of the orphan nuclear receptor NGFI-B/Nur77. *J Biol Chem* 284: 14147-14156, 2009.
322. **Ratter SJ, Gillies G, Hope J, Hale AC, Grossman A, Gaillard R, Cook D, Edwards CR, and Rees LH**. Pro-opiocortin related peptides in human pituitary and ectopic ACTH secreting tumours. *Clin Endocrinol (Oxf)* 18: 211-218, 1983.
323. **Ray DW, Gibson S, Crosby SR, Davies D, Davis JR, and White A**. Elevated levels of adrenocorticotropin (ACTH) precursors in post-adrenalectomy Cushing's disease and their regulation by glucocorticoids. *J Clin Endocrinol Metab* 80: 2430-2436, 1995.
324. **Ray DW, Ren SG, and Melmed S**. Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway. *J Clin Invest* 97: 1852-1859, 1996.
325. **Ray DW, Ren SG, and Melmed S**. Leukemia inhibitory factor regulates proopiomelanocortin transcription. *Ann N Y Acad Sci* 840: 162-173, 1998.
326. **Richter WO, and Schwandt P**. Physiologic concentrations of beta-lipotropin stimulate lipolysis in rabbit adipocytes. *Metabolism* 34: 539-543, 1985.

327. **Riegel AT, Lu Y, Remenick J, Wolford RG, Berard DS, and Hager GL**. Proopiomelanocortin gene promoter elements required for constitutive and glucocorticoid-repressed transcription. *Mol Endocrinol* 5: 1973-1982, 1991.
328. **Rius RA, Chikuma T, and Loh YP**. Prenatal processing of pro-opiomelanocortin in the brain and pituitary of mouse embryos. *Brain research Developmental brain research* 60: 179-185, 1991.
329. **Roberts JL, and Herbert E**. Characterization of a common precursor to corticotropin and beta-lipotropin: cell-free synthesis of the precursor and identification of corticotropin peptides in the molecule. *Proc Natl Acad Sci U S A* 74: 4826-4830, 1977.
330. **Robinson P, Bateman A, Mulay S, Spencer SJ, Jaffe RB, Solomon S, and Bennett HP**. Isolation and characterization of three forms of joining peptide from adult human pituitaries: lack of adrenal androgen-stimulating activity. *Endocrinology* 129: 859-867, 1991.
331. **Roselli-Rehfuss L, Mountjoy KG, Robbins LS, Mortrud MT, Low MJ, Tatro JB, Entwistle ML, Simerly RB, and Cone RD**. Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. *Proc Natl Acad Sci U S A* 90: 8856-8860, 1993.
332. **Rotundo RL, and Fambrough DM**. Secretion of acetylcholinesterase: relation to acetylcholine receptor metabolism. *Cell* 22: 595-602, 1980.
333. **Rousseau K, Kauser S, Pritchard LE, Warhurst A, Oliver RL, Slominski A, Wei ET, Thody AJ, Tobin DJ, and White A**. Proopiomelanocortin (POMC), the ACTH/melanocortin precursor, is secreted by human epidermal keratinocytes and melanocytes and stimulates melanogenesis. *FASEB J* 21: 1844-1856, 2007.
334. **Rubinstein M, Mogil JS, Japon M, Chan EC, Allen RG, and Low MJ**. Absence of opioid stress-induced analgesia in mice lacking beta-endorphin by site-directed mutagenesis. *Proc Natl Acad Sci U S A* 93: 3995-4000, 1996.
335. **Rubinstein M, Stein S, and Udenfriend S**. Characterization of pro-opiocortin, a precursor to opioid peptides and corticotropin. *Proc Natl Acad Sci U S A* 75: 669-671, 1978.
336. **Rudman D, Hollins BM, Kutner MH, Moffitt SD, and Lynn MJ**. Three types of alpha-melanocyte-stimulating hormone: bioactivities and half-lives. *The American journal of physiology* 245: E47-54, 1983.
337. **Russell GM, Henley DE, Leendertz J, Douthwaite JA, Wood SA, Stevens A, Woltersdorf WW, Peeters BW, Ruigt GS, White A, Veldhuis JD, and Lightman SL**. Rapid glucocorticoid receptor-mediated inhibition of hypothalamic-pituitary-adrenal ultradian activity in healthy males. *J Neurosci* 30: 6106-6115, 2010.
338. **Russell GM, Kalafatakis K, and Lightman SL**. The importance of biological oscillators for hypothalamic-pituitary-adrenal activity and tissue glucocorticoid response: coordinating stress and neurobehavioural adaptation. *J Neuroendocrinol* 27: 378-388, 2015.
339. **Samuels ME, Gallo-Payet N, Pinard S, Hasselmann C, Magne F, Patry L, Chouinard L, Schwartzentruber J, Rene P, Sawyer N, Bouvier M, Djemli A, Delvin E, Huot C, Eugene D, Deal CL, Van Vliet G, Majewski J, Deladoey J, and Consortium FC**. Bioinactive ACTH causing glucocorticoid deficiency. *J Clin Endocrinol Metab* 98: 736-742, 2013.
340. **Santoro N, del Giudice EM, Cirillo G, Raimondo P, Corsi I, Amato A, Grandone A, and Perrone L**. An insertional polymorphism of the proopiomelanocortin gene is associated with fasting insulin levels in childhood obesity. *J Clin Endocrinol Metab* 89: 4846-4849, 2004.
341. **Sapolsky R, Rivier C, Yamamoto G, Plotsky P, and Vale W**. Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. *Science* 238: 522-524, 1987.

342. **Sarkar DK, and Yen SS**. Changes in beta-endorphin-like immunoreactivity in pituitary portal blood during the estrous cycle and after ovariectomy in rats. *Endocrinology* 116: 2075-2079, 1985.
343. **Schauer E, Trautinger F, Kock A, Schwarz A, Bhardwaj R, Simon M, Ansel JC, Schwarz T, and Luger TA**. Proopiomelanocortin-derived peptides are synthesized and released by human keratinocytes. *J Clin Invest* 93: 2258-2262, 1994.
344. **Schiller M, Raghunath M, Kubitscheck U, Scholzen TE, Fisbeck T, Metze D, Luger TA, and Bohm M**. Human dermal fibroblasts express prohormone convertases 1 and 2 and produce proopiomelanocortin-derived peptides. *J Invest Dermatol* 117: 227-235, 2001.
345. **Schnabel E, Mains RE, and Farquhar MG**. Proteolytic processing of pro-ACTH/endorphin begins in the Golgi complex of pituitary corticotropes and AtT-20 cells. *Mol Endocrinol* 3: 1223-1235, 1989.
346. **Scholzen TE, Konig S, Fastrich M, Bohm M, and Luger TA**. Terminating the stress: peripheral peptidolysis of proopiomelanocortin-derived regulatory hormones by the dermal microvascular endothelial cell extracellular peptidases neprilysin and angiotensin-converting enzyme. *Endocrinology* 148: 2793-2805, 2007.
347. **Scopsi L, Gullo M, Rilke F, Martin S, and Steiner DF**. Proprotein convertases (PC1/PC3 and PC2) in normal and neoplastic human tissues: their use as markers of neuroendocrine differentiation. *J Clin Endocrinol Metab* 80: 294-301, 1995.
348. **Seger MA, and Bennett HP**. Structure and bioactivity of the amino-terminal fragment of pro-opiomelanocortin. *J Steroid Biochem* 25: 703-710, 1986.
349. **Seidah NG**. The proprotein convertases, 20 years later. *Methods in molecular biology* 768: 23-57, 2011.
350. **Seidah NG, Benjannet S, Hamelin J, Mamarbachi AM, Basak A, Marcinkiewicz J, Mbikay M, Chretien M, and Marcinkiewicz M**. The subtilisin/kexin family of precursor convertases. Emphasis on PC1, PC2/7B2, POMC and the novel enzyme SKI-1. *Ann N Y Acad Sci* 885: 57-74, 1999.
351. **Seidah NG, and Chretien M**. Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. *Brain research* 848: 45-62, 1999.
352. **Seidah NG, Gaspar L, Mion P, Marcinkiewicz M, Mbikay M, and Chretien M**. cDNA sequence of two distinct pituitary proteins homologous to Kex2 and furin gene products: tissue-specific mRNAs encoding candidates for pro-hormone processing proteinases. *DNA Cell Biol* 9: 415-424, 1990.
353. **Seidah NG, Marcinkiewicz M, Benjannet S, Gaspar L, Beaubien G, Mattei MG, Lazure C, Mbikay M, and Chretien M**. Cloning and primary sequence of a mouse candidate prohormone convertase PC1 homologous to PC2, Furin, and Kex2: distinct chromosomal localization and messenger RNA distribution in brain and pituitary compared to PC2. *Mol Endocrinol* 5: 111-122, 1991.
354. **Seidah NG, Rochemont J, Hamelin J, Benjannet S, and Chretien M**. The missing fragment of the pro-sequence of human pro-opiomelanocortin: sequence and evidence for C-terminal amidation. *Biochem Biophys Res Commun* 102: 710-716, 1981.
355. **Seksek O, Biwersi J, and Verkman AS**. Direct measurement of trans-Golgi pH in living cells and regulation by second messengers. *J Biol Chem* 270: 4967-4970, 1995.
356. **Shen FS, Aguilera G, and Loh YP**. Altered biosynthesis and secretion of pro-opiomelanocortin in the intermediate and anterior pituitary of carboxypeptidase E-deficient, Cpe(fat)/ Cpe(fat)mice. *Neuropeptides* 33: 276-280, 1999.
357. **Shen FS, and Loh YP**. Intracellular misrouting and abnormal secretion of adrenocorticotropin and growth hormone in cpefat mice associated with a carboxypeptidase E mutation. *Proc Natl Acad Sci U S A* 94: 5314-5319, 1997.
358. **Shizume K, Lerner AB, and Fitzpatrick TB**. In vitro bioassay for the melanocyte stimulating hormone. *Endocrinology* 54: 553-560, 1954.

359. **Skibicka KP, and Grill HJ**. Energetic responses are triggered by caudal brainstem melanocortin receptor stimulation and mediated by local sympathetic effector circuits. *Endocrinology* 149: 3605-3616, 2008.
360. **Skobowiat C, Dowdy JC, Sayre RM, Tuckey RC, and Slominski A**. Cutaneous hypothalamic-pituitary-adrenal axis homolog: regulation by ultraviolet radiation. *Am J Physiol Endocrinol Metab* 301: E484-493, 2011.
361. **Slominski A**. A nervous breakdown in the skin: stress and the epidermal barrier. *J Clin Invest* 117: 3166-3169, 2007.
362. **Slominski A, Ermak G, Mazurkiewicz JE, Baker J, and Wortsman J**. Characterization of corticotropin-releasing hormone (CRH) in human skin. *J Clin Endocrinol Metab* 83: 1020-1024, 1998.
363. **Slominski A, Heasley D, Mazurkiewicz JE, Ermak G, Baker J, and Carlson JA**. Expression of proopiomelanocortin (POMC)-derived melanocyte-stimulating hormone (MSH) and adrenocorticotropic hormone (ACTH) peptides in skin of basal cell carcinoma patients. *Hum Pathol* 30: 208-215, 1999.
364. **Slominski A, Paus R, and Wortsman J**. On the potential role of proopiomelanocortin in skin physiology and pathology. *Mol Cell Endocrinol* 93: C1-6, 1993.
365. **Slominski A, Pisarchik A, Tobin DJ, Mazurkiewicz JE, and Wortsman J**. Differential expression of a cutaneous corticotropin-releasing hormone system. *Endocrinology* 145: 941-950, 2004.
366. **Slominski A, Wortsman J, Luger T, Paus R, and Solomon S**. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. *Physiol Rev* 80: 979-1020, 2000.
367. **Slominski A, Zbytek B, Nikolakis G, Manna PR, Skobowiat C, Zmijewski M, Li W, Janjetovic Z, Postlethwaite A, Zouboulis CC, and Tuckey RC**. Steroidogenesis in the skin: implications for local immune functions. *J Steroid Biochem Mol Biol* 137: 107-123, 2013.
368. **Slominski A, Zbytek B, Semak I, Sweatman T, and Wortsman J**. CRH stimulates POMC activity and corticosterone production in dermal fibroblasts. *J Neuroimmunol* 162: 97-102, 2005.
369. **Slominski A, Zbytek B, Szczesniewski A, Semak I, Kaminski J, Sweatman T, and Wortsman J**. CRH stimulation of corticosteroids production in melanocytes is mediated by ACTH. *Am J Physiol Endocrinol Metab* 288: E701-706, 2005.
370. **Slominski A, Zbytek B, Zmijewski M, Slominski RM, Kauser S, Wortsman J, and Tobin DJ**. Corticotropin releasing hormone and the skin. *Front Biosci* 11: 2230-2248, 2006.
371. **Smart JL, and Low MJ**. Lack of proopiomelanocortin peptides results in obesity and defective adrenal function but normal melanocyte pigmentation in the murine C57BL/6 genetic background. *Ann N Y Acad Sci* 994: 202-210, 2003.
372. **Smart JL, Tolle V, and Low MJ**. Glucocorticoids exacerbate obesity and insulin resistance in neuron-specific proopiomelanocortin-deficient mice. *J Clin Invest* 116: 495-505, 2006.
373. **Smart JL, Tolle V, Otero-Corchon V, and Low MJ**. Central dysregulation of the hypothalamic-pituitary-adrenal axis in neuron-specific proopiomelanocortin-deficient mice. *Endocrinology* 148: 647-659, 2007.
374. **Smeekens SP, Avruch AS, LaMendola J, Chan SJ, and Steiner DF**. Identification of a cDNA encoding a second putative prohormone convertase related to PC2 in AtT20 cells and islets of Langerhans. *Proc Natl Acad Sci U S A* 88: 340-344, 1991.
375. **Smeekens SP, and Steiner DF**. Identification of a human insulinoma cDNA encoding a novel mammalian protein structurally related to the yeast dibasic processing protease Kex2. *J Biol Chem* 265: 2997-3000, 1990.
376. **Smith PE**. Experimental Ablation of the Hypophysis in the Frog Embryo. *Science* 44: 280-282, 1916.

377. **Smith SR, Gawronska-Kozak B, Janderova L, Nguyen T, Murrell A, Stephens JM, and Mynatt RL**. Agouti expression in human adipose tissue: functional consequences and increased expression in type 2 diabetes. *Diabetes* 52: 2914-2922, 2003.
378. **Smyth DG**. 60 YEARS OF POMC: Lipotropin and beta-endorphin: a perspective. *J Mol Endocrinol* 56: T13-25, 2016.
379. **Soares SM, Thompson M, and Chini EN**. Role of the second-messenger cyclic-adenosine 5'-diphosphate-ribose on adrenocorticotropin secretion from pituitary cells. *Endocrinology* 146: 2186-2192, 2005.
380. **Sollner T, Whiteheart SW, Brunner M, Erdjument-Bromage H, Geromanos S, Tempst P, and Rothman JE**. SNAP receptors implicated in vesicle targeting and fusion. *Nature* 362: 318-324, 1993.
381. **Stavreva DA, Wiench M, John S, Conway-Campbell BL, McKenna MA, Pooley JR, Johnson TA, Voss TC, Lightman SL, and Hager GL**. Ultradian hormone stimulation induces glucocorticoid receptor-mediated pulses of gene transcription. *Nat Cell Biol* 11: 1093-1102, 2009.
382. **Steiner DF, Cunningham D, Spigelman L, and Aten B**. Insulin biosynthesis: evidence for a precursor. *Science* 157: 697-700, 1967.
383. **Steiner DF, and Oyer PE**. The biosynthesis of insulin and a probable precursor of insulin by a human islet cell adenoma. *Proc Natl Acad Sci U S A* 57: 473-480, 1967.
384. **Stevens A, and White A**. ACTH: cellular peptide hormone synthesis and secretory pathways. *Results Probl Cell Differ* 50: 63-84, 2010.
385. **Stewart PM, Gibson S, Crosby SR, Penn R, Holder R, Ferry D, Thatcher N, Phillips P, London DR, and White A**. ACTH precursors characterize the ectopic ACTH syndrome. *Clin Endocrinol (Oxf)* 40: 199-204, 1994.
386. **Stijnen P, Brouwers B, Dirkx E, Ramos-Molina B, Van Lommel L, Schuit F, Thorrez L, Declercq J, and Creemers JW**. Endoplasmic reticulum-associated degradation of the mouse PC1/3-N222D hypomorph and human PCSK1 mutations contributes to obesity. *International journal of obesity* 40: 973-981, 2016.
387. **Stijnen P, Ramos-Molina B, O'Rahilly S, and Creemers JW**. PCSK1 Mutations and Human Endocrinopathies: From Obesity to Gastrointestinal Disorders. *Endocr Rev* 37: 347-371, 2016.
388. **Stocco DM, and Clark BJ**. Regulation of the acute production of steroids in steroidogenic cells. *Endocr Rev* 17: 221-244, 1996.
389. **Strehl C, and Buttgereit F**. Unraveling the functions of the membrane-bound glucocorticoid receptors: first clues on origin and functional activity. *Ann N Y Acad Sci* 1318: 1-6, 2014.
390. **Sudhof TC, and Rizo J**. Synaptotagmins: C2-domain proteins that regulate membrane traffic. *Neuron* 17: 379-388, 1996.
391. **Takahashi H, Hakamata Y, Watanabe Y, Kikuno R, Miyata T, and Numa S**. Complete nucleotide sequence of the human corticotropin-beta-lipotropin precursor gene. *Nucleic acids research* 11: 6847-6858, 1983.
392. **Talaber G, Tuckermann JP, and Okret S**. ACTH controls thymocyte homeostasis independent of glucocorticoids. *FASEB J* 29: 2526-2534, 2015.
393. **Tanaka S**. Comparative aspects of intracellular proteolytic processing of peptide hormone precursors: studies of proopiomelanocortin processing. *Zoological science* 20: 1183-1198, 2003.
394. **Tanaka S, Yora T, Nakayama K, Inoue K, and Kurosumi K**. Proteolytic processing of pro-opiomelanocortin occurs in acidifying secretory granules of AtT-20 cells. *The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society* 45: 425-436, 1997.
395. **Tasker JG, Di S, and Malcher-Lopes R**. Minireview: rapid glucocorticoid signaling via membrane-associated receptors. *Endocrinology* 147: 5549-5556, 2006.

396. **Taylor T, Dluhy RG, and Williams GH**. beta-endorphin suppresses adrenocorticotropin and cortisol levels in normal human subjects. *J Clin Endocrinol Metab* 57: 592-596, 1983.
397. **Thody AJ, Ridley K, Penny RJ, Chalmers R, Fisher C, and Shuster S**. MSH peptides are present in mammalian skin. *Peptides* 4: 813-816, 1983.
398. **Thomas L, Leduc R, Thorne BA, Smeekens SP, Steiner DF, and Thomas G**. Kex2-like endoproteases PC2 and PC3 accurately cleave a model prohormone in mammalian cells: evidence for a common core of neuroendocrine processing enzymes. *Proc Natl Acad Sci U S A* 88: 5297-5301, 1991.
399. **Tooze J, and Tooze SA**. Clathrin-coated vesicular transport of secretory proteins during the formation of ACTH-containing secretory granules in AtT20 cells. *J Cell Biol* 103: 839-850, 1986.
400. **Tooze J, Tooze SA, and Fuller SD**. Sorting of progeny coronavirus from condensed secretory proteins at the exit from the trans-Golgi network of AtT20 cells. *J Cell Biol* 105: 1215-1226, 1987.
401. **Torres TE, de Mendonca PO, and Lotfi CF**. Synthetic modified N-POMC(1-28) controls in vivo proliferation and blocks apoptosis in rat adrenal cortex. *Cell Tissue Res* 341: 239-250, 2010.
402. **Tsagarakis S, Navarra P, Rees LH, Besser M, Grossman A, and Navara P**. Morphine directly modulates the release of stimulated corticotrophin-releasing factor-41 from rat hypothalamus in vitro. *Endocrinology* 124: 2330-2335, 1989.
403. **Tsigos C, Crosby SR, Gibson S, Young RJ, and White A**. Proopiomelanocortin is the predominant adrenocorticotropin-related peptide in human cerebrospinal fluid. *J Clin Endocrinol Metab* 76: 620-624, 1993.
404. **Tsujii S, and Bray GA**. Acetylation alters the feeding response to MSH and beta-endorphin. *Brain Res Bull* 23: 165-169, 1989.
405. **Tung YC, Piper SJ, Yeung D, O'Rahilly S, and Coll AP**. A comparative study of the central effects of specific proopiomelancortin (POMC)-derived melanocortin peptides on food intake and body weight in pomc null mice. *Endocrinology* 147: 5940-5947, 2006.
406. **Turan S, Hughes C, Atay Z, Guran T, Haliloglu B, Clark AJ, Bereket A, and Metherell LA**. An atypical case of familial glucocorticoid deficiency without pigmentation caused by coexistent homozygous mutations in MC2R (T152K) and MC1R (R160W). *J Clin Endocrinol Metab* 97: E771-774, 2012.
407. **Uhler M, and Herbert E**. Complete amino acid sequence of mouse pro-opiomelanocortin derived from the nucleotide sequence of pro-opiomelanocortin cDNA. *J Biol Chem* 258: 257-261, 1983.
408. **Vale W, Vaughan J, Smith M, Yamamoto G, Rivier J, and Rivier C**. Effects of synthetic ovine corticotropin-releasing factor, glucocorticoids, catecholamines, neurohypophysial peptides, and other substances on cultured corticotropic cells. *Endocrinology* 113: 1121-1131, 1983.
409. **Valverde P, Healy E, Jackson I, Rees JL, and Thody AJ**. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. *Nature genetics* 11: 328-330, 1995.
410. **Van der Salm AL, Pavlidis M, Flik G, and Wendelaar Bonga SE**. Differential release of alpha-melanophore stimulating hormone isoforms by the pituitary gland of red porgy, Pagrus pagrus. *Gen Comp Endocrinol* 135: 126-133, 2004.
411. **Varlamov O, Eng FJ, Novikova EG, and Fricker LD**. Localization of metallocarboxypeptidase D in AtT-20 cells. Potential role in prohormone processing. *J Biol Chem* 274: 14759-14767, 1999.
412. **Verburg-Van Kemenade BM, Jenks BG, and Driessen AG**. GABA and dopamine act directly on melanotropes of Xenopus to inhibit MSH secretion. *Brain Res Bull* 17: 697-704, 1986.

413. **Vieau D, Massias JF, Girard F, Luton JP, and Bertagna X**. Corticotrophin-like intermediary lobe peptide as a marker of alternate pro-opiomelanocortin processing in ACTH-producing non-pituitary tumours. *Clin Endocrinol (Oxf)* 31: 691-700, 1989.
414. **Wakamatsu K, Graham A, Cook D, and Thody AJ**. Characterisation of ACTH peptides in human skin and their activation of the melanocortin-1 receptor. *Pigment Cell Res* 10: 288-297, 1997.
415. **Walker JJ, Spiga F, Waite E, Zhao Z, Kershaw Y, Terry JR, and Lightman SL**. The origin of glucocorticoid hormone oscillations. *PLoS biology* 10: e1001341, 2012.
416. **Walker JJ, Terry JR, and Lightman SL**. Origin of ultradian pulsatility in the hypothalamic-pituitary-adrenal axis. *Proc Biol Sci* 277: 1627-1633, 2010.
417. **Wallingford N, Perroud B, Gao Q, Coppola A, Gyengesi E, Liu ZW, Gao XB, Diament A, Haus KA, Shariat-Madar Z, Mahdi F, Wardlaw SL, Schmaier AH, Warden CH, and Diano S**. Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents. *J Clin Invest* 119: 2291-2303, 2009.
418. **Wardlaw SL**. Regulation of beta-endorphin, corticotropin-like intermediate lobe peptide, and alpha-melanotropin-stimulating hormone in the hypothalamus by testosterone. *Endocrinology* 119: 19-24, 1986.
419. **Wardlaw SL, and Ferin M**. Interaction between beta-endorphin and alpha-melanocyte-stimulating hormone in the control of prolactin and luteinizing hormone secretion in the primate. *Endocrinology* 126: 2035-2040, 1990.
420. **Wardman JH, Zhang X, Gagnon S, Castro LM, Zhu X, Steiner DF, Day R, and Fricker LD**. Analysis of peptides in prohormone convertase 1/3 null mouse brain using quantitative peptidomics. *Journal of neurochemistry* 114: 215-225, 2010.
421. **Wen T, Peng B, and Pintar JE**. The MOR-1 opioid receptor regulates glucose homeostasis by modulating insulin secretion. *Mol Endocrinol* 23: 671-678, 2009.
422. **Westphal CH, Muller L, Zhou A, Zhu X, Bonner-Weir S, Schambelan M, Steiner DF, Lindberg I, and Leder P**. The neuroendocrine protein 7B2 is required for peptide hormone processing in vivo and provides a novel mechanism for pituitary Cushing's disease. *Cell* 96: 689-700, 1999.
423. **White A, and Gibson S**. ACTH precursors: biological significance and clinical relevance. *Clin Endocrinol (Oxf)* 48: 251-255, 1998.
424. **White A, Gray C, and Ratcliffe JG**. Characterisation of monoclonal antibodies to adrenocorticotrophin. *Journal of immunological methods* 79: 185-194, 1985.
425. **White A, and Ray DW**. ACTH precursors in different pathalogical conditions. In: *The ACTH axis: Pathogenesis, Diagnosis and Treatment*, edited by Gaillard R. The Netherlands: Kluwer Academic Publishers, 2003, p. 85-107.
426. **White A, Ray DW, Talbot A, Abraham P, Thody AJ, and Bevan JS**. Cushing's syndrome due to phaeochromocytoma secreting the precursors of adrenocorticotropin. *J Clin Endocrinol Metab* 85: 4771-4775, 2000.
427. **White A, Smith H, Hoadley M, Dobson SH, and Ratcliffe JG**. Clinical evaluation of a two-site immunoradiometric assay for adrenocorticotrophin in unextracted human plasma using monoclonal antibodies. *Clin Endocrinol (Oxf)* 26: 41-51, 1987.
428. **Wierzbicka JM, Zmijewski MA, Antoniewicz J, Sobjanek M, and Slominski AT**. Differentiation of Keratinocytes Modulates Skin HPA Analog. *J Cell Physiol* 232: 154-166, 2017.
429. **Wilkinson CW**. Roles of acetylation and other post-translational modifications in melanocortin function and interactions with endorphins. *Peptides* 27: 453-471, 2006.
430. **Williams DL, Bowers RR, Bartness TJ, Kaplan JM, and Grill HJ**. Brainstem melanocortin 3/4 receptor stimulation increases uncoupling protein gene expression in brown fat. *Endocrinology* 144: 4692-4697, 2003.
431. **Wintzen M, Yaar M, Burbach JP, and Gilchrest BA**. Proopiomelanocortin gene product regulation in keratinocytes. *J Invest Dermatol* 106: 673-678, 1996.
432. **Wittert G, Hope P, and Pyle D**. Tissue distribution of opioid receptor gene expression in the rat. *Biochem Biophys Res Commun* 218: 877-881, 1996.

433. **Yalow RS, and Berson SA**. Size heterogeneity of immunoreactive human ACTH in plasma and in extracts of pituitary glands and ACTH-producing thymoma. *Biochem Biophys Res Commun* 44: 439-445, 1971.
434. **Yalow RS, Glick SM, Roth J, and Berson SA**. Radioimmunoassay of Human Plasma Acth. *J Clin Endocrinol Metab* 24: 1219-1225, 1964.
435. **Yamamoto H, Yamane T, Iguchi K, Tanaka K, Iddamalgoda A, Unno K, Hoshino M, and Takeda A**. Melanin production through novel processing of proopiomelanocortin in the extracellular compartment of the auricular skin of C57BL/6 mice after UV-irradiation. *Sci Rep* 5: 14579, 2015.
436. **Yang Y**. Structure, function and regulation of the melanocortin receptors. *European journal of pharmacology* 660: 125-130, 2011.
437. **Yaswen L, Diehl N, Brennan MB, and Hochgeschwender U**. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. *Nat Med* 5: 1066-1070, 1999.
438. **Yonemoto IT, Kroon GJ, Dyson HJ, Balch WE, and Kelly JW**. Amylin proprotein processing generates progressively more amyloidogenic peptides that initially sample the helical state. *Biochemistry* 47: 9900-9910, 2008.
439. **Young EA, Lewis J, and Akil H**. The preferential release of beta-endorphin from the anterior pituitary lobe by corticotropin releasing factor (CRF). *Peptides* 7: 603-607, 1986.
440. **Zakarian S, and Smyth DG**. beta-Endorphin is processed differently in specific regions of rat pituitary and brain. *Nature* 296: 250-252, 1982.
441. **Zhang CF, Snell CR, and Loh YP**. Identification of a novel prohormone sorting signal-binding site on carboxypeptidase E, a regulated secretory pathway-sorting receptor. *Mol Endocrinol* 13: 527-536, 1999.
442. **Zhang X, Che FY, Berezniuk I, Sonmez K, Toll L, and Fricker LD**. Peptidomics of Cpe(fat/fat) mouse brain regions: implications for neuropeptide processing. *Journal of neurochemistry* 107: 1596-1613, 2008.
443. **Zhang X, Pan H, Peng B, Steiner DF, Pintar JE, and Fricker LD**. Neuropeptidomic analysis establishes a major role for prohormone convertase-2 in neuropeptide biosynthesis. *Journal of neurochemistry* 112: 1168-1179, 2010.
444. **Zhang ZH, and Felder RB**. Melanocortin receptors mediate the excitatory effects of blood-borne murine leptin on hypothalamic paraventricular neurons in rat. *Am J Physiol Regul Integr Comp Physiol* 286: R303-310, 2004.
445. **Zhou A, Bloomquist BT, and Mains RE**. The prohormone convertases PC1 and PC2 mediate distinct endoproteolytic cleavages in a strict temporal order during proopiomelanocortin biosynthetic processing. *J Biol Chem* 268: 1763-1769, 1993.
446. **Zhou A, and Mains RE**. Endoproteolytic processing of proopiomelanocortin and prohormone convertases 1 and 2 in neuroendocrine cells overexpressing prohormone convertases 1 or 2. *J Biol Chem* 269: 17440-17447, 1994.
447. **Zhou Y, and Lindberg I**. Enzymatic properties of carboxyl-terminally truncated prohormone convertase 1 (PC1/SPC3) and evidence for autocatalytic conversion. *J Biol Chem* 269: 18408-18413, 1994.
448. **Zhu X, Orci L, Carroll R, Norrbom C, Ravazzola M, and Steiner DF**. Severe block in processing of proinsulin to insulin accompanied by elevation of des-64,65 proinsulin intermediates in islets of mice lacking prohormone convertase 1/3. *Proc Natl Acad Sci U S A* 99: 10299-10304, 2002.
449. **Zhu X, Zhou A, Dey A, Norrbom C, Carroll R, Zhang C, Laurent V, Lindberg I, Ugleholdt R, Holst JJ, and Steiner DF**. Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. *Proc Natl Acad Sci U S A* 99: 10293-10298, 2002.

Processing in the anterior lobe of the pituitary in humans



Processing in the Hypothalamus, Skin, Pars Intermedia of pituitary



Figure 1: Processing of POMC in different tissues



Figure 2: Species differences in cleavage sites of POMC



Figure 3: POMC processing in neurons



Figure 4: Alternative secretory pathways for precursors and POMC-derived peptides.

Melanocortin Receptor	POMC derived peptides
MC1R	α-MSH = ACTH > β-MSH > γ-MSH
MC2R	ACTH only
MC3R	α-MSH = β-MSH = γ-MSH = ACTH
MC4R	α-MSH = ACTH > β-MSH > γ-MSH
MC5R	α-MSH > ACTH > β-MSH > δ-MSH

Table 1: Melanocortin receptors and ligand selectivity



Figure 5: POMC processing generates numerous functional peptides.



Figure 6: Regulatory processes for secretion of POMC and its peptides.



Figure 7: ACTH precursor secretion in ectopic ACTH syndrome



Figure 8: Concentrations of ACTH precursors in different patient groups.



Figure 9: Monoclonal antibody based assays to POMC derived peptides.